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Abstract
PDZ (PSD95/Disc Large/Zona Occludens) domain-containing proteins are scaffolding
proteins that play important roles in regulating the activity of G protein-coupled receptors.
Corticotropin Releasing Factor Receptor 1 (CRFR1) and Serotonin 2A Receptor (5-HT2AR)
are two GPCRs that are commonly associated with mental disorders. Both receptors also
contain a class I PDZ-binding motif at the carboxyl terminal tail. In the first chapter, we
investigate the effects of CAL (CFTR-associated ligand) on regulating the trafficking and
signaling of CRFR1. We demonstrate a role for CAL in inhibiting CRFR1 endocytosis, cell
surface expression, and CRF-mediated ERK1/2 signaling via the CRFR1 PDZ-binding motif.
Additionally, CAL can elicit its effects on CRFR1 by mediating the post-translational
glycosylation of the nascent receptor at the Golgi apparatus. The second and third chapters
focus on the MAGI (MAGUK with inverted orientation PDZ) proteins; MAGI-1, MAGI-2 and
MAGI-3. We observe distinct functions for the MAGI proteins in regulating the trafficking
and signaling of CRFR1 compared to that of 5-HT2AR. MAGI proteins can mediate CRFR1
endocytosis via regulating β-arrestin recruitment to the receptor. No effect is observed on the
basal plasma membrane expression of CRFR1 or CRF-stimulated cAMP formation in response
to overexpression or knockdown of MAGI proteins. On the other hand, MAGI proteins
regulate 5-HT2AR-stimulated inositol phosphate accumulation as well as surface expression
levels but do not have an effect on the internalization of the receptor. MAGI proteins can also
mediate ERK1/2 signaling activated by both CRFR1 and 5-HT2AR. We propose a
compensatory mechanism of regulation between MAGI-1, MAGI-2 and MAGI-3 based on
their similar functional roles. Our work characterizes the interactions between two different
GPCRs and four PDZ proteins, further confirming the importance of this diverse family of
scaffolding proteins and providing possible targets for specific drug design.

Keywords
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trafficking, signaling, mental disorders, anxiety, depression
ii

Co-Authorship Statement
In Chapter 2, Dr. Henry A. Dunn and I collaborated on the flow cytometry experiments
in Figure 3. Dr. Cornelia Walther contributed the CAL-YFP construct. Dr. Stephen S.G.
Ferguson and I collaborated on the experimental design and the preparation of the manuscript.
In Chapter 3, Dr. Henry A. Dunn and I collaborated on the flow cytometry experiments
in Figure 6. Dr. Stephen S.G. Ferguson and I collaborated on the experimental design and the
preparation of the manuscript.
In Chapter 4, Dr. Henry A. Dunn and I collaborated on data analysis in Figures 2, 4 and
5. Dr. Stephen S.G. Ferguson and I collaborated on the experimental design and the preparation
of the manuscript.

iii

Dedication

To My Wonderful Family…

My lovely parents, Hanan Abuhantash and Mahmoud Hammad,
Thank you for giving me all the love and encouragement to be where I am
today…
My great siblings, May, Hammad, Mohammad and Shahed,
Thank you for inspiring me each in your own way…

iv

Acknowledgements
I would like to thank my supervisor Dr. Stephen Ferguson for his support and help during the
past years. Thank you for welcoming me in the lab. Thank you for always having my side and
for your encouraging words. Thank you for giving me the great opportunity to travel to cool
places like California and Hawaii! Thank you Steve.
I would like to thank Dr. Henry Dunn for being an amazing mentor over the years. It was a
great honor and pleasure to work with you and learn from you. Thank you for always being
excited about my data. Thank you for the countless conversations, the surprise strudels and the
crazy competitions. You made my degree much easier and way more fun. Thank you Henry.
I would like to thank Dr. Fabiana Caetano Crowley and Dr. Christina Godin Vanderboor.
Thank you for making my life easier in the lab and for always being so kind, thoughtful and
understanding. Thank you for your lovely friendship and for always being there to listen
whenever I needed to complain about Science or life. Thank you Fabi, Thank you Christie.
I would like to thank all the Ferguson lab. members for being part of my PhD journey. I would
also like to thank all the trainees and scientists I encountered at both the University of Western
Ontario and the University of Ottawa for their help.
Last but not least, a sincere thank you for people who supported me outside the lab. specially
my friends in crime (Anfal and Sana) who understood my passion and all my crazy decisions.

v

Table of Contents

Abstract ............................................................................................................................... ii
Co-Authorship Statement................................................................................................... iii
Dedication .......................................................................................................................... iv
Acknowledgements ............................................................................................................. v
Table of Contents ............................................................................................................... vi
List of Tables .................................................................................................................... xii
List of Figures .................................................................................................................. xiii
List of Abbreviations ....................................................................................................... xvi
Chapter 1 ............................................................................................................................. 1
1 Introduction .................................................................................................................... 1
1.1 G Protein-Coupled Receptors ................................................................................. 1
1.2 G Protein-Coupled Receptor Trafficking................................................................ 2
1.2.1

Anterograde Pathway (GPCR Biosynthesis) .............................................. 2
1.2.1.1 GPCR Synthesis at the Endoplasmic Reticulum .......................... 2
1.2.1.2 GPCR Trafficking from ER to Golgi Apparatus .......................... 4
1.2.1.3 GPCR Trafficking from Golgi to the Plasma Membrane ............. 4

1.2.2

The Life Cycle of G Protein-Coupled Receptors ........................................ 5
1.2.2.1 GPCR Desensitization .................................................................. 5
1.2.2.2 GPCR Endocytosis ....................................................................... 6
1.2.2.3 GPCR Recycling .......................................................................... 8
1.2.2.4 GPCR Degradation ....................................................................... 8

1.3 G Protein-Coupled Receptor Signaling .................................................................. 9
1.3.1

G Protein-Dependent Signaling Pathways .................................................. 9
vi

1.3.1.1 cAMP Signaling Pathway............................................................. 9
1.3.1.2 IP3 Signaling Pathway ............................................................... 10
1.3.1.3 Rho Activation Signaling Pathway ............................................ 10
1.3.2

G Protein-Independent Signaling Pathways ............................................. 10

1.4 Regulation of GPCR Trafficking and Signaling ................................................... 11
1.4.1

GPCR Regulation by Post-Translational Modifications ........................... 11
1.4.1.1 Glycosylation .............................................................................. 11
1.4.1.2 Phosphorylation .......................................................................... 12
1.4.1.3 Palmitoylation............................................................................. 13
1.4.1.4 Ubiquitination ............................................................................. 13

1.4.2

GPCR Regulation by Modulator Proteins................................................. 15

1.5 PDZ Domain-Containing Proteins ........................................................................ 15
1.5.1

Golgi- Associated PDZ Proteins (PDZ Proteins that Regulate Golgi
Trafficking and Sorting) ........................................................................... 19
1.5.1.1 CFTR-Associated Ligand (CAL) ............................................... 19
1.5.1.2 GAIP-Interacting Protein (GIPC) ............................................... 19
1.5.1.3 Sorting Nexin 27 (SNX27) ......................................................... 20

1.5.2

Membrane-Associated Guanylate-like kinases (MAGUKs) .................... 20
1.5.2.1 MAGUK with Inverted orientation PDZ (MAGIs) .................... 21
1.5.2.2 Discs Large (DLGs) ................................................................... 22

1.5.3

PDZ Proteins Network .............................................................................. 23

1.6 G Protein-Coupled Receptors and Disease ........................................................... 25
1.6.1

Mental Disorders ....................................................................................... 27

1.6.2

Targeting Protein- Protein Interactions as a Pharmacological Tool ......... 28

1.7 Corticotropin Releasing Factor Receptors ............................................................ 29
1.8 Serotonin Receptors .............................................................................................. 30
vii

1.9 Corticosteroid-Serotonin Interactions ................................................................... 34
1.9.1

Hypothalamo-Pituitary-Adrenal (HPA) Axis ........................................... 34

1.9.2

Serotonergic System ................................................................................. 34

1.10 Hypothesis and Objectives .................................................................................... 35
1.11 References ............................................................................................................. 37
Chapter 2 ........................................................................................................................... 50
2 Role of CAL in regulating CRFR1 activity ................................................................. 50
2.1 Introduction ........................................................................................................... 51
2.2 Materials and Methods .......................................................................................... 54
2.2.1

Materials ................................................................................................... 54

2.2.2

Plasmids .................................................................................................... 54

2.2.3

Cell culture and transfection ..................................................................... 55

2.2.4

Co-immunoprecipitation ........................................................................... 55

2.2.5

Confocal microscopy ................................................................................ 55

2.2.6

Receptor endocytosis ................................................................................ 56

2.2.7

Bioluminescent Resonance Energy Transfer-based biosensor cAMP assay
................................................................................................................... 56

2.2.8

ERK phosphorylation................................................................................ 57

2.2.9

Western blot analysis ................................................................................ 57

2.2.10 Statistical analysis ..................................................................................... 58
2.3 Results ................................................................................................................... 59
2.3.1

CAL interacts with CRFR1 in a PDZ-binding motif-dependent manner . 59

2.3.2

HA-CRFR1 co-localizes with CAL-YFP in the Golgi apparatus ............. 59

2.3.3

Effect of CAL expression on agonist-stimulated CRFR1 endocytosis ..... 62

2.3.4

Effect of CAL expression on cAMP signaling ......................................... 62

2.3.5

Effect of CAL expression on ERK1/2 signaling....................................... 65
viii

2.3.6

Effect of CAL on CRFR1 glycosylation and degradation ........................ 65

2.3.7

Subcellular localization and signaling of CRFR1 glycosylation mutants 70

2.4 Discussion ............................................................................................................. 74
2.5 Conclusion ............................................................................................................ 78
2.6 References ............................................................................................................. 79
Chapter 3 ........................................................................................................................... 83
3 Role of MAGI proteins in regulating CRFR1 activity ................................................. 83
3.1 Introduction ........................................................................................................... 84
3.2 Materials and Methods .......................................................................................... 88
3.2.1

Materials ................................................................................................... 88

3.2.2

Plasmids .................................................................................................... 88

3.2.3

Cell Culture and Transfection ................................................................... 88

3.2.4

Co-immunoprecipitation ........................................................................... 89

3.2.5

Bioluminescent Resonance Energy Transfer-based biosensor cAMP Assay
................................................................................................................... 89

3.2.6

Receptor Endocytosis................................................................................ 90

3.2.7

Western Blot Analysis .............................................................................. 90

3.2.8

Bioluminescent Resonance Energy Transfer ............................................ 91

3.2.9

Statistical Analysis .................................................................................... 91

3.3 Results ................................................................................................................... 92
3.3.1

MAGI proteins interact with CRFR1 via the PDZ-binding motif
independent of CRF activation ................................................................. 92

3.3.2

Effect of MAGI proteins expression on cAMP signaling ......................... 92

3.3.3

Effect of MAGI proteins on cell surface expression ................................ 95

3.3.4

Effect of MAGI proteins on CRF-mediated ERK1/2 signaling................ 95

3.3.5

Effect of MAGI proteins expression on agonist-stimulated CRFR1
endocytosis ................................................................................................ 99
ix

3.3.6

MAGI proteins can regulate CRFR1 endocytosis by mediating β-arrestin
recruitment to the receptor ........................................................................ 99

3.3.7

Knockdown of one MAGI proteins can lead to the upregulation in the
expression level of the others .................................................................. 102

3.4 Discussion ........................................................................................................... 104
3.5 Conclusion .......................................................................................................... 109
3.6 References ........................................................................................................... 110
Chapter 4 ......................................................................................................................... 114
4 Role of MAGI proteins in regulating 5-HT2AR activity ............................................ 114
4.1 Introduction ......................................................................................................... 115
4.2 Materials and Methods ........................................................................................ 118
4.2.1

Materials ................................................................................................. 118

4.2.2

Plasmids .................................................................................................. 118

4.2.3

Cell Culture and Transfection ................................................................. 118

4.2.4

Co-immunoprecipitation ......................................................................... 119

4.2.5

Measurement of Inositol Phosphate Formation ...................................... 119

4.2.6

Receptor Endocytosis.............................................................................. 120

4.2.7

Western Blot Analysis ............................................................................ 120

4.2.8

ERK Phosphorylation ............................................................................. 121

4.2.9

Statistical Analysis .................................................................................. 121

4.3 Results ................................................................................................................. 122
4.3.1

MAGI proteins co-immunoprecipitate with Flag-5-HT2AR ................... 122

4.3.2

Effect of MAGI proteins on agonist-stimulated 5-HT2AR endocytosis .. 122

4.3.3

MAGI proteins modulate 5-HT2AR-stimulated IP formation ................. 125

4.3.4

MAGI proteins can enhance cell surface trafficking of 5-HT2AR to the
plasma membrane ................................................................................... 125

4.3.5

MAGI-3 can enhance the recruitment of PLCβ3 to 5-HT2AR ................ 128
x

4.3.6

Effect of MAGI proteins on regulating 5-HT-mediated ERK1/2
phosphorylation....................................................................................... 128

4.4 Discussion ........................................................................................................... 133
4.5 References ........................................................................................................... 137
Chapter 5 ......................................................................................................................... 140
5 Discussion .................................................................................................................. 140
5.1 Summary ............................................................................................................. 140
5.2 Regulation of GPCRs Trafficking by MAGI and CAL Proteins ........................ 143
5.3 Regulation of GPCRs Signaling by MAGI and CAL Proteins ........................... 145
5.4 Mechanisms of GPCRs Regulation by MAGI and CAL Proteins ...................... 148
5.5 MAGI and CAL Proteins in Disease .................................................................. 148
5.6 Future Directions ................................................................................................ 150
5.7 References ........................................................................................................... 152
Appendices ...................................................................................................................... 156
Curriculum Vitae ............................................................................................................ 170

xi

List of Tables
Table 1: PZD proteins and their role in GPCRs regulation…………………..……………...18

xii

List of Figures
Figure 1.1: Schematic representation of the Anterograde (Forward) Trafficking of a GPCR . 3
Figure 1.2: Schematic representation of the life cycle of a GPCR ........................................... 7
Figure 1.3: PDZ proteins that regulate Golgi sorting and MAGUKs ..................................... 17
Figure 1.4: Signaling pathways activated by CRFR1 ............................................................. 31
Figure 1.5: Signaling pathways activated by 5-HT2AR........................................................... 33
Figure 2.1: CAL-YFP co-immunoprecipitates with HA-CRFR1 in a PDZ-binding motifdependent manner ................................................................................................................... 60
Figure 2.2: CAL-YFP co-localizes with HA-CRFR1 in the Golgi in a PDZ-binding motifdependent manner ................................................................................................................... 61
Figure 2.3: Effect of CAL expression on agonist-stimulated CRFR1 endocytosis ................ 63
Figure 2.4: CAL does not regulate CRFR1-mediated cAMP formation ................................ 64
Figure 2.5: CAL negatively regulates HA-CRFR1-mediated ERK1/2 phosphorylation ....... 66
Figure 2.6: Effect of CAL on CRFR1 glycosylation and degradation ................................... 68
Figure 2.7: Glycosylation of HA-CRFR1-N38Q, -N78Q, -N90Q and -N98Q mutants in the
absence and presence of CAL ................................................................................................. 69
Figure 2.8: Subcellular localization of HA-CRFR1 glycosylation site mutants in the presence
and absence of CAL ................................................................................................................ 71
Figure 2.9: Cell surface expression, cAMP signaling and ERK1/2 signaling of CRFR1
glycosylation site mutants ....................................................................................................... 72
Figure 3.1: MAGI proteins co-immunoprecipitate with HA-CRFR1 in a PDZ-binding motifdependent manner ................................................................................................................... 93

xiii

Figure 3.2: MAGI proteins do not regulate CRFR1-mediated cAMP formation. .................. 94
Figure 3.3: Effect of MAGI proteins on cell surface expression ............................................ 96
Figure 3.4: Effect of MAGI proteins overexpression on CRFR1-mediated ERK1/2 signaling
................................................................................................................................................. 97
Figure 3.5: Effect of MAGI proteins knockdown on CRF-mediated ERK1/2 signaling ....... 98
Figure 3.6: Effect of MAGI proteins expression on agonist-stimulated CRFR1 endocytosis
............................................................................................................................................... 100
Figure 3.7: Effect of MAGI proteins expression on β-arrestin recruitment to CRFR1 ........ 101
Figure 3.8: Knockdown of one MAGI protein results in an increase of expression of the other
MAGI proteins ...................................................................................................................... 103
Figure 4.1: MAGI proteins co-immunoprecipitate with Flag-5-HT2AR in a PDZ-binding
motif-dependent manner and an agonist-independent manner ............................................. 123
Figure 4.2: Effect of MAGI proteins on 5-HT2AR endocytosis ............................................ 124
Figure 4.3: MAGI proteins regulate 5-HT2AR-stimulated IP formation in PDZ motifindependent manner. ............................................................................................................. 126
Figure 4.4: Effect of MAGI proteins on the trafficking of 5-HT2AR to the plasma membrane
............................................................................................................................................... 127
Figure 4.5: MAGI-3 can enhance the association of PLCβ3 with 5-HT2AR ........................ 129
Figure 4.6: Effect of MAGI proteins on 5-HT2AR-mediated ERK1/2 signaling .................. 131
Figure 4.7: Effect of MAGI proteins on 5-HT2AR-SCV-mediated ERK1/2 signaling ...... 132
Figure 5.1: A schematic representation of the processes in GPCRs endocytosis and
biosynthesis ........................................................................................................................... 144

xiv

Figure 5.2: A schematic representation of the signaling pathways activated by CRFR1 and 5HT2AR ................................................................................................................................... 146

xv

List of Abbreviations
5-HT

5-hydroxytryptamine (serotonin)

5-HT2AR

5-HT2A receptor

5-HT2CR

5-HT2C receptor

7TMRs

seven Transmembrane Domain Receptors

AC

Adenylyl Cyclase

ACTH

adrenocorticotropin hormone

AEBSF

4-(2-aminoethyl) benzenesulfonyl fluoride

AT1R

angiotensin II type 1 receptor

ANOVA

analysis of variance

β1-AR

β1-adrenergic receptor

BAI-1

brain-specific angiogenesis inhibitor-1

CAL

cystic fibrosis transmembrane conductance regulator-associated ligand

CaMK

calmodulin kinase-like

cAMP

cyclic adenosine monophosphate

CNS

Central Nervous System

CRF

corticotropin-releasing factor

CRFR1

CRF receptor 1

CRFR2

CRF receptor 2

DAG

diacylglycerol

DLGs

discs larges

ECLs

extracellular loops

EPAC

Exchange protein directly activated by cyclic AMP

ERGIC

ER-Golgi Intermediate Compartment

ERK1/2

extracellular signal-regulated kinase

ESCRT

endosomal sorting complex required for transport

FIG

fused in glioblastoma

GAPs

GTPase-activating proteins

GASPs

GPCR-associated sorting proteins

GEF

guanine nucleotide exchange factor

GIP

GPCR-interacting protein
xvi

GIPC

Gα-Binding Protein Interacting Protein Carboxyl-Terminus

GK

guanylate kinase-like

GOPC

Golgi-associated PDZ and coiled-coil motif-containing protein

GPCR

G protein-coupled receptor

GRK

G protein-coupled receptor kinase

HA

hemagglutinin

HBSS

HEPES-buffered saline solution

HEK 293

human embryonic kidney 293

HPA

Hypothalamo-Pituitary-Adrenal Axis

ICLs

intracellular loops

ILVs

intraluminal vesicles

IP3

inositol-1,4,5-trisphosphate

LPA2R

lysophosphatidic acid-activated receptor subtype-2

MAGI

MAGUK with Inverted orientation PDZ

MAGUK

Membrane Associated Guanylate Kinase

MAPK

mitogen activated protein kinase

PAR

protease activated receptor

PDZ

PSD95/ Disc Large/ Zona Occludens

PIP2

phosphatidylinositol-4,5-bisphosphate

PIST

PDZ domain protein interacting specifically with TC10

PLCβ

phospholipase Cβ

PNGase F

Peptide N-Glycosidases F

PTB

phosphotyrosine binding

PTEN

protein phosphatase and tensin homolog

PTH1R

parathyroid hormone 1 receptor

PVN

paraventricular nucleus

RA

Ras-associated

RAMPs

receptor activity modifying proteins

RGS

regulators of G-protein signaling

SAP97

synapse-associated protein 97

SH2

Src-homology

shRNA

short hairpin RNA
xvii

SNX27

Sorting Nexin 27

SSRIs

Selective Serotonin Reuptake Inhibitors

SSTR5

Somatostatin Receptor Subtype 5

TGN

trans-Golgi network

V2R

vasopressin V2 receptor

VPAC1

Vasoactive Intestinal Polypeptide Type 1 receptor/Pituitary
Adenylate Cyclase-activating peptide

xviii

1

Chapter 1

1

Introduction

1.1 G Protein-Coupled Receptors
G Protein-coupled Receptors (GPCRs) represent the largest receptor superfamily
and regulate numerous physiological responses. These include neurotransmission, immune
function, reproduction, cardiac function, metabolism, and homeostasis (Gurevich and
Gurevich, 2008). The number of GPCRs in the human genome is estimated to be 800 to
1000 and more than 40% of the currently prescribed drugs target GPCRs (Marchese et al.,
1999; Urs et al., 2014). GPCRs share a similar structure that consists of seven
transmembrane α helical domains connected by three extracellular loops (ECLs) and three
intracellular loops (ICLs), an extracellular N-terminal domain and an intracellular Cterminal domain and they are also known as seven Transmembrane Domain Receptors
(7TMRs). The extracellular and transmembrane regions of the receptor are involved in
ligand binding while the intracellular domains are important for signal transduction and for
feedback modulation of receptor function (Marchese et al., 1999). GPCRs can be bound
and activated by a wide number of ligands such as photons of light, odorants, hormones,
neurotransmitters, peptides, chemokines, amino acids and Ca2+ ions to name a few
(Gurevich and Gurevich, 2008). GPCRs mediate their effects by coupling to a variety of
heterotrimeric guanine nucleotide-binding proteins (G proteins). G proteins have two
states; the inactive (GDP bound) and the active (GTP bound). Ligand binding to a receptor
results in the exchange between GDP and GTP. This active G protein (GTP bound)
dissociates into Gα subunit and Gβγ subunit. These dissociated subunits can mediate
several downstream effectors such as adenylyl cyclases (AC), GPCR kinases (GRKs) and
phospholipases and that ultimately leads to the activation of different signaling pathways.
The compounds that bind GPCRs can be classified into four classes based on their
effects. 1) Full agonists which by binding the receptor stabilize the active conformation
and result in maximal receptor activity, 2) partial agonists which bind the receptor without
causing maximal activity 3) inverse agonists which decrease the constitutive or
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spontaneous activity of the receptor by stabilizing the inactive conformation of the receptor
and 4) full antagonists block agonists and inverse agonists activity either by binding to the
same binding site as the endogenous ligand (competitive) or binding to an allosteric site
(non-competitive) (Luttrell, 2008; Prazeres and Martins, 2015).
GPCRs are commonly classified into five major phylogenetic families. Those are
rhodopsin (Class A), secretin (Class B), glutamate (Class C), adhesion and frizzled
(Krishnan and Schioth, 2015; Prazeres and Martins, 2015).

1.2 G Protein-Coupled Receptor Trafficking
1.2.1

Anterograde Pathway (GPCR Biosynthesis)
Anterograde trafficking (forward trafficking) of GPCRs can be defined as the

synthesis of GPCRs at the endoplasmic reticulum (ER) followed by their transport from
the ER to the plasma membrane (Fig. 1.1). Therefore, it is an essential checkpoint in
determining the level of expression of the functional receptors at the surface and this in
turn dictates the strength of the signal initiated by the receptor. This process is mediated by
multiple factors including ER chaperones, Rab GTPases, receptor activity modifying
proteins (RAMPs), exit motifs encoded by the receptor sequence and post-translational
modifications (Wu, 2012).

1.2.1.1

GPCR Synthesis at the Endoplasmic Reticulum

GPCRs are plasma membrane proteins and like many other membrane proteins,
they are synthesized via ribosomes at the membranes of the rough endoplasmic reticulum
(ER). They undergo the first set of post-translational modifications at the ER and this
facilitates their proper folding and maturation (Achour et al., 2008). Key factors are
involved in regulating this process including molecular chaperones such as Bip, calnexin,
calreticulin, ERp57, HSP70, PDI and GRP94. The interactions that occur between the
newly synthesized polypeptides and those ER-proteins slow the folding process, prevent
aggregation and stabilize the intermediate forms of proteins (Dupré et al., 2012).
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Figure 1.1: Schematic representation of the Anterograde (Forward) Trafficking of a
GPCR: The receptor is synthesized at the Endoplasmic Reticulum (ER) then transported
via COPII vesicles to the Golgi apparatus. The receptor undergoes post-translational
modifications to achieve proper folding before trafficking to the plasma membrane.
Immature forms of the receptor are transported back from the Golgi apparatus to ER via
COPI vesicles. Different Rab GTPases are involved in regulating the steps in the pathway.
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In addition, in order for the receptor to form its native conformation, enzymatic
processes are required to catalyze disulfide-bond formation or peptidyl-prolyl cis–trans
isomerization. These ER processes represent a crucial quality control system to ensure
proper folding of proteins and any misfolded polypeptides are sent for the proteasome for
degradation (ER-associated degradation) (Achour et al., 2008; Jean-Alphonse and
Hanyaloglu, 2011).

1.2.1.2

GPCR Trafficking from ER to Golgi Apparatus

Once the receptor is mature and properly folded, it traffics from the ER exit sites to
the Golgi complex via COPII-coated vesicles. The interaction of GPCRs with the
components of the COPII vesicles is mediated by ER export motifs expressed at their
carboxyl-terminal tails. These motifs consist of either di-acidic residues (Asp-x-Glu, where
x = any amino acid), pairs of aromatic residues (Phe-Phe, Tyr-Tyr or Phe-Tyr) or bulky
hydrophobic residues (Leu-Leu or Ile-Leu) (Achour et al., 2008). This transport of the
receptor through the ER-Golgi Intermediate Compartment (ERGIC) is facilitated by many
different regulator proteins including COPI, Rab GTPases and ARF GTPases. Studies on
GPCRs transport suggest that Rab1 plays a role in anterograde trafficking from ER to
Golgi, while Rab2 regulate the retrograde trafficking from the Golgi apparatus back to the
ER and Rab6 is important for GPCRs transport through the Golgi cisternae (AppenzellerHerzog and Hauri, 2006; Achour et al., 2008; Wu, 2012). Similar to Rab GTPases, ARF
GTPases are also important and different members play different roles at distinct cellular
compartments. ARF1 plays a role in both anterograde and retrograde trafficking by
recruitment of the COPII complex proteins (Appenzeller-Herzog and Hauri, 2006; Wu,
2012).

1.2.1.3

GPCR Trafficking from Golgi to the Plasma Membrane

The trans-Golgi network (TGN) is known to function as the sorting center for newly
synthesized proteins where their final destination is determined between the plasma
membrane, lysosomes or endosomes. The vesicles that regulate post-Golgi transport are
believed to be clathrin-coated vesicles. The vesicles that are involved in protein transport
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from the Golgi apparatus to lysosomes are composed of clathrin and the adaptor proteins
GGAs (Golgi-associated, γ-adaptin homologous, ARF-interacting proteins). GGAs have
four main domains to facilitate their function. An N-terminal VHS domain that recognizes
the sorting signals on the carboxyl-terminal tail of the protein being transported, a GAT
domain that interacts with ARF1, a hinge domain that recruits clathrin and the C-terminal
GAE domain that binds to accessory proteins (Wu, 2012). On the other hand, the vesicles
regulating cargo transport from the Golgi apparatus to the plasma membrane are unknown
and it has been suggested that they could be large pleiomorphic carriers. However, studies
show that post-Golgi trafficking to the plasma membrane is also highly regulated by Rab
GTPases and conserved sorting motifs. Rab8 is important for the transport of
transmembrane proteins and GPCRs specifically from the Golgi apparatus to the plasma
membrane. It has been previously shown that using Rab8 mutants or knocking down Rab8
expression results in reduced surface expression of the adrenergic receptors α2B-AR and
β2-AR and retention of the receptors in the intracellular compartments (Dong et al., 2010;
Wang and Wu, 2012). As for motifs, studies show an importance for the di-leucine (LL)
residues at the carboxyl-terminal tail of certain family A GPCRs in plasma membrane
expression (Schulein et al., 1998; Duvernay et al., 2004; Carrel et al., 2006; Sawyer et al.,
2010). It has been shown that this motif is highly conserved in α2B-AR, α1B-AR, β2-AR,
angiotensin II type 1 receptor (AT1R), serotonin 5-HT1A and 5-HT1B receptors, vasopressin
V2 receptor, and M1-muscarinc receptor and mutations lead to the retention of these
receptors intracellularly and therefore reduced cell surface levels. In addition to the
conserved motifs at the carboxyl-terminal end of GPCRs, studies illustrate an important
role for the N-terminal end in GPCRs trafficking. Reports show that mutations of the Nterminal YS motif in some adrenergic receptors results in their retention in the Golgi (Wu,
2012).

1.2.2

The Life Cycle of G Protein-Coupled Receptors

1.2.2.1

GPCR Desensitization

GPCR desensitization is defined as the reduced strength of receptor activity or
responsiveness. The process is mainly initiated after a ligand binds to a receptor to activate
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it. The mechanisms underlying GPCR signal attenuation include G-protein uncoupling
from the phosphorylated receptor, receptor internalization to the intercellular
compartments and receptor degradation. Depending on the receptor structure as well as the
cellular environment, desensitization can vary from reduced activity to complete loss of
signaling. G protein uncoupling occurs once the receptor is phosphorylated either by
second messenger-dependent kinases (PKA and PKC) or by G protein-coupled receptor
kinases (GRKs). These enzymes commonly phosphorylate threonine and serine residues
on the intracellular loop or the carboxyl-terminal tail of the receptor (Ferguson, 2001). In
addition, different GRKs can phosphorylate different sites on the receptor resulting in a bar
code that dictates the fate of the receptor (Lefkowitz and Shenoy, 2005).

1.2.2.2

GPCR Endocytosis

GPCR endocytosis is an important process for the regulation of receptor levels at
the plasma membrane and hence receptor activity. Different GPCR subtypes undergo
internalization via various mechanisms. The classical common pathway for internalization
requires the binding of an agonist to the receptor resulting in a conformational change that
leads to receptor phosphorylation by GRKs and β-arrestin recruitment (Ferguson and
Caron, 1998) (Fig. 1.2). When β-arrestin binds the receptor, it uncouples G proteins and
dissociates the heterotrimeric G protein complex from the receptor. β-arrestin binding also
results in the recruitment of adaptor proteins AP-2 and clathrin. Studies showed that the
carboxyl-terminal end of β-arrestin binds the amino-terminal globular region of the clathrin
heavy chain and the β2-adaptin subunit of the AP-2 heterotetromeric complex (Ferguson
and Caron, 1998; Ferguson, 2001; Sorkin and von Zastrow, 2009). The β2-adaptin subunit
is important for the formation of the clathrin coat and the targeting of the receptor to the
coated pits. These clathrin-coated pits are vesicular structures that are covered on the inner
cytoplasmic surface by clathrin triskelions, which consist of three clathrin heavy chains
and three clathrin light chains assembled into the clathrin lattice. The pits contain the
receptor and the ligand and pinch off from the plasma membrane by a process that is
mediated by the GTPase dynamin (Ferguson and Caron, 1998; Ferguson, 2001; Sorkin and
von Zastrow, 2009). These vesicles are targeted to the endosomal compartment where they
either recycle back to the plasma membrane or traffic to the lysosomes for degradation
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Figure 1.2: Schematic representation of the life cycle of a GPCR: Upon activation of
the receptor with a ligand, it is phosphorylated by GRK. This phosphorylation results in
the recruitment of β-arrestin and the initiation of endocytosis via clathrin-coated pits. The
receptor is then internalized to the early endosomes and its fate is determined between
either recycling back to the plasma membrane or getting transported to lysosomes for
degradation. Rab GTPases as well as PDZ proteins are key modulators of the steps in this
pathway. Modified from (Ferguson and Caron, 1998).
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depending on certain motifs usually at the cytoplasmic tail of a GPCR (Sorkin and von
Zastrow, 2009).
Although there is data supporting this mechanism for many receptors, there is also
evidence for alternate steps and mechanisms for endocytosis. Despite the importance of
GRKs and specially GRK2 for initiating the internalization process, some reports showed
that phosphorylation by second messenger kinases such as PKA and PKC can also result
in β-arrestin recruitment and G protein uncoupling. Furthermore, some studies illustrate
that having sufficient levels of β-arrestin 1 and β-arrestin 2 could eliminate the requirement
for receptor phosphorylation (Ferguson and Caron, 1998; Ferguson, 2001).

1.2.2.3

GPCR Recycling

One of the pathways that the receptor can go through after endocytosis is to recycle
from the endosomes to the plasma membrane. Studies show that Rab GTPases play an
important role in regulating this process. While Rab1 and Rab2 are the Rab proteins that
control the anterograde and retrograde trafficking of GPCRs, Rab4 and Rab11 are involved
in receptors recycling (Zerial and McBride, 2001). This reflects the specificity of the
members of the small Rab GTPases family and their distinct distribution among the
intracellular compartments. Rab4, Rab5 and Rab11 are expressed in the endosomal
compartment. Furthermore, studies show that Rab5 regulates the transport of clathrincoated vesicles from the plasma membrane to the endosomes and facilitates tethering and
fusion of the vesicles to the early endosomes (Zerial and McBride, 2001). Rab4 and Rab11
on the other hand have a role in sorting and recycling either through the early endosomes
(Rab4) or the perinuclear recycling endosomes (Rab11). In addition, recycling via Rab4containing endosomes is rapid while Rab11-containing endosomes facilitate the slower
recycling mechanism (Zerial and McBride, 2001).

1.2.2.4

GPCR Degradation

The other common fate for GPCRs following endocytosis is degradation in the
lysosomes. When the early endosomes mature to multivesicular bodies (MVBs) and late
endosomes, their cargo of internalized receptors is contained in the intraluminal vesicles
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(ILVs) which are formed by ESCRT (endosomal sorting complex required for transport)
complexes (Soldati and Schliwa, 2006; von Zastrow and Williams, 2012). Late endosomes
and MVBs are then fused to the lysosomes that contain proteolytic enzymes to breakdown
receptors. Similar to the anterograde pathway, certain motifs and post-translational
modifications are important for initiating degradation (Sorkin and von Zastrow, 2009).
However, the most common process that marks receptors for degradation is ubiquitination.
The process consists of three key steps; First E1 (ubiquitin-activating enzyme) activates a
ubiquitin molecule in an ATP-dependent step, then E2 (ubiquitin-conjugating enzyme)
receives the active ubiquitin and transfers it to E3 (ubiquitin ligase) which would recognize
the protein and label it with the ubiquitin molecule (Sorkin and von Zastrow, 2009; Alonso
and Friedman, 2013).

1.3 G Protein-Coupled Receptor Signaling
1.3.1

G Protein-Dependent Signaling Pathways
The classical view of GPCRs signaling involves coupling to G proteins as their

name suggests. Upon agonist binding, the GDP on the Gα subunit is displaced by a GTP
and this results in the functional disassociation of the heterotrimeric G protein (Gα and
Gβγ). This would then allow each of the subunits to activate different effectors including
ion channels and enzymes and eventually multiple signaling pathways. GTPase-activating
proteins (GAPs) then bind Gα resulting in the hydrolysis of GTP to GDP, which deactivates
Gα and causes disengagement of the effector (Gilman, 1987; Hepler and Gilman, 1992).
Finally, Gα reassociates with Gβγ. Therefore, upon activation, the receptor acts as a
guanine nucleotide exchange factor (GEF) for the heterotrimeric G protein. G proteins
signaling can be classified into 4 major categories based on the G protein subtype that the
receptor couples to; Gαs, Gαi, Gαq/11 and G12/13.

1.3.1.1

cAMP Signaling Pathway

The cAMP (cyclic adenosine monophosphate) signaling pathway is a downstream
pathway that is mediated when a GPCR couples to either the stimulatory- or inhibitoryregulatory G proteins (Gαs and Gαi) (Kristiansen, 2004). The effector that the G proteins
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bind to in this case is adenylyl cyclase (AC), an enzyme that synthesizes cAMP from ATP.
cAMP would in turn activates PKA as well as certain cAMP-regulated guanine nucleotide
exchange factors, such as EPAC1 and EPAC2. There are 10 isoforms of AC and all of
which can be stimulated by Gαs. However only some of them can be stimulated by Gβγ or
inhibited by Gαi. The activity of AC can be also modulated through phosphorylation by
PKA and PKC (Luttrell, 2008).

1.3.1.2

IP3 Signaling Pathway

The inositol 1,4,5-trisphosphate (IP3) signaling pathway is the downstream
pathway that is mediated when a GPCR couples to Gαq/11 subunit (Kristiansen, 2004). The
main effector for Gαq is phospholipase Cβ (PLCβ), a membrane-bound enzyme that
converts phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and IP3.
IP3 binds to IP3 receptor in the ER and this results in the release of Ca2+ from intracellular
stores, while DAG activates PKC. There are four known isoforms for PLCβ, PLCβ1-4 and
they are known to be regulated by the Gα subunits as well as the Gβγ subunits of Gαq/11. In
fact, it has been suggested that certain isoforms (PLCβ2 and PLCβ3) are more sensitive to
Gβγ regulation than others (PLCβ1) (Luttrell, 2008).

1.3.1.3

Rho Activation Signaling Pathway

The Rho activation signaling pathway is a less common pathway and it is mediated
when the GPCR couples to G12/13 subunit. G12/13 is implicated in the regulation of Ras
homology (Rho) guanine nucleotide exchange factors (RhoGEFs) which is considered to
function as a link between the heterotrimeric G protein and small GTPase pathways. G12/13
can control cytoskeletal rearrangement and affect cellular growth (Luttrell, 2008).

1.3.2

G Protein-Independent Signaling Pathways
GPCRs can signal via G-protein independent mechanisms and the best

characterized example is β-arrestin-mediated signaling via Src and mitogen-activated
kinase pathways (Naor et al., 2000; Kristiansen, 2004; Lefkowitz and Shenoy, 2005).
Stimulation of many GPCRs leads to the activation of mitogen-activated protein (MAP)
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kinases. There are three classes of MAP kinase, the extracellular signal-regulated kinases
(ERK), c-Jun N-terminal kinase/Stress-activated protein kinases (JNK/SAPK) and
p38/HOG1 MAP kinases (Naor et al., 2000; Belcheva and Coscia, 2002; Lefkowitz and
Shenoy, 2005). MAP kinases are regulated via a series of modular kinase cascades. Each
cascade is composed of three kinases that successively phosphorylate and activate the
downstream component. β-arrestin acts as a multifunctional scaffold protein and helps
assemble the MAP kinase modules with a GPCR to target it to the endosome of the cell
(Lefkowitz, 1998; Ferguson, 2001; Lefkowitz et al., 2006). It is important to mention that
this is a divergent pathway that can also be activated by multiple intracellular intermediates
such as Ca2+, Ras, PLC, proline-rich tyrosine kinase 2, cAMP, c-Src, and PI3K. For
example, the activation of Gαs and Gαq via PKA and PKC leads to the phosphorylation of
Ras. Ras would then activate Raf to phosphorylate MEK which subsequently
phosphorylate ERK (Luttrell et al., 1999; Belcheva and Coscia, 2002; Kristiansen, 2004).

1.4 Regulation of GPCR Trafficking and Signaling
The various steps in the trafficking and signaling pathways of GPCRs are very
efficiently regulated by two main factors; post-translational modifications and modulatory
proteins.

1.4.1

GPCR Regulation by Post-Translational Modifications
Post-translational modifications serve as a method to label or mark the receptor

particularly for the trafficking between cellular compartments by the addition of specific
chemical groups or molecules on certain residues of the receptor. The four major types of
post-translational modifications that have been well-characterized are glycosylation,
phosphorylation, palmitoylation, and ubiquitination (Alonso and Friedman, 2013). These
processes have distinct roles in regulating the expression and function of GPCRs.

1.4.1.1

Glycosylation

There are two forms of glycosylation; N- linked glycosylation and O-linked
glycosylation. N-glycosylation is the addition of oligosaccharide to the nitrogen in the side-
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chain amid of asparagine residues and it is the more common way of GPCRs glycosylation.
Approximately 90% of all GPCRs are glycosylated on their extracellular domains at
conserved consensus sites Asn-x-Ser/Thr (where x = any amino acid except proline). This
process usually starts at the ER and is completed during the transport through the Golgi.
O-Glycosylation on the other hand is the transfer of N-acetyl-galactosamine to a serine or
threonine residue on the target protein (Qiu and Law, 2011). Studies with the β2-AR and
opioid receptors demonstrate an importance of glycosylation in receptor expression at the
cell surface (McLawhon et al., 1983; Stiles et al., 1984; Law et al., 1985; George et al.,
1986). Studies with the protease activated receptors (PARs) point to an effect for
glycosylation on receptor signaling (Grimsey et al., 2011). It is suggested that inhibiting
PAR1 glycosylation can enhance its signaling either due to the lack of the bulky sugars
allowing for more efficient interaction of the newly generated tethered ligand with the
second extracellular loop or a change in conformation that provide more flexibility of the
ECL2 domain and more efficient G protein coupling (Grimsey et al., 2011). Receptor
glycosylation is studied using different methods including monitoring the mobility of
receptors on SDS-PAGE, enzymatic deglycosylation and site-directed mutagenesis.
Multiple glycosidases have been characterized and shown to cleave the glycan chain
differently (Spiro, 2002). Those include neuraminidases that cleave terminal Naceylneuraminic acid, α-mannosidases that cleave mannose, endoglycosidases H that
cleave asparagine-linked mannose rich oligosaccharides, Peptide N-Glycosidases F
(PNGase F) which remove all types of N-linked glycosylation and O-glycosidase that
cleaves O-linked glycan chains (Qiu and Law, 2011).

1.4.1.2

Phosphorylation

As explained earlier, GPCRs are phosphorylated by GRKs upon agonist activation.
GPCRs can also be phosphorylated by protein kinase C (PKC), protein kinase A (PKA),
casein kinases and receptor tyrosine kinases (Ferguson, 2001). Receptor phosphorylation
occurs mainly on serine or threonine residues within the carboxyl-terminal tail or third
intracellular loop. Studies with β2-AR demonstrate the importance of GPCRs
phosphorylation

in

regulating

desensitization

and

internalization.

Receptor

phosphorylation promotes the association of arrestins to the activated receptor. This not
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only uncouples the receptor from G protein to stop signaling (desensitization) but also
recruits the receptor to the endocytic machinery (internalization) (Ferguson, 2001).
Therefore, phosphorylation is an important factor in determining the fate of the receptor.
In addition, studies on phosphorylation of the opioid receptors show an effect for this
modification on the activity of adenylyl cyclase (Zhang et al., 2009). This suggests that
post-translational modifications can play important roles in regulating receptor signaling
in addition to the role they play in regulating trafficking. Studies on PAR1 illustrate that
phosphorylation sites can be very specific in terms of regulating different functions
meaning that different residues can differentially regulate association with clathrin
adaptors that facilitate receptor internalization versus uncoupling from G protein signaling
(Grimsey et al., 2011). Receptor phosphorylation is commonly studied by [32P]
orthophosphate labeling, mass spectrometry and phospho-specific antibodies.

1.4.1.3

Palmitoylation

Palmitoylation involves the attachment of palmitate to cysteine residues on the
carboxyl-terminal tail or intracellular loop of the receptor through a thioester linkage. It is
a covalent lipid modification that is observed with many GPCRs including rhodopsin, β2AR and the opioid receptors MOR and DOR (Qiu and Law, 2011). It usually occurs very
early during protein synthesis. Therefore, it is important for receptor maturation and hence
for receptor expression on the cell surface. However, there is evidence indicating that the
receptor can undergo palmitoylation and depalmitoylation cycles in an agonist-dependent
manner but the role of these processes is still unknown (Qanbar and Bouvier, 2003). There
are multiple methods used to assess receptor palmitoylation such as metabolic labeling with
[3H] palmitate followed by immunoprecipitation, fatty acyl exchange labeling, SDS-PAGE
and fluorography.

1.4.1.4

Ubiquitination

As described in the GPCR degradation section, ubiquitination is an important label
that drives the receptor towards the degradation pathway. Furthermore, ubiquitination is
important during the biosynthetic pathway to identify misfolded proteins and send them
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for proteasomal degradation (ER-associated degradation) (Achour et al., 2008; JeanAlphonse and Hanyaloglu, 2011). Ubiquitination involves the covalent addition of
ubiquitin to the lysine side chains of the receptor which is facilitated by three enzymes; E1,
ubiquitin-activating enzyme, E2, ubiquitin-carrying enzyme and E3, ubiquitin ligase
(Sorkin and von Zastrow, 2009; Alonso and Friedman, 2013; Marchese and Trejo, 2013).
First, ubiquitin is activated by E1 and transferred to the active site of the enzyme in an
ATP-dependent process. Then, the ubiquitin molecule is passed on to E2 by a
transthiolation reaction. Finally, E3 recognizes the target protein and label it with ubiquitin
(Alonso and Friedman, 2013; Marchese and Trejo, 2013). Ubiquitination of GPCRs mainly
occurs on the lysine residues of the carboxyl-terminal tail but studies show ubiquitin sites
on the first cytoplasmic loop for µ-opioid receptor and on the third intracellular loop for
the vasopressin V2 receptor (V2R) and β2-AR receptor. Ubiquitin is a highly conserved
76-amino acid polypeptide and since it contains lysine residues, the peptide itself can be
ubiquitinated forming polyubiquitin chains. In addition to its role in targeting the receptor
to the late endosomes for degradation in the lysosomes, ubiquitination can serve as a quality
control step for newly synthesized receptors resulting in this case in their proteosomal
degradation. Studies with the DOR, MOR and thyrotropin-releasing hormone receptor
show that when the receptor is misfolded, it gets retranslocated to the ER where it is labeled
with ubiquitin to be degraded by the proteasome (Chaturvedi et al., 2001; Petaja-Repo et
al., 2001; Shenoy, 2007). GPCRs can also be deubiquitinated by deubiquitination enzymes
130 and this leads to their rescue from degradation and an increase in their cell surface
expression levels (Sorkin and von Zastrow, 2009). Furthermore, studies on PAR1 illustrate
the importance for ubiquitination in the constitutive internalization of the receptor (Alonso
and Friedman, 2013). In addition to regulating GPCRs trafficking, ubiquitination can
indirectly regulate GPCRs signaling by regulating GRKs, MAPKs and β-arrestins (Alonso
and Friedman, 2013; Marchese and Trejo, 2013). Ubiquitination is commonly studied by
protease inhibitors and ubiquitin antibodies.

In addition to the previous main post-translational modifications that GPCRs
undergo, recent studies are exploring two more processes; isoprenylation and sumoylation
(Qiu and Law, 2011). Isoprenylation is a lipid modification of proteins characterized by
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the addition of an isoprenoid moiety to the sulfhydryl group of a cysteine residue via a
thioether bond. It has been suggested that isoprenylation and palmitoylation may
collectively regulate GPCRs function (Miggin et al., 2003). Isoprenylation of prostacyclin
receptors is suggested to be important for G-protein coupling, as well as receptor
internalization (Miggin et al., 2002). Sumoylation is the covalent attachment of SUMO (an
ubiquitin-like peptide) to lysine on the target receptor but unlike ubiquitin, it is not used to
label the proteins for degradation. It appears to be important for transcriptional regulation,
protein stability and receptor trafficking. Studies suggest that metabotropic glutamate
receptors contains a sumoylation motif and can undergo this modification (Qiu and Law,
2011; Tang et al., 2005). However, further characterization of both isoprenylation and
sumoylation is still required to understand their effects on regulating GPCRs activity.

1.4.2

GPCR Regulation by Modulator Proteins
Many intracellular and transmembrane proteins associate with GPCRs to regulate

their processing in the endoplasmic reticulum, trafficking to the cell surface,
compartmentalization to the plasma membrane microdomains, endocytosis and trafficking
between intracellular membrane compartments. Examples include β-arrestins, receptor
activity-modifying proteins (RAMPs), PSD95/Disc Large/Zona Occludens (PDZ) domaincontaining proteins, small GTPases, regulators of G-protein signaling (RGS), GPCRassociated sorting proteins (GASPs), molecular chaperones, Homer, GRKs and protein
phosphatases (Magalhaes et al., 2012).

1.5 PDZ Domain-Containing Proteins
PDZ domains comprise ~90 residues and PDZ domain-containing proteins are
mainly known to be scaffolding proteins. They modulate protein interactions by
recognizing short amino acid motifs usually at the carboxyl-terminal end of their target
proteins (Lee and Zheng, 2010; Romero et al., 2011). They are found on more than 100
proteins in the human genome and there is usually more than one domain on the same
protein to enable them to bind multiple proteins simultaneously and form functional
molecular complexes. These complexes can regulate multiple biological processes such as
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transport, ion channel signaling, protein trafficking and other signal transduction systems
(Dunn and Ferguson, 2015). PDZ domains contain a conserved sequence that consists of
glycine-leucine-glycine-phenylalanine and forms the globular structure of the domain that
recognizes the PDZ-binding motif. PDZ motifs are usually classified into three classes.
Class I is identified by their final three–amino acid sequence which consists of S/T-x-φ,
where x symbolizes any amino acid and φ symbolizes any hydrophobic amino acid. The
most common hydrophobic amino acids are found to be valine, isoleucine, or leucine
(Songyang et al., 1997; Bezprozvanny and Maximov, 2001; Sheng and Sala, 2001; Vaccaro
and Dente, 2002). Class II is characterized by having φ-x-φ as the final three amino acids.
Class III is characterized by having Ѱ-x-Ѱ as the final three amino acids, where Ѱ
symbolizes any acidic amino acid residue (Sheng and Sala, 2001).
PDZ domain-containing proteins also contain multiple other modular protein
interaction domains such as: Src-homology 2 (SH2), SH3, phosphotyrosine binding (PTB),
WW motifs, guanylate kinase-like (GK), calmodulin kinase-like (CaMK) and Rasassociated (RA) domains (Harris and Lim, 2001; Magalhaes et al., 2012) (Fig. 1.3). Some
of the recent studies show that PDZ proteins have distinct functions depending on the
receptor being investigated (Table 1). A good example for that is MUPP1, which can
enhance GABAB receptor signaling (Balasubramanian et al., 2007), uncouple the
melatonin-1 receptor from Gαi and facilitate the dephosphorylation (Guillaume et al., 2008)
and resensitization of the 5-HT2CR (Parker et al., 2003). Other studies show that unique
PDZ proteins can regulate different pathways of the same receptor. For example, MAGI-2
has been shown to promote β1-AR internalization while MAGI-3 seems to selectively
attenuate β1-AR signaling via ERK1/2 (He et al., 2006).
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Figure 1.3: PDZ proteins that regulate Golgi sorting and MAGUKs: PDZ domaincontaining proteins possess multiple domains that facilitate their function, binding to their
target and subcellular localization. (Dunn and Ferguson, 2015).
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Table 1: PDZ proteins and their role in GPCRs regulation (The table is part of tables
published in Dunn and Ferguson, 2015)
PDZ protein
CAL/GOPC

GIPC

SNX27
MAGI-2

MAGI-3

SAP97

PSD-95

SAP102

Effect on GPCR
↓ Membrane localization
↓ Recycling
↑ Golgi localization
↓ ERK
↓ Gi coupling
↑ Protein kinase B, ↑ Trafficking to
early endosome
↓ ERK
↑ Endosome/Golgi localization
↑ Membrane stability
↑ Recycling
↓ endocytosis
↑ endocytosis
↑ Golgi localization
↓ cAMP
↑ ERK
↑ Rho
↓ ERK
↑ Inositol 1,4,5-trisphosphate, ↑ ERK
↑ ERK
↓ Endocytosis
↑ Inositol 1,4,5-trisphosphate
↑ cfos, ↑ Desensitization of Ca2+,
↑ Endocytosis
↑ Membrane localization
↓ or = cAMP, ↑ Recycling,
↑ Endocytosis
↓ Endocytosis
↓ Endocytosis, ↓ β-arrestin recruitment
↑ ERK, ↓ Mobility

Receptor
β1-AR, SSTR5
β1-AR
SSTR5
mGluR1, β1-AR
Dopamine 3 receptor
LPA1R
β1-AR
D2R, dopamine 3 receptor
Human LH receptor
β2-AR, β1-AR, SSTR5
VPAC1
β1-AR
mGluR1a
VPAC1
BAI-1, LPA2R
LPA2R
β1-AR, β2-AR
5-HT2AR
CRFR1, CRFR2
CRFR1, 5-HT2AR
5-HT2AR
5-HT2CR
GPR30
D1R
β1-AR, 5-HT2AR
CRFR1
A2AR
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1.5.1

Golgi- Associated PDZ Proteins (PDZ Proteins that Regulate
Golgi Trafficking and Sorting)

1.5.1.1

CFTR-Associated Ligand (CAL)

The Golgi-localized cystic fibrosis transmembrane conductance regulatorassociated ligand (CAL) is a single PDZ domain-containing protein with two coiled-coil
motifs and two evolutionally conserved regions which are required for its Golgi
localization (Charest et al., 2001; Yao et al., 2001; Cheng et al., 2002). CAL is also known
as GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein), PIST (PDZ
domain protein interacting specifically with TC10) and FIG (fused in glioblastoma). CAL
overexpression reduces cell surface expression of the β1-AR and mGluR1a by retaining the
receptor inside the cell via a direct interaction (He et al., 2004; Zhang et al., 2008). CAL
also interacts with mGluR5a and stabilizes receptor expression by a mechanism that is
proposed to involve the inhibition of ubiquitination-dependent degradation (Cheng et al.,
2010). CAL also contributes to the regulation of somatostatin receptor recycling and
degradation (Wente et al., 2005; Bauch et al., 2014).

1.5.1.2

GAIP-Interacting Protein (GIPC)

Another PDZ-binding protein involved in regulating the trafficking and sorting
from Golgi is the Gα-Binding Protein Interacting Protein Carboxyl-Terminus (GIPC) (Liu
et al., 2001). Similar to CAL/GOPC, GIPC contains one PDZ domain. GIPC is also known
as Tax interaction protein 2 (TIP-2) and Synectin (Dunn and Ferguson, 2015). GIPC
facilitates the trafficking of D2R to the endosomes and Golgi (Jeanneteau et al., 2004).
Similarly it has been found to enhance the trafficking of LPA1R to the early endosomes
and promote the receptor activation of the protein kinase B signaling pathway (Varsano et
al., 2012). GIPC is also shown to regulate the trafficking of the human luteinizing hormone
receptor and stabilize its expression at the plasma membrane (Hirakawa et al., 2003). In
addition, GIPC plays a role in regulating the signaling of β1-AR via the MAPK pathway
but has no effect on the Gαs pathway since GIPC can reduce β1-AR-stimulated ERK1/2
phosphorylation but does not interfere with cAMP formation (Hu et al., 2003). However,
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GIPC prevents the coupling of Dopamine 3 receptor to Gαi to reduce signaling through the
G protein-dependent pathway. (Jeanneteau et al., 2004; Dunn and Ferguson, 2015).

1.5.1.3

Sorting Nexin 27 (SNX27)

Sorting Nexin 27 (SNX27) contains one amino terminal PDZ domain, a Phox
homology domain and a Ras-associating domain (Joubert et al., 2004). SNX27 can drive
multiple GPCRs to the recycling pathway and therefore prevent their degradation. These
include β2-AR, β1-AR and SSTR5 (Lauffer et al., 2010; Temkin et al., 2011; Nakagawa
and Asahi, 2013; Bauch et al., 2014; Dunn and Ferguson, 2015). One of the mechanisms
suggested for this role in recycling is that SNX27 can target the receptor to the retromer
tubule by interacting with the endosomal WASH complex (Temkin et al., 2011).

1.5.2

Membrane-Associated Guanylate-like kinases (MAGUKs)
Membrane Associated Guanylate Kinase (MAGUK) family proteins are synaptic

scaffolding proteins within a structured protein network responsible for the spatial
organization of the presynaptic and postsynaptic compartments. They play a crucial role in
the formation and function of synapses in the Central Nervous System (CNS) by regulating
multiple aspects of synapse physiology such as synaptogenesis, receptor trafficking,
synaptic function, and plasticity (Funke et al., 2005; Feng and Zhang, 2009; Yamagata and
Sanes, 2010). MAGUKs are well-conserved throughout evolution and are widelyexpressed in the brain and periphery. They include multiple subfamilies including
membrane palmitoylated proteins (MPPs), zona occludens (ZO), caspase recruitment
domain-containing MAGUK protein (CARMA), discs larges (DLGs) and MAGUK with
inverted orientation PDZ proteins (MAGIs) (Oliva et al., 2012). Generally, these proteins
contain multiple domains that control their function and facilitate their interactions with
their targets. The two common domains among all members are PDZ domains and
guanylate kinase (GK) domains (Oliva et al., 2012). An important target for the MAGUKs
scaffolding proteins is the G protein-coupled receptors (GPCRs) family (Dunn and
Ferguson, 2015). This protein-protein interaction between the receptor and MAGUKs
results in the regulation of GPCRs function. MAGUK proteins play a key role in mediating
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the subcellular localization, trafficking, cell surface expression and signal transduction of
multiple GPCRs and different proteins have both overlapping and distinct roles in the
regulation of GPCR activity (Harris and Lim, 2001; Lee and Zheng, 2010; Romero et al.,
2011; Magalhaes et al., 2012). One of the important subfamilies of MAGUKs is MAGIs.
It consists of three members; MAGI-1, MAGI-2 and MAGI-3. All three proteins share a
similar structure containing one GK domain, two tryptophan tryptophan (WW) domains
and six PDZ domains (te Velthuis et al., 2007; Oliva et al., 2012; Dunn and Ferguson,
2015).

1.5.2.1

MAGUK with Inverted orientation PDZ (MAGIs)

MAGI-1, also known as BAP-1 (BAI-1-associated protein 1), has 7 isoforms that
are widely expressed in different tissues. Isoform 1, isoform 2 and isoform 6 are highly
expressed in colon, kidney, lung, liver, and pancreas. Isoform 5 is predominantly expressed
in brain and heart. Isoform 3 and isoform 4 are highly expressed in pancreas and brain
(Dobrosotskaya et al., 1997; Laura et al., 2002). MAGI-1 interacts with BAI-1 (brainspecific angiogenesis inhibitor-1), a family B GPCR that functions as an adhesion molecule
(Shiratsuchi et al., 1998). Therefore, it is suggested that MAGI-1 might play an important
role in the organization of membrane proteins and cytoskeleton by transmitting signals
related to cell- cell or cell- matrix interactions through BAI-1 (Shiratsuchi et al., 1998;
Stetak et al., 2009; Stephenson et al., 2013). MAGI-1 also regulates AMPA receptor
activity and modulate behavioral plasticity (Emtage et al., 2009).
MAGI-2, also known as S-SCAM (synaptic scaffolding molecule), is specifically
expressed in the brain and has 2 isoforms (Wood et al., 1998). Previous studies illustrate
an association between MAGI-2 and β1-AR that is enhanced upon agonist stimulation (Xu
et al., 2001). The study also demonstrate an increase in agonist-induced internalization of
β1-AR when MAGI-2 is co-expressed but no effect on cAMP generation induced by
isoproterenol stimulation. Alternatively, a study of the effects of MAGI-2 on vasoactive
intestinal polypeptide type1 (VPAC1) receptor demonstrate an opposite function, where
MAGI-2 overexpression results in the inhibition of VPAC1-mediated cAMP production
and agonist-induced VPAC1 internalization (Gee et al., 2009).
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MAGI-3 is widely expressed in different tissues. It has been shown to interact with
β2-AR and reduce signaling via the extracellular signal-regulated kinase 1 and 2 (ERK1/2)
pathway (Yang et al., 2010). MAGI-3 can also associate with lysophosphatidic acidactivated receptor subtype-2 (LPA2R) and contrary to the effect observed with β2-AR,
knockdown of MAGI-3 results in a decrease of receptor-mediated ERK1/2 signaling
(Zhang et al., 2007). The study also reports a significant reduction in Rho activation upon
knockdown of MAGI-3.

1.5.2.2

Discs Large (DLGs)

This subfamily of MAGUKs contain five proteins (DLGs 1-4) also known as
SAP97 (DLG1), PSD-93 (DLG2), SAP102 (DLG3) and PSD-95 (DLG4) as well as a Discs
Large Homolog 5 (DLG5). All members contain an SH3 domain, a GK domain and three
PDZ domains (with the exception of DLG5 which has 4 PDZ domains). All PDZ domains
are type I domains (they bind class I PDZ binding motif consisting of T/S-x-φ) (Oliva et
al., 2012). Similar to MAGIs, DLGs are widely expressed in the central nervous system
and have been shown to regulate synaptic function (Dunn and Ferguson, 2015).
SAP97 (DLG1) regulates the trafficking and signaling of different members of the
GPCRs family. It can antagonize the agonist-induced internalization of both CRFR1 and
5-HT2AR when overexpressed. Furthermore, it plays an essential role in regulating the
MAPK pathway for multiple GPCRs including CRFR1, CRFR2 and 5-HT2AR. The fact
that CRFR2 does not possess a PDZ-binding motif suggests that this role for SAP97 in
regulating ERK1/2 activation does not require an interaction with the receptor and could
be a global role for the regulation of MAPK pathway (Dunn et al., 2013). SAP97 can also
enhance 5-HT-induced IP3 formation which illustrates how one PDZ-binding protein can
regulate G protein-dependent as well as G protein-independent signaling pathways
activated by the same receptor. In addition, SAP97 facilitates the recycling of β1-AR and
this emphasizes the involvement of PDZ proteins at different steps of the GPCRs life cycle.
PSD-95 (DLG4) has been shown to regulate a number of GPCRs. It has been shown
to antagonize the internalization of both β1-AR and 5-HT2AR (Hu et al., 2000; Xia et al.,
2003). It also has an enhancement effect on Gαq signaling mediated by 5-HT2AR.
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Interestingly, PSD-95 has been shown to have an opposite effect on 5-HT2CR since it can
enhance the internalization of the receptor and decrease its cell surface expression
(Gavarini et al., 2006). There are reports of an association between PSD-95 and D1R
resulting in an increase in internalization and reduction in cAMP formation by the receptor
(Zhang et al., 2007). Other studies suggest that PSD-95 can enhance the recycling of D1R
without affecting its signaling via Gαs (Sun et al., 2009). A recent study has illustrated the
effects of PSD-95 in regulating CRFR1 function. Similar to the effects observed with β 1AR and 5-HT2AR, PSD-95 can reduce the endocytosis of CRFR1 (Dunn et al., 2016). The
study also provide a mechanism for this regulation presented by a negative effect of PSD95 on β-arrestin recruitment. The role of PSD-93 (DLG2) is not fully characterized yet.
Reports indicate that PSD-93 and PSD-95 can compensate for one another and hence it is
suggested they have similar functions (Sun and Turrigiano, 2011).
SAP102 (DLG3) is another understudied member of the DLGs subfamily. It has an
effect on the adenosine A2A receptor since it can regulate the mobility of the receptor and
enhance ERK1/2 activation by the receptor (Thurner et al., 2014). Further studies are
required to fully assess and understand the function of SAP102 in regulating GPCRs.
DLG5 has some differences in topology compared to the other four members of the
subfamily. It contains four PDZ domains as opposed to three domains in the other proteins.
It also contains a caspase activation and recruitment domain (CARD) at the amino terminal
that is not present in any of the other DLGs (de Mendoza et al., 2010). There are no reports
that suggest a direct role for DLG5 in regulating GPCRs function. However, it can scaffold
PKC isoforms which might be a mechanism for mediating GPCRs signaling.

1.5.3

PDZ Proteins Network
The previous section highlighted the role that PDZ domain-containing proteins

have in regulating different functions of GPCRs including their internalization, recycling,
degradation and signaling. However, another important aspect that should always be
considered when studying PDZ proteins is the interplay between the different proteins
themselves. Bearing in mind the similar domains that PDZ proteins possess and their
overlapping functions, there is a possibility for these proteins to either have
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“complementary” effects or “competitive” effects. This also provides a possible
explanation for the observation that one receptor can be mediated by multiple PDZ
proteins.
A recent example that illustrates a complementary effect is the regulation of the
somatostatin receptor subtype 5 (SSTR5) by PDZ proteins (Bauch et al., 2014). The
trafficking of the receptor was studied and it appears that CAL, SNX27 and NHERF1 are
involved in mediating the different steps to determine the subcellular distribution and
membrane availability of the receptor. The data demonstrate that the receptor’s interaction
with SNX27 can drive the trafficking pathway away from lysosomal targeting and towards
the recycling pathway (Bauch et al., 2014). It also shows that while CAL overexpression
leads to the retention of SSTR5 in the Golgi, NHERF1 can reverse this effect and is able
to release the receptor and enhance its trafficking to the cell surface. The study also
suggests that the protein interacting with C kinase 1 (PICK1), a fourth PDZ protein, and
SNX27 act antagonistically to mediate receptor recycling. This is an example showing that
PDZ proteins can perhaps sequentially perform their function depending on the stage of
receptor trafficking. Another study on β1-AR demonstrated that PSD-95 can antagonize the
intracellular retention of β1-AR upon CAL overexpression and restore plasma membrane
expression (Koliwer et al., 2015).
A similar observation is reported between CAL and two other PDZ proteins when
the transmembrane protein Cadherin 23 is investigated (Xu et al., 2010). Overexpression
of CAL can lead to the retention of Cadherin 23 in the transgolgi network and hence to a
reduction in plasma membrane expression. This effect is reversed by MAGI-1 as well as
harmonin.
In addition to the regulation of trafficking, the interplay between PDZ proteins can
be important for regulation of GPCR signaling. It has been shown that NHERF2 and
MAGI-3 can compete for binding to LPA2R and this can bias the signaling of the receptor
(Lee et al., 2011). The study shows that MAGI-3 can increase the coupling of Gα12/13 to
LPA2R and hence decrease PLC activation while NHERF2 promotes the coupling of Gαq
to the receptor resulting in an enhancement in PLC activity. Therefore, MAGI-3 and
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NHERF2 exhibit opposite effects on LPA-induced PLC activity by differentially regulating
G protein coupling.
A similar role of PDZ proteins in regulating GPCRs signaling resulting in bias from
one pathway to another was reported with the Parathairoid Hormone receptor 1 (PTH1R).
The study showed that NHERF1 can bias signaling from activating adenylyl cyclase to
activating PLCβ. In addition, NHERF1 was shown to interfere with β-arrestin recruitment
to PTH1R and hence reduce receptor internalization (Mahon et al., 2002).
An example for a compensation effect between PDZ proteins is between PSD-93
and PSD-95 (Sun and Turrigiano, 2011). Double knockout studies show a functional
compensation between PSD-95 and PSD-93 during scaling up in young cortical neurons.

1.6 G Protein-Coupled Receptors and Disease
In addition to being involved in regulating all physiological processes from
neurotransmission and cardiovascular function to inflammation, metabolism and endocrine
function, dysregulation or dysfunction of GPCRs has been associated with a broad range
of pathological conditions. This is not surprising given their regulation of all physiological
processes as well as their wide distribution in the different organs of the body. These
conditions include neurological and cardiovascular disorders, renal and pulmonary
diseases, immunological diseases, pain and cancer.
One important example that has been well studied would be heart diseases. There
are approximately 200 members of the GPCR superfamily that have been shown to regulate
heart function (cardiac GPCRs) (Salazar et al., 2007). However, most of the drugs used to
treat heart problems act on the angiotensin and adrenergic receptors. These available drugs,
although improving the quality of life for patients, still have their limitations since they
show major side effects in some cases due to off target effects or the ubiquitous distribution
of the receptors in organs other than the heart. To produce better drugs with fewer side
effects, further characterization of GPCRs, their assembly into signaling complexes, their
interacting partners as well as their trafficking from the endoplasmic reticulum to the cell
surface is required to establish a complete understanding of the key factors in the processes.
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The example that is going to be the focus for this project is psychiatric disorders.
The role of GPCRs in regulating neurotransmission and the function of the central nervous
system has been well documented. The two families that demonstrate crucial effects on
synaptic transmission, synapse formation, axon guidance and development of neuronal
circuits are Rhodopsin and Glutamate. Rhodopsin family GPCRs have this role because
they are the main molecular targets for various neurotransmitters such as serotonin,
dopamine, acetylcholine, histamine, adrenaline and norepinephrine and neuropeptides such
as somatostatin, melanocortins, neuropeptide Y and neuropeptide FF. The same reason
applies for Glutamate receptors being the target for glutamate which represent the principal
excitatory neurotransmitter of the CNS.
A common disorder that has been associated with mGluR activation is Fragile X
mental retardation (FMR) where it has been suggested that FMR results from unbalanced
activation of Group I mGluRs and impaired synaptic maturation. mGluRs have also been
associated with dementia and Alzhiemer’s disease (Bear, 2005; Yan et al., 2005).
As for the rhodopsin family, the 5-HT2C receptor has been shown to play an
essential role in the regulation of mood and alteration of its functional activity has been
implicated in the etiology of anxio-depressive states (Millan et al., 2005). Therefore, it has
been targeted by antidepressants as a therapeutic approach. 5-HT2CR is not the only 5-HTactivated receptor to be implicated in mood disorders and have antidepressants actions.
Dopamine signaling via D1 and D2 receptors plays a key role in schizophrenia and
blocking dopamine D2 receptors with any antipsychotic drug is thought to alleviate
positive symptoms, but not sufficiently address negative symptoms and cognitive deficits
(Meltzer et al., 1989). The A2a receptor plays an important role in modulation of
dopaminergic and glutamatergic neurotransmission and has been used as a target for the
treatment of drug addiction, anxiety and depression (Komatsu, 2015).
Recently, some attention is being directed toward the role of adhesion GPCRs in
regulating neurotransmission (Stephenson et al., 2014). For example, studies show effects
of GPR56 on regulating brain development and brain-specific angiogenesis inhibitor (BAI)
subfamily in mediating synaptogenesis. Another examples is GPR88 since the knockout
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mouse model for this receptor shows abnormal behaviors associated with schizophrenia
such as disrupted sensorimotor gating and impaired learning and bipolar disorder (Logue
et al., 2009; Quintana et al., 2012; Komatsu, 2015).

1.6.1

Mental Disorders
Depression and Anxiety are co-morbid disorders that associate with stressful events

(Anisman et al., 2008). According to Health Canada and Statistics Canada, 10-15% of
Canadians are affected by depression and anxiety, and females are at higher risk since the
number of women affected is doubled compared to men. Also, anxiety and depression are
the leading causes of disability in females and the second cause generally just after
ischemic heart disease (Nemeroff and Owens, 2004). The causes of depression and anxiety
vary to include genetic determinants and environmental factors, but early life experiences
and the effect of the environment seem to be more crucial, especially in the progression of
the disease. There are some drugs available for the relief of symptoms associated with
depression and anxiety. Despite being regularly prescribed to patients, these drugs still
have limitations with the onset of action, response, remission rates, and side-effect profiles,
especially that they are only effective in 50% of patients. These medications include
serotonin 2A receptor (5-HT2AR) antagonists, CRF receptor 1 (CRFR1) antagonists,
selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants and monoamine
oxidase inhibitors (Marek et al., 2003; Holtzheimer and Nemeroff, 2006).
Two of the major molecules implicated in these disorders are the corticotropinreleasing factor (CRF) and serotonin (5-HT). CRF is known to regulate physiological
responses in anxiety states and behavioral mechanisms of defense and it can trigger some
changes in the other neurotransmitter systems such as serotonergic signaling (Macri et al.,
2007). Serotonin is also important in the central nervous system (CNS) and it modulates
the etiology of anxiety and the response to anxiolytic drugs via its different receptors
(Holmes et al., 2003; Holsboer, 2003). Different members of the serotonin receptors family
are used as targets for the treatment of brain-related disorders such as schizophrenia,
depression, anxiety, eating disorders and obesity (Roth et al., 2004). These two
neurotransmitters elicit their effects via acting on their corresponding G protein-coupled
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receptors. CRF activates two receptors, CRFR1 and CRFR2 while serotonin receptors form
a bigger family with 15 members. Among these GPCRs, 5-HT2AR and CRFR1 have been
directly associated with anxiety behaviours (Magalhaes et al., 2010). Also, the role of 5HT2AR and CRFR1 in modulating anxiety and depression is clear given that the currently
available drugs act directly or indirectly on these receptors.

1.6.2

Targeting Protein- Protein Interactions as a Pharmacological
Tool
An increasing number of neurological and psychiatric disorders have been found to

result from an alteration in the interaction between a GPCR and GPCR-interacting protein.
This can provide new tools for therapeutic intervention. Many studies that investigated the
association between GPCRs and diseases conclude that sometimes it is these interactions
between the receptor and a specific protein that could be causing the problem (Bockaert et
al., 2010). For example, it has been demonstrated that the interaction of Homer protein
with mGluRs is associated with schizophrenia and anxiety (Norton et al., 2003; Szumlinski
et al., 2005). Similarly, the interaction of Shank proteins and specifically Shank3 with
mGluRs and somatostatin SSTR2 receptor is associated with autism (Durand et al., 2007).
In addition, the interaction between mGluR7 and PICK1 (protein interacting with C kinase
1) is implicated with neurological disorders like epilepsy and in fact, in vivo studies showed
that injecting rats and mice with a cell permeable mimetic peptide to specifically disrupt
this interaction display a phenotype characteristic of absence epilepsy (Bockaert et al.,
2010).
Serotonin receptors were the focus of many similar studies as well. It is suggested
that targeting the interaction between 5-HT2C receptor and PTEN (protein phosphatase and
tensin homolog) might be an effective strategy for the treatment of addiction-related
behaviors, with perhaps less pronounced side effects than 5-HT2C agonists (Ji et al., 2006).
Other proteins with important associations with the serotonin receptors are the PDZ
domain-binding proteins. Proteins like PSD-95 and MAGUK p55 subfamily member 3
(MPP3) can mediate receptors desensitization and internalization (Gavarini et al., 2006).
Therefore, targeting 5-HTR-PDZ protein interactions can be an attractive strategy to
develop new drugs that may improve the therapeutic efficacy of antidepressants. P11 (also
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called S100A10 or calpactin 1 light chain or annexin 2 light chain) is another important
interactor with 5-HT receptors (Svenningsson et al., 2006; Warner-Schmidt et al., 2009).
The interaction between p11 and 5-HT1B receptors is implicated in the response of
Parkinson’s disease patients to L-DOPA treatment. It is also suggested to be involved in
the anxiolytic effects of 5-HT1B and 5-HT4 receptors (Bockaert et al., 2010).

1.7 Corticotropin Releasing Factor Receptors
This family consists of two Class B GPCRs; CRFR1 and CRFR2. They are both
activated by CRF and although they share 71% sequence homology, CRFR1 has ten-fold
higher affinity for CRF than CRFR2 (Dautzenberg and Hauger, 2002). CRF is released in
response to stress and it regulates the secretion of adrenocorticotropin (ACTH) from the
anterior pituitary gland. In addition to anxiety and depression, CRF receptors are also
known to regulate cardiovascular and inflammatory processes since they were shown to
play a role in cardio-protection against ischemia reperfusion injury (Brar et al., 2004) and
in the regulation of IL-18 expression.
The tissue distribution of CRFR1 and CRFR2 is also different. CRFR1 is expressed
widely in the brain (neocortex and cerebellum) and pituitary, while CRFR2 is usually found
in the heart and skeletal muscle (Chalmers et al., 1995; Dautzenberg and Hauger, 2002).
Also, CRFR1 has a PDZ-binding motif on the carboxyl-terminal tail composed of three
amino acids; threonine, alanine and valine (TAV), while CRFR2 does not (Myers et al.,
1998; Chen et al., 2005). Upon CRF activation, both receptors mainly signal via coupling
to Gαs to activate adenylyl cyclase resulting in the formation of cAMP. Interestingly, this
cAMP pathway plays a central role in amplifying and diversifying the signaling pathways
activated by CRF receptors. cAMP formation results in the activation of PKA and this leads
to the activation of diverse downstream signaling molecules including membrane guanylyl
cyclase, the NF-kB transcription factor, glycogen synthase kinase-3 and the Wnt/β-catenin
pathway, ERK1/2, tyrosine hydroxylase and ion channels (Haug and Storm, 2000;
Aggelidou et al., 2002; Kovalovsky et al., 2002; Zhao and Karalis, 2002; Facci et al., 2003;
Nemoto et al., 2005; Khattak et al., 2010). One of these important signaling pathways is
the MAPK pathway. Studies show that PKA activation can have opposite effects on
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ERK1/2 signaling depending on the tissues or type of cells investigated. For example, in
the hippocampus, neuronal cells or pituitary, PKA activation leads to enhanced ERK1/2
phosphorylation, while in the myometrium, endometrial adenocarcinoma and breast
cancer, PKA activation via CRF results in the inhibition of ERK activity (Elliott-Hunt et
al., 2002; Kovalovsky et al., 2002; Graziani et al., 2007) (Fig. 1.4).

1.8 Serotonin Receptors
This family consists of 7 receptor types and 15 subtypes that belong to Class A
GPCRs (except for 5-HT3Rs which are ligand-gated ion channels). Serotonin receptors are
involved in the modulation of sleep-wake cycles, appetite, mood, memory, breathing,
cognition and sexual behavior (McCorvy and Roth, 2015). Serotonin has been the focus of
many pharmacological studies for the treatment of neuropsychiatric disorders with drugs
that target either the serotonin receptors or serotonin reuptake. Examples include serotoninselective reuptake inhibitors (SSRIs), dual serotonin-norepinephrine reuptake inhibitor
(SNRI) and partial agonist or antagonist for the serotonin receptors.
The 5-HT1 subfamily consists of 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F and
mainly couples to Gαi resulting in the inhibition of the activity of adenylyl cyclase and
reduction in cAMP formation. 5-HT1AR has been implicated in anxiety and depression
while the other subtypes have been associated with migraine.
5-HT2 subfamily consists of three subtypes; 5-HT2A, 5-HT2B and 5-HT2C. The
family mainly couples to Gαq for the activation of phospholipase C (PLC) which
hydrolyzes the phosphatidylinositol diphosphate releasing diacylglycerol (DAG), protein
kinase C (PKC) and inositol triphosphate (IP3). This also leads to the release of Ca2+ from
intracellular stores (Roth et al., 2004; Gray and Roth, 2001). 5-HT2AR has been suggested
to be a good target for the treatment of a number of mental illnesses including
schizophrenia, depression, and Tourette’s syndrome given its high levels in the cortex
(Meltzer and Roth, 2013). Similarly, 5-HT2CR is ubiquitously distributed in the CNS and
has been shown to regulate dopamine release upon treatment with antidepressants
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Figure 1.4: Signaling pathways activated by CRFR1: CRFR1 couples mainly to Gαs to
stimulate Adenylyl Cyclase (AC) leading to the formation of cAMP. It can also signal via
the MAPK pathway to activate ERK1/2 phosphorylation.
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(Mengod et al., 1996; Millan et al., 2005). Little is known about the 5-HT2BR other than
being unselectively activated by 5-HT2A and 5-HT2C receptor ligands. There is also some
evidence to support that 5-HT2B activation can result in cardiac hypertrophy.
5-HT4 receptors couple to Gαs to activate AC leading to cAMP release. They are
expressed in different tissues and therefore their activation can result in variable effects
such as long-term potentiation (LTP) in hippocampus and peristalsis in the gut (McCorvy
and Roth, 2015). It has been suggested that blocking the receptor with selective 5-HT4R
antagonists can be useful in the treatment of atrial fibrillation, irritable bowel syndrome,
and urinary incontinence.
Similar to 5-HT1, 5-HT5 receptors couple to Gαi. The family has two subtypes; 5HT5A and 5-HT5B that have been associated with psychiatric disorders but have not been
used as pharmacological targets (Thomas, 2006). Both 5-HT6 and 5-HT7 receptors, are
Gαs-coupled and expressed in the CNS (thalamus, hypothalamus and hippocampus) and
peripheral tissues. Similar to the rest of serotonin receptors, they have been proposed as
targets for the treatment of depression (McCorvy and Roth, 2015).
Among these serotonin receptor subtypes, the most ubiquitous and extensively
studied serotonin receptors in the human brain are the 5-HT1AR and 5-HT2AR. These
receptors have been shown to have potential roles in different neuropsychiatric diseases
such as Alzheimer’s disease, Schizophrenia, depression and suicide (Burnet et al., 1995).
This project particularly focuses on 5-HT2AR which is expressed in the neocortex (mainly
prefrontal, parietal, and somatosensory cortex). It is involved in the modulation of mood
and perception (Hall et al., 2000). Similar to the CRFR1, the 5-HT2AR has a PDZ-binding
motif at the carboxyl-terminal tail formed by three amino acids; serine, cysteine and valine
(SCV). Furthermore, in addition to coupling to Gαq for the activation of PLC, it can activate
the MAPK pathway resulting in ERK1/2 phosphorylation (Fig. 1.5).
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Figure 1.5: Signaling pathways activated by 5-HT2AR: 5-HT2AR couples mainly to Gαq
to stimulate phospholipase Cβ (PLCβ) leading to the hydrolysis of phosphatidylinositol4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3).
IP3 results in the release of Ca2+ from intracellular stores while DAG activates PKC. It can
also signal via the MAPK pathway to activate ERK1/2 phosphorylation.
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1.9 Corticosteroid-Serotonin Interactions
The studies on stress-related disorders such as depression have revealed that the
two main systems involved are the Hypothalamo-Pituitary-Adrenal (HPA) Axis and the
monoaminergic system and in particular the serotonergic (5-hyroxytryptamine) system.
Studies show cross-regulation of the HPA axis and 5-HT system under normal
physiological conditions, as well as pathological conditions.

1.9.1

Hypothalamo-Pituitary-Adrenal (HPA) Axis
The Hypothalamo-Pituitary-Adrenal (HPA) Axis is a neuroendocrine system that

is responsible for regulating the stress response to restore homeostasis (Macri et al., 2007;
Pompili et al., 2010). When the body is exposed to a stressor, the paraventricular nucleus
(PVN) of the hypothalamus releases corticotrpoin-releasing hormone (CRH) and argininevasopressin (AVP). CRH and AVP activate the anterior pituitary gland to release
adrenocorticotropin hormone (ACTH). ACTH which is secreted into the circulation
stimulates the adrenal cortex to produce glucocorticoids. These are represented by the
secretion of cortisol in human and corticosteroids in rodents. These hormones can control
the response via a negative feedback mechanism by activating glucocorticoid receptor
(GR) in the adrenal cortex, anterior pituitary gland, hypothalamus and hippocampus
(Lanfumey et al., 2008; Pompili et al., 2010). Many reports demonstrate the effect that the
serotonin system has on the release of corticosteroids. One example is the increase in
ACTH and cortisol levels upon administration of 5-HT1A agonists. Other studies show that
5-HT acts via synaptic contacts between the serotonergic terminals and CRH-containing
cells in the PVN (Liposits et al., 1987). This is demonstrated when the activation of 5-HT1A
receptors on the PVN results in the secretion of ACTH (Lanfumey et al., 2008).

1.9.2

Serotonergic System
The serotonergic network is one of the most important systems in the brain, since

the serotonergic neurons project to all parts of the CNS (Macri et al., 2007; Lanfumey et
al., 2008; Pompili et al., 2010). One of these main structures is the hippocampus which
receives many 5-HT projections from the neurons in the raphe nucleus. Therefore, different
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5-HT receptor types are expressed in the hippocampus. The serotonin system can regulate
variable functions such as food intake, learning and memory, thermoregulation,
locomotion, cardiovascular function, sleep, endocrine regulation and sexual behavior.
Studies demonstrate that the activation of HPA axis can result in a significant increase in
the synthesis and production of 5-HT.

1.10

Hypothesis and Objectives
The previous section highlighted that there is plenty of evidence to support the

interaction between the HPA axis and the serotonergic system. Interestingly, a recent study
from our laboratory illustrates a crosstalk between the two systems at the receptor level.
The study demonstrates a sensitization effect of 5-HT2AR signaling upon pretreatment with
CRF (Magalhaes et al., 2010). The study also proposes that this phenomena is dependent
on the internalization and trafficking pathways of both receptors and suggests the
involvement of a PDZ protein as a key regulator for this crosstalk. The role of PDZ proteins
in regulating GPCRs function has been the focus of many studies in the last decade which
confirms their significance and the important roles they play in that field. However, many
interactions remain to be characterized to gain better understanding of the role of PDZ
proteins in regulating GPCRs activity. Achieving complete characterization of PDZGPCRs interactions can provide an interesting pharmacological tool to develop more
specific drugs. Targeting protein-protein interactions that are involved in pathological
conditions is a challenging, yet very attractive, concept and focusing on the domains that
mediate these interactions (such as PDZ domains) should be the priority. Such drugs will
be very selective compared to agonists/antagonists of receptors and will therefore have
fewer side effects. In order to be able to assess the effects of different PDZ proteins on the
crosstalk between CRFR1 and 5-HT2AR, we would have to first study these effects on each
receptor separately. The PDZ proteins that this project focuses on are CAL, MAGI-1,
MAGI-2 and MAGI-3. The MAGI proteins have been shown to regulate synaptic function
and have effects on learning and memory. CAL on the other hand has not been shown to
be associated with mental disorders, but it is expressed in multiple regions of the brain
including the cortex, hypothalamus and hippocampus which suggests a role that still needs
to be explored.
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Our HYPOTHESIS is that MAGI and CAL PDZ domain-containing proteins can
differentially regulate the activity of GPCRs. The objectives are to determine the role of
our PDZ proteins of interest in regulating the trafficking and signaling of CRFR1 and 5HT2AR. The three main aims for this project are:
1. To determine the role of CAL in regulating the trafficking and
signaling of CRFR1 and the mechanism for this regulation

2. To determine the role of MAGI proteins in regulating the trafficking
and signaling of CRFR1 and the mechanism for this regulation

3. To determine the role of MAGI proteins in regulating the trafficking
and signaling of 5-HT2AR and the mechanism for this regulation

We use Human Embryonic Kidney 293 (HEK 293) cells to test the effects of
overexpressing or knocking down the PDZ proteins of interest. We use coimmunoprecipitation and immunofluorescent microscopy to assess the interactions
between the receptors and PDZ proteins. We employ flow cytometry assays to assess the
trafficking and internalization of receptors. We examine the effects of PDZ proteins on
GPCR signaling by BRET-based assays for cAMP formation, scintillation proximity
assays for IP formation and western blotting for ERK1/2 activation.
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Chapter 2

2

Role of CAL in regulating CRFR1 activity

A version of this chapter has been published in the Journal of Cellular Signaling
Hammad, M.M., Dunn, H.A., Walther, C., and Ferguson, S.S., (2015). Role of cystic
fibrosis transmembrane conductance regulator-associated ligand (CAL) in regulating the
trafficking and signaling of corticotropin-releasing factor receptor 1. Cell. Signal. 27 ,
2120-2130.
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2.1 Introduction
Corticotropin-releasing factor (CRF) is a 41 amino acid polypeptide that is secreted
from the paraventricular nucleus of the hypothalamus in response to stress subsequently
leading to the activation of the hypothalamic-pituitary-adrenal axis (HPA axis) (Vale et al.,
1981; Arzt and Holsboer, 2006). CRF activates two Class B G protein-coupled receptor
(GPCR) subtypes, CRFR1 and CRFR2, which are widely expressed in the brain (neocortex
and cerebellum) and pituitary (Chalmers et al., 1995; Palchaudhuri et al., 1998). CRF can
regulate the endocrine response to stress by triggering the anterior pituitary gland to release
adrenocorticotropin hormone (ACTH) into circulation. ACTH then stimulates the secretion
of glucocorticoids from the adrenal cortex. Glucocorticoids regulate various functions both
in the central nervous system (CNS) and at the periphery (Lanfumey et al., 2008). In
addition, studies have shown a link between pathophysiological changes in the CRF system
and various neuropsychiatric disorders such as major depression, panic disorder, anorexia
nervosa, and Alzheimer's disease (Behan et al., 1996; Lanfumey et al., 2008). CRFRs are
primarily coupled to Gαs for the activation of adenylyl cyclase leading to the formation of
cyclic adenosine monophosphate (cAMP) (Chalmers et al., 1996) as well as the mitogen
activated protein kinase (MAPK) signaling pathway (Kageyama et al., 2007).
GPCRs can interact with a wide range of different proteins that control the
trafficking, cell surface expression and signal transduction. Examples of these proteins
include: β-arrestins, GPCR-associated sorting proteins (GASPs), small GTPases and
PSD95/Disc Large/Zona Occludens (PDZ) proteins (Magalhaes et al., 2012). Many
GPCRs, including CRFR1, encode a short class I PDZ domain recognition motif (S/T-x-ϕ,
where ϕ is any aliphatic amino acid residue) at the end of the carboxyl-terminal tail. PDZ
proteins are comprised of one or more 90 amino acid residue protein interaction domains
that are thought to scaffold signaling complexes (Lee and Zheng, 2010; Romero et al.,
2011). PDZ proteins function to regulate the subcellular localization, trafficking and signal
transduction of multiple GPCRs and different PDZ proteins have both overlapping and
distinct roles in the regulation of GPCR activity (Harris and Lim, 2001; Lee and Zheng,
2010; Romero et al., 2011; Magalhaes et al., 2012).
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It is now recognized that PDZ proteins have distinct functions depending upon the
particular GPCR with which they are associated. For example, MUPP1 interactions
enhance GABAB receptor signaling (Balasubramanian et al., 2007), whereas MUPP1
functions to uncouple the melatonin-1 receptor from Gαi (Guillaume et al., 2008) and
facilitates resensitization of the 5-HT2CR (Parker et al., 2003). In the case of the β1adrenergic receptor (β1-AR), MAGI-2 has been shown to promote β1-AR internalization,
whereas MAGI-3 selectively attenuates β1-AR-mediated ERK1/2 signaling (Xu et al.,
2001; He et al., 2006). In contrast, PSD-95 inhibits the internalization of β1-AR and
facilitates the formation of β1-AR heterodimer with N-methyl-D-aspartate receptors (Hu et
al., 2000). SAP97 functions to antagonize the internalization of both CRFR1 and 5-HT2AR,
whereas PDZK1 reduces the extent of 5-HT2AR internalization, but has no significant effect
on the endocytosis of CRFR1 (Dunn et al., 2013; Dunn et al., 2014; Walther et al., 2015).
Although SAP97 regulates GPCR ERK1/2 signaling in a receptor-interaction independent
manner, PDZK1 overexpression increases CRFR1- but not 5-HT2AR-mediated ERK1/2
activity.
The Golgi-localized cystic fibrosis transmembrane conductance regulatorassociated ligand (CAL) is a single PDZ domain-containing protein with two coiled-coil
motifs and two evolutionally conserved regions which are required for its Golgi
localization (Charest et al., 2001; Yao et al., 2001; Cheng et al., 2002). CAL is also known
as GOPC, PIST and FIG. CAL overexpression reduces the cell surface expression of the
β1-AR and mGluR1a by retaining the receptor inside the cell via a direct interaction (He et
al., 2004; Zhang et al., 2008). CAL interacts with mGluR5a and stabilizes receptor
expression by a mechanism that is proposed to involve the inhibition of ubiquitinationdependent degradation (Cheng et al., 2010). CAL also contributes to the regulation of
somatostatin receptor recycling and degradation (Wente et al., 2005; Bauch et al., 2014).
In the present study, we have identified CAL as a protein that interacts with CRFR1.
We find that CAL overexpression leads to the retention of CRFR1 in the Golgi apparatus
and alters the post-translational N-glycosylation status of the receptor, suggesting that CAL
negatively regulates the anterograde transport of CRFR1 from the ER-Golgi to the plasma
membrane surface. We also find that CAL knockdown enhances ERK1/2 phosphorylation
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in response to CRFR1 activation, but that CAL expression does not influence cAMP
signaling. Taken together, our results indicate that CAL interactions with CRFR1 play an
important role in regulating the maturation and cell surface expression of CRFR1.
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2.2 Materials and Methods
2.2.1

Materials

Protein G beads were purchased from GE Healthcare (Oakville, ON, Canada). CRF was
purchased from R&D Systems (Minneapolis, MN, USA). HA peroxidase high affinity
antibody was purchased from Roche (Mississauga, ON, Canada). Rabbit anti-GFP
antibody was obtained from Invitrogen/Life Technologies (Burlington, ON, Canada). ECL
Western blotting detection reagents were purchased from Bio-Rad (Mississauga, ON,
Canada).

Alexa

Fluor

647

anti-mouse

IgG

antibody

was

purchased

from

Invitrogen/Molecular Probes (Burlington, ON, Canada). Rabbit CAL antibody was
purchased from Abcam (Toronto, ON, Canada). Rabbit anti-phospho-p44/42 MAP kinase
(Thr202/Tyr402), and rabbit anti-p44/42 MAP kinase antibodies were obtained from Cell
Signaling

Technology

(Pickering,

ON,

Canada).

Mouse

anti-HA

antibody,

endoglycosidases F and H and all other biochemical reagents were purchased from SigmaAldrich (Oakville, ON, Canada).

2.2.2

Plasmids

HA-CRFR1 and HA-CRFR1-ΔTAV were described previously (Holmes et al., 2006;
Magalhaes et al., 2010). Human CAL was kindly provided by Dr. Randy Hall (Emory
University, School of Medicine). The CAL cDNA was subcloned into the expression
vector pEYFP-N1. CAL siRNA (Hs_GOPC_3) GCUGCAGCUUCAUGCUAAATT was
purchased from Qiagen (Toronto, ON, Canada). For the negative controls, we used Silencer
Negative Control #1 AM4635 AGUACUGCUUACGAUACGGTT from Invitrogen
(Burlington, ON, Canada). The exchange proteins directly activated by cAMP biosensor
(EPAC) was a gift from Drs. Ali Salahpour (University of Toronto) and Marc Caron (Duke
University) (Barak et al., 2008). TGN-CFP was kindly provided by Dr. Stephen Pasternak
(University of Western Ontario). Site-directed mutagenesis was used to introduce N to Q
in the following constructs: CRFR1 N38Q, CRFR1 N78Q, CRFR1 N90Q and CRFR1
N98Q and mutations were confirmed by sequencing.
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2.2.3

Cell culture and transfection

Human embryonic kidney (HEK 293) cells were grown in Eagle's minimal essential
medium supplemented with 10% fetal bovine serum. Cells were plated on 10-cm dishes
24h prior to transfection. All experiments were performed on 75–80% confluent plates.
Transfections were performed using calcium phosphate protocol except for siRNA
transfections which were performed using Lipofictamine 2000 following manufacturer's
instructions. Transfections were performed with 1 μg of each construct. Empty pcDNA3.1
vector was used to equalize the total amount of plasmid cDNA used to transfect cells. 18h
post transfection, cells were washed with phosphate-buffered saline (PBS) and
resuspended with trypsin, 0.25% EDTA. Experiments were performed approximately 48h
after transfection except for knockdown experiments which were performed 72h post
transfection since this protocol resulted in the maximum knockdown of CAL.

2.2.4

Co-immunoprecipitation

24h after transfection, HEK 293 cells were seeded onto 10-cm dishes. Cells were starved
with HBSS for 1h at 37 °C then stimulated with 100 nM CRF agonist for 30 min. Cells
were then lysed in 500 μL lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1%
Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 μg/ml leupeptin, and 2.5
μg/ml aprotinin) for 20 min on a rocking platform at 4 °C. Samples were collected into 1.5
ml Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4 °C to pellet insoluble
material. A Bradford protein assay was performed, and 150 μg of protein was incubated
for 2–4h at 4 °C with protein G-Sepharose and mouse anti-HA antibody (1:50). Beads were
washed three times with cold lysis buffer and incubated overnight at room temperature in
3xSDS loading buffer containing 2-mercaptoethanol. Samples were separated by SDSPAGE, transferred to a nitrocellulose membrane, and western blots were then performed
with the indicated antibodies (rabbit anti-GFP, 1:10000), (HA-POD, 1:1000).

2.2.5

Confocal microscopy

HEK 293 cells were co-transfected with HA-CRFR1, CAL-YFP and TGN-CFP in 10-cm
dishes and 24h after transfection, cells were reseeded onto glass coverslips. 24h later, cells
were washed with HBSS, fixed with 4% paraformaldehyde in PBS, and permeabilized with
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0.5% Triton X-100 in PBS for 5 min at room temperature. After rinsing with PBS, cells
were blocked with 5% donkey serum in PBS for 1h at room temperature then labeled with
mouse HA antibody (1:1000) for 1h at room temperature. The reaction proceeded by
incubation with a secondary antibody, donkey anti-mouse Alexa Fluor 647 (1:1000) for 1h
at room temperature. Coverslips were mounted on slides using Pro- Long Gold Antifade
Reagent. Confocal microscopy was performed using a Zeiss LSM510 META laserscanning confocal microscope equipped with a Zeiss 63X, 1.4 numerical aperture, oilimmersion lens.

2.2.6

Receptor endocytosis

Following transfection, HEK 293 cells were re-seeded into 12- well plates. Cells were
serum-starved in HBSS for 1h at 37 °C then stimulated for 0, 30 or 60 min with 500 nM
CRF in HBSS at 37 °C. Cells were washed with cold HBSS and incubated with mouse
anti- HA antibody (1:1000) for 1h on ice. Cells were washed with cold HBSS then labeled
with Alexa Fluor 647 donkey anti-mouse IgG (1:1000) for 1h on ice in the dark. Cells were
washed with cold HBSS and treated with 5 mM EDTA in PBS for 5 min on ice. Cells were
collected and transferred to flow cytometry tubes containing 4% formaldehyde in PBS.
Samples were run on a FACS Calibur cytometer using BD Cell Quest Pro software (BD
Biosciences, Mississauga, ON, Canada) until 10,000 cells were counted. The geometric
mean of fluorescence was determined using Flow Jo analysis software and was
representative of the expression levels of the receptor on the plasma membrane (BD
Biosciences, Mississauga, ON, Canada).

2.2.7

Bioluminescent Resonance Energy Transfer-based biosensor
cAMP assay

HEK 293 cells were co-transfected with HA-CRFR1 (WT or ΔTAV) and either pcDNA3.1,
CAL, scrambled (SCR) siRNA or CAL siRNA as well as 2 μg of an EPAC (exchange
proteins directly activated by cAMP) construct in 10-cm dishes. 48h post-transfection, cells
were re-seeded into 96-well plate (~10,000 cells/well) and left for another 24h. On the
following day, cells were serum-starved for 1h in induction buffer (200 μM isobutyl-1methylxanthine (IBMX) in HBSS). Coelenterazine was then added to the wells at a final
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concentration of 5 μM. Cells were then stimulated with increasing concentrations of CRF
peptide for 10 min. The plate was then read by a Victor Plate Reader (Perkin-Elmer) and
the BRET signal was determined by calculating the ratio of the light emitted at 505 to 555
nm to the light emitted at 465 to 505 nm.

2.2.8

ERK phosphorylation

Following 48h of transfection, HEK 293 cells were re-seeded into 6- well plates. Cells were
serum starved for 1h at 37 °C in HBSS and then stimulated with 500 nM CRF agonist for
0, 5 and 15 min. Cells were lysed with lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl,
and 1% Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 μg/ml leupeptin,
and 2.5 μg/ml aprotinin) and phosphatase inhibitors (10 mM NaF and 500 μM Na3VO4)
for 20 min on a rocking platform at 4 °C. Samples were collected into 1.5 ml Eppendorf
tubes and centrifuged at 15,000 g for 15 min at 4 °C to pellet insoluble material. A Bradford
protein assay was performed, and 30–50 μg of protein was incubated overnight at room
temperature in 3xSDS loading buffer containing 2-mercaptoethanol. Samples were
separated by SDS-PAGE, transferred to a nitrocellulose membrane, and western blot
analysis was performed for ERK1/2 (rabbit anti-p44/42MAPK, 1:1000), phospho-ERK1/2
(rabbit anti-phospho-p44/42 MAPK, 1:1000), CAL-YFP (rabbit CAL, 1:1000), HACRFR1 (HA-POD, 1:1000), and actin.

2.2.9

Western blot analysis

75–90 μl of the samples from the different assays which is equivalent to about 30–50 μg
of protein was diluted in β-mercaptoethanol containing 3x loading buffer and then applied
to 10% SDS-PAGE (30% acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10% ammonium
persulfate and TEMED). Separated proteins were then transferred to nitrocellulose
membranes and membranes were then blocked in 10% milk in TBS for 1h. Membranes
were then blotted overnight by incubation with the appropriate antibody at 4 °C. 24h later
membranes were washed at least three times with 1X TBS with 0.05% Tween 20, and then
incubated with a horseradish peroxidase- conjugated secondary antibody (1:10,000) for 1h.
Membranes were finally washed again with 1X TBS with 0.05% Tween 20 three times
before being developed using a BioRad chemiluminescence system.
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2.2.10

Statistical analysis

All measurements are represented as mean ± SEM. Comparisons were performed using
one way analysis of variance test (ANOVA) followed by Bonferroni's or Dunn's Multiple
comparisons test to determine significance. The symbol * indicates P values less than 0.05
and is considered to be significant.
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2.3 Results
2.3.1

CAL interacts with CRFR1 in a PDZ-binding motif-dependent
manner

CAL is a PDZ domain-containing protein that was previously shown to interact with the
β1-AR and Group I mGluRs (He et al., 2004; Zhang et al., 2008; Cheng et al., 2010). We
previously identified CAL as one of several PDZ domain-containing proteins that interact
with a GST fusion of the CRFR1 carboxyl-terminal tail (Dunn et al., 2013). To further
validate this potential interaction between CAL and CRFR1, we performed coimmunoprecipitation experiments with CAL-YFP and either wild-type HA-tagged CRFR1
(HA-CRFR1) or a HA-tagged CRFR1 mutant that lacked a class I PDZ-binding motif (HACRFR1-ΔTAV) in transiently transfected HEK 293 cells. We found that CAL-YFP was
co-immunoprecipitated with HA-CRFR1, but not CRFR1-ΔTAV and that the interaction
of CAL-YFP with HA-CRFR1 was not increased following agonist treatment with 100 nM
CRF (Fig. 2.1A and 2.1B). We also observed that CAL overexpression resulted in a shift
in the molecular weight of CRFR1 and this will be discussed in section 2.3.6.

2.3.2

HA-CRFR1 co-localizes with CAL-YFP in the Golgi apparatus

To further address whether CAL forms a complex with CRFR1, we assessed whether the
two proteins could be co-localized in HEK 293 cells in a PDZ motif-dependent manner. In
cells transfected to express HA-CRFR1 and YFP as a control, the HA-CRFR1 labeled with
Alexa Fluor 647 primary mouse anti-HA antibody in permeabilized cells showed
predominant localization at the cell surface with some co-localization with Golgi marker
TGN-CFP (Fig. 2.2A). In HEK 293 cells transfected with HA-CRFR1 and CAL-YFP,
CAL-YFP fluorescence was extensively co-localized with TGN-CFP consistent with
previous reports where CAL was localized to the Golgi apparatus and could be used as a
marker for this organelle (Fig. 2.2B) (Charest et al., 2001; Yao et al., 2001). In
permeabilized HEK 293 cells, HA-CRFR1 immunofluorescence was co-localized with
CAL-YFP with extensive co-localization in the Golgi (Fig. 2.2B). Similar to what was
observed for HA-CRFR1, HA-CRFR1-ΔTAV immunofluorescence was localized at the
cell surface of HEK 293 cells in YFP transfected cells (Fig. 2.2C), but unlike what was
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Figure 2.1: CAL-YFP co-immunoprecipitates with HA-CRFR1 in a PDZ-binding
motif-dependent manner: HEK 293 cells were co-transfected with HA-CRFR1 (WT or
ΔTAV) and YFP or CAL-YFP. A) Representative immunoblot of CAL-YFP coimmunoprecipitated (IP) with HA-CRFR1 but not HA-CRFR1-ΔTAV which lacks the
PDZ-binding motif. SDS-PAGE was used to analyze samples and immunoblots were
performed with rabbit anti-GFP. B) Effect of CRF treatment was quantified using
densitometry and had no significant difference on the amount of CAL-YFP coimmunoprecipitated with HA-CRFR1. Data are representative of 5 independent
experiments. NT: non-transfected, IB: immunoblot.
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Figure 2.2: CAL-YFP co-localizes with HA-CRFR1 in the Golgi in a PDZ-binding
motif-dependent manner: A) Representative confocal microscopy image of fixed HEK
293 cells transfected with TGN-CFP (blue), YFP (green), and HA-CRFR1 (red). B)
Representative confocal microscopy image of fixed HEK 293 cells transfected with TGNCFP (blue), CAL-YFP (green), and HA-CRFR1 (red). C) Representative confocal
microscopy image of fixed HEK 293 cells transfected with TGN-CFP (blue), YFP (green),
and HA-CRFR1-ΔTAV (red). D) Representative confocal microscopy image of fixed HEK
293 cells transfected with TGN-CFP (blue), CAL-YFP (green), and HA-CRFR1-ΔTAV
(red). Scale bar=10 μM. Images are representative of 20 cells from five independent
experiments.
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observed for HA-CRFR1 it was not extensively localized to the Golgi to co-localize with
CAL-YFP (Fig. 2.2D). In contrast, HA-CRFR1-ΔTAV immunofluorescence remained
predominantly localized to the cell surface. Taken together these observations support the
concept that CAL forms a complex with CRFR1 resulting in the accumulation of the
receptor in the Golgi.

2.3.3

Effect of CAL expression on agonist-stimulated CRFR1
endocytosis

To determine whether CAL contributed to the regulation of CRFR1 endocytosis, we
employed

flow

cytometry to

assess

the

loss

of

cell

surface

HA-CRFR1

immunofluorescence. We found that CAL overexpression attenuated agonist-stimulated
HA-CRFR1 internalization following treatment with 500 nM CRF for 30 and 60 min (Fig.
2.3A). The internalization of the mutant HA-CRFR1-ΔTAV was not altered by CAL
overexpression (Fig. 2.3B). Thus, CAL overexpression attenuated CRFR1 endocytosis in
a PDZ motif-dependent manner.

2.3.4

Effect of CAL expression on cAMP signaling

PDZ domain-containing proteins were previously shown to have the potential to regulate
cAMP signaling of some GPCRs (Wang et al., 2007; Magalhaes et al., 2012). Therefore,
we tested whether CAL contributed to the regulation of CRFR1- mediated cAMP
formation. In HEK 293 cells transfected with either HA-CRFR1 or HA-CRFR1-ΔTAV,
with or without CAL, and treated with increasing concentrations of CRF for 10 min, there
was no significant change in the maximum efficacy for CRF-stimulated cAMP signaling
(Fig. 2.4A and 2.4B). In addition we assessed whether the attenuation of CAL expression
might alter CRFR1 cAMP signaling. We found that transfection of HEK 293 cells with
CAL siRNA previously demonstrated to knockdown CAL expression (Cheng et al., 2010)
had no effect on either HA-CRFR1- or HA-CRFR1-ΔTAV- stimulated cAMP signaling in
response to the treatment of transfected HEK 293 cells with increasing concentrations of
CRF (Fig. 2.4C and 2.4D). These results suggest that CAL does not contribute to the
regulation of CRFR1 activation of the cAMP pathway.

63

Figure 2.3: Effect of CAL expression on agonist-stimulated CRFR1 endocytosis:
Agonist stimulated internalization of either A) HA-CRFR1 or B) HA-CRFR1-ΔTAV in
the presence and absence of CAL overexpression following 500 nM CRF treatment for
either 30 or 60 min. The data represent the mean ± SEM of 4 independent experiments. *P
< 0.05 versus empty vector control.
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Figure 2.4: CAL does not regulate CRFR1-mediated cAMP formation: Dose response
for CRF stimulated cAMP formation assessed using a BRET-based cAMP biosensor assay.
A) CRFR1- and B) CRFR1-ΔTAV-mediated cAMP formation in either plasmid vector or
CAL transfected HEK 293 cells. C) CRFR1- and D) CRFR1-ΔTAV-mediated cAMP
formation in either scrambled or CAL siRNA transfected HEK 293 cells. The data
represent the mean ± SEM of 3–5 independent experiments.
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2.3.5

Effect of CAL expression on ERK1/2 signaling

In addition to being coupled to the Gαs-dependent activation of adenylyl cyclase, agonist
activation of CRFR1 leads to increased ERK1/2 phosphorylation (Kageyama et al., 2007;
Dunn et al., 2013; Dunn et al., 2014). Therefore, we assessed whether either CAL-YFP
overexpression or siRNA-mediated knockdown of endogenous CAL would alter CRFR1mediated ERK1/2 phosphorylation in a PDZ interaction- dependent manner in response to
500 nM CRF treatment for 5 and 15 min. CAL overexpression resulted in a statistically
significant reduction in ERK1/2 phosphorylation and siRNA knockdown of endogenously
expressed CAL increased HA-CRFR1- stimulated ERK1/2 phosphorylation following the
activation of HA-CRFR1 for 5 and 15 min with 500 nM CRF (Fig. 2.5A). In contrast,
neither CAL overexpression nor CAL knockdown affected HA-CRFR1-ΔTAV-stimulated
ERK1/2 phosphorylation (Fig. 2.5B). Taken together, these data suggested that CAL
negatively regulates CRFR1-mediated ERK1/2 signaling via a PDZ binding motif
interaction-dependent signaling mechanism.

2.3.6

Effect of CAL on CRFR1 glycosylation and degradation

CAL overexpression consistently altered the molecular migration of HA-CRFR1, but not
HA-CRFR1-ΔTAV by SDS-PAGE (Fig. 2.1 and Fig. 2.5). To further characterize this
CAL expression-dependent change in the molecular mass of the HA-CRFR1, we cotransfected HEK 293 cells with either HA-CRFR1 or HA-CRFR1-ΔTAV along with
increasing cDNA concentrations of CAL and then performed western blotting on HEK 293
cell lysates for receptor expression (Fig. 2.6A). We found that, even at the lowest levels of
CAL overexpression, the molecular mass of a substantial proportion of HA-CRFR1
decreased as evidenced by an increased mobility on the SDS-PAGE gel, suggesting that
this represented an immature, non-glycosylated form of the receptor (Fig. 2.6A). In
contrast, CAL overexpression did not alter the mobility of the HA-CRFR1-ΔTAV on an
SDS PAGE gel (Fig. 2.6A). Densitometric analysis of the gels revealed that there was a
significant reduction in the higher molecular mass HA-CRFR1 receptor band following
CAL overexpression, whereas, CAL overexpression did not alter the proportion of the
higher molecular mass HA-CRFR-ΔTAV band (Fig. 2.6B). To ascertain that the lower
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Figure 2.5: CAL negatively regulates HA-CRFR1-mediated ERK1/2
phosphorylation: A) Representative immunoblot showing ERK1/2 phosphorylation in
response to 500 nM CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293
cells, and HEK 293 cells transfected with HA-CRFR1 along with either YFP, CAL-YFP,
scrambled (SCR) siRNA or CAL siRNA. Also shown are corresponding immunoblots for
total ERK1/2, CAL and HA-CRFR1 protein expression. Shown below is the densitometric
analysis of ERK1/2 phosphorylation in response to 500 nM CRF treatment for 0, 5, and 15
min in non-transfected (NT) HEK 293 cell, and HEK 293 cells transfected with HACRFR1 along with either YFP, CAL-YFP, scrambled (SCR) siRNA or CAL siRNA. The
data represent the mean ± SEM of six independent experiments. * P < 0.05 versus SCR
siRNA treated cells. B) Representative immunoblot showing ERK1/2 phosphorylation in
response to 500 nM CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293
cells, and HEK 293 cells transfected with HA-CRFR1-ΔTAV along with either YFP, CALYFP, scrambled (SCR) siRNA or CAL siRNA. Also shown are corresponding
immunoblots for total ERK1/2, CAL and HA-CRFR1-ΔTAV protein expression. Shown
below is the densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells
transfected with HA-CRFR1-ΔTAV along with either YFP, CAL-YFP, scrambled (SCR)
siRNA or CAL siRNA. The data represent the mean ± SEM of 6 independent experiments.
* P < 0.05 versus SCR siRNA treated cells.
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molecular mass species of the HA-CRFR1 construct was not the consequence of increased
receptor degradation following CAL overexpression, we stimulated HA-CRFR1
expressing cells with 100 nM CRF for 0, 2, 4 or 6 h in the presence of scrambled siRNA,
CAL or CAL siRNA. However, we did not observe any time-dependent change in the
fraction of the lower molecular mass HA-CRFR1 species in CAL overexpressing cells (Fig.
2.6C). Consistent with the hypothesis that CAL interactions with HA-CRFR1, but not
CRFR1-ΔTAV, affected the maturation of the glycosylation state of the receptor, both
endoglycosidase F (1h) and H (3h) treatment reduced the molecular mass of the lower
molecular weight HA-CRFR1 species (Fig. 2.6D). Taken together, these results indicated
that PDZ motif-dependent interactions with the CRFR1 altered CRFR1 glycosylation. The
amino-terminal domain of CRFR1 has five potential N-linked glycosylation sites at
positions N38, N45, N78, N90 and N98 (Assil and Abou-Samra, 2001). Therefore, we
generated point mutations where potentially glycosylated asparagine residues were
replaced with glutamine, HA-CRFR1-N38Q, HA-CRFR1-N78Q, HA-CRFR1-N90Q and
HA-CRFR1-N98Q. When expressed with YFP in HEK 293 cells HA-CRFR1-N38Q and
HA-CRFR1-N78Q exhibited a wild-type pattern of protein expression (Fig. 2.7). However,
when transfected with YFP, HA-CRFR1-N90Q and HA-CRFR1-N98Q had a mobility
pattern on SDS-PAGE that was similar to what was observed following CAL-YFP
overexpression with HA-CRFR1 (Fig. 2.7). However, overexpression of CAL-YFP
resulted in the appearance of a lower molecular mass species for the wild-type, as well as
the N38Q and N78Q CRFR1 mutants (Fig. 2.7). CAL-YFP overexpression resulted in
nearly the complete loss of upper molecular mass protein band for the HA-CRFR1-N90Q
and HACRFR1-N98Q mutants (Fig. 2.7). Taken together, CRFR1 N90 and N98 appear to
be the primary residues that undergo receptor glycosylation.
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Figure 2.6: Effect of CAL on CRFR1 glycosylation and degradation: A) Representative
immunoblot of 1 μg HA-CRFR1 and HA-CRFR1-ΔTAV cell lysates from transfected
HEK 293 cells immunoblotted with HA antibody. Cells were co-transfected with
increasing amounts of plasmid cDNA encoding CAL (0, 0.25, 0.5, 1, and 2 μg plasmid
cDNA). Shown below are representative immunoblots for CAL and actin expression. B)
Densitometric analysis of the relative amount of the upper molecular mass CRFR1
immunoreactive band compared to total receptor immunoreactivity. The data represent the
mean ± SEM of 5 independent experiments. * P < 0.05 versus cells expressing receptor
alone. C) Representative immunoblot (n= 3) of 1 μg HA-CRFR1 cell lysates from
transfected HEK 293 cells immunoblotted with HA-antibody following CRF treatment 0,
2, 4, 6 h, in cells transfected with scrambled siRNA, CAL, or CAL siRNA. Shown below
is a representative immunoblot for CAL expression. D) Representative immunoblot (n= 5)
of 1 μg HA-CRFR1 and HA-CRFR1-ΔTAV cell lysates from transfected HEK 293 cells
immunoblotted with HA-antibody. Cells were co-transfected with and without plasmid
cDNA encoding CAL-YFP and treated with and without endoglycosidase (Endo) F and H
for 60 and 180 min, respectively. Shown below is representative immunoblot for CAL
expression.
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Figure 2.7: Glycosylation of HA-CRFR1-N38Q, -N78Q, -N90Q and -N98Q mutants
in the absence and presence of CAL: Shown is a representative immunoblot of 1 μg HACRFR1, HA-CRFR1-N38Q, HA-CRFR1-N78Q, HA-CRFR1-N90Q and HA-CRFR1N98Q cell lysates from HEK 293 cells co-transfected with either YFP or CAL-YFP. Blots
are representative of four independent experiments.
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2.3.7

Subcellular localization and signaling of CRFR1 glycosylation
mutants

To examine whether the glycosylation status of the CRFR1 was important for cell surface
expression, we assessed the subcellular localization of both the HA-CRFR1-N78Q mutant
that exhibited a wild-type glycosylation pattern, and the HA-CRFR1-N90Q mutant that
exhibited altered glycosylation in the presence and absence of CAL-YFP by
immunofluorescence microscopy. We found that the HA-CRFR1-N78Q mutant was
expressed at the cell surface of HEK 293 cells and was not co-localized with TGN-CFP
Golgi marker in YFP expressing cells (Fig. 2.8A), but was retained in the Golgi following
CAL-YFP overexpression (Fig. 2.8B). In contrast, the HA-CRFR1-N90Q mutant exhibited
extensive co-localization with TGN-CFP Golgi marker in both the absence and presence
of CAL-YFP (Fig. 2.8C and 2.8D). Consistent with this observation, the cell surface
expression of both the HA-CRFR1-N90Q and HA-CRFR1-N98Q mutants was reduced to
the same extent as what was observed for the HA-CRFR1 in the presence of CAL-YFP
while the cell surface expression of the HA-CRFR1-N38Q and HA-CRFR1-N78Q was
similar to the HA-CRFR1 (presented as the dotted line) (Fig. 2.9A). The reduction in cell
surface expression was not sufficient to impair G protein coupling but all glycosylationdeficient mutations decreased the efficacy of CRF treatment for CRFR1-stimulated cAMP
formation (Fig. 2.9B). Thus, a fully glycosylated CRFR1 was required for appropriate cell
surface expression of the CRFR1 and mutation of any glycosylation site reduces the
efficacy for CRF-stimulated cAMP formation. This unique effect on cAMP formation was
not observed with the over-expression of CAL which suggests that introducing mutations
and their effect on the structure and folding of the receptor has a more prominent effect
than CAL interaction with the receptor. In addition to cAMP formation, we have also
assessed ERK1/2 signaling by the glycosylation-deficient mutants. Our data showed that
both CRFR1-N90Q and CRFR1-N98Q have altered ERK1/2 signaling illustrated as a
reduction in phosphorylation that is about 50% less compared to CRF-stimulated ERK1/2
phosphorylation by CRFR1 (Fig. 2.9C).
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Figure 2.8: Subcellular localization of HA-CRFR1 glycosylation site mutants in the
presence and absence of CAL: A) Representative confocal microscopy image of fixed
HEK 293 cells transfected with TGN-CFP (blue), YFP (green), and HA-CRFR1-N78Q
(red). B) Representative confocal microscopy image of fixed HEK 293 cells transfected
with TGN-CFP (blue), CAL-YFP (green), and HA-CRFR1-N78Q (red). C) Representative
confocal microscopy image of fixed HEK 293 cells transfected with TGN-CFP (blue), YFP
(green), and HA-CRFR1-N90Q (red). D) Representative confocal microscopy image of
fixed HEK 293 cells transfected with TGN-CFP (blue), CAL-YFP (green), and HACRFR1-N90Q (red). Scale bar= 10 μM. Images are representative of 12 cells from three
independent experiments.
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Figure 2.9: Cell surface expression, cAMP signaling and ERK1/2 signaling of CRFR1
glycosylation site mutants: A) Cell surface expression in HEK 293 cells expressing either
HA-CRFR1 along with CAL, HA-CRFR1-N90Q, HA-CRFR1-N98Q, HA-CRFR1-N38Q
or HA-CRFR1-N78Q expressed as measured by flow cytometry. Data is normalized to
HA-CRFR1 expression (as illustrated by the dotted line). The data represent the mean ±
SEM of 5 independent experiments. * P < 0.05 versus HA-CRFR1 cell surface expression.
B) Dose-response for CRF-mediated cAMP activation in HEK 293 cells expressing either
HA-CRFR1, HA-CRFR1 along with CAL, HA-CRFR1-N90Q, HA-CRFR1-N98Q, HACRFR1-N38Q or HA-CRFR1-N78Q. The data represent the mean ± SEM of 5 independent
experiments. C) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM
CRF treatment for 0, 5, and 15 min in HEK 293 cells transfected with HA-CRFR1, HACRFR1-N90Q, HA-CRFR1-N98Q, HA-CRFR1-N38Q or HA-CRFR1-N78Q. The data
represent the mean ± SEM of three independent experiments. * P < 0.05 versus cells
transfected with HA-CRFR1.
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On the other hand, ERK1/2 signaling of both CRFR1-N38Q and CRFR1-N78Q was similar
to that of CRFR1. This data is consistent with the mobility patterns observed in Fig. 2.7
where both CRFR1-N90Q and CRFR1-N98Q had a similar pattern to CAL overexpression
with the receptor and CAL overexpression also reduced ERK1/2 phosphorylation. This
confirms the importance of CRFR1 glycosylation specifically of resides Asn90 and Asn98
for proper maturation and signaling. It also supports our hypothesis that CAL's interaction
with CRFR1 and the effects it has on receptor trafficking and signaling is the result of its
role in mediating glycosylation.
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2.4 Discussion
We previously reported that CAL is one of a series of CRFR1- interacting PDZ
proteins identified in a proteomic screen, but the functional role of this interaction has not
been characterized (Dunn et al., 2013). In this study, we have identified the role of CAL in
the regulation of the CRFR1 function as a protein that negatively regulates cell surface
CRFR1 expression. We propose that CAL can regulate cell surface expression by
modulating the post-translational modification involving the glycosylation of aminoterminal Asn residues which is required for proper maturation and folding of GPCRs
(Wheatley and Hawtin, 1999; Duvernay et al., 2005). This suggests an important role for
CAL in the anterograde trafficking of transmembrane proteins through the ER-Golgi
complex. We also demonstrate a negative functional effect of CAL on CRFR1-stimulated
ERK1/2 signaling in the absence of alterations in CRFR1-mediated cAMP formation.
Mutagenesis analysis of putative sites of glycosylation revealed active glycosylation at Asn
residues 90 and 98 and that mutation of these residues reduced cell surface CRFR1
expression and decreased the efficacy for CRF-stimulated cAMP formation.
The role of PDZ proteins is generally considered to be limited to scaffolding molecular
complexes, but these proteins have started to emerge as important regulators of GPCR
expression and signaling (Magalhaes et al., 2012). CAL has been shown to associate with
and regulate the activity of a number of other GPCRs including: the β1-AR (He et al., 2004),
metabotropic glutamate receptor 1 and 5 (mGluR1a and mGluR5) (Zhang et al., 2008;
Cheng et al., 2010) and the somatostatin receptor subtype 5 (SSTR5) (Wente et al., 2005;
Bauch et al., 2014). A common finding in both our current study and previous reports
examining the role of CAL in regulating GPCR function is that the overexpression of CAL
results in the intracellular retention of the receptors in the ER-Golgi resulting in the
reduction of receptor expression at the plasma membrane and this has been shown in
multiple different cell lines. Moreover, CAL appears to play a role in the ER-Golgi
retention not only of GPCRs, but also of other transmembrane proteins such as the CFTR
(Cheng et al., 2002) and the voltage-gated potassium channel (KV10.1) (Herrmann et al.,
2013). However, the mechanism for this regulation is still not clear, especially for GPCRs.
It has been suggested that CAL can reduce cell surface expression of CFTR by enhancing
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their ubiquitination, thereby targeting them for lysosomal degradation. In contrast, opposite
conclusions were drawn with regards to the mechanism by which CAL regulates mGluR5.
In the case of mGluR5 it is suggested that CAL may stabilize the receptor by inhibiting its
ubiquitination-dependent degradation process. This is not the case for CRFR1 as we have
found that CAL overexpression does not contribute to increased CRFR1 degradation
following CRF stimulation for up to 6h.
We find that CAL overexpression results in the appearance of a lower molecular mass
HA-immunoreactive protein band that is not prominently observed in the absence of CAL
expression. We have hypothesized that this band represents an immature partially
glycosylated form of the CRFR1. Similar conclusions have been previously made
regarding the effect of CAL overexpression on the glycosylation status of SSTR5 (Wente
et al., 2005; Bauch et al., 2014). GPCR maturation is associated with post-translational
modification of the receptors that can result in the glycosylation of Asn residues localized
on the extracellular surfaces of the receptors. In the present study, we find that the
introduction of point mutations at Asn90 and Asn98, results in impaired CRFR1
glycosylation that is indistinguishable from the effect of overexpressing CAL. We show
that the addition of polysaccharide chains at either of these two residues is important for
cell surface CRFR1 expression and the efficacy for CRF-stimulated cAMP formation.
These results are in contradiction with a previous study of CRFR1 and the parathyroid
hormone receptor (PTH) glycosylation (Assil and Abou-Samra, 2001). In the previous
study, altered CRFR1 function required the mutation of at least three N-glycosylation sites
and suggested that the loss of either one or two polysaccharide chains is well-tolerated
(Assil and Abou-Samra, 2001). It is likely that the observed differences between these
studies may be attributed to differences in the methodologies used to measure cell surface
expression and cAMP formation and the cell types used.
CAL has been shown to interact with Golgi proteins involved in sorting such as
Syntaxin 6 or Golgin160 (Herrmann et al., 2013). In addition, CAL can associate with
many transmembrane proteins and retain them in the transgolgi network (Cheng et al.,
2002; Herrmann et al., 2013). This suggests that CAL may play an important role as either
an ER-Golgi sorting molecule or contribute directly to the ER-Golgi quality control process
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to ensure that only properly folded terminally glycosylated proteins exit the ER-Golgi
complex to traffic to the plasma membrane. If the protein is still not ready, CAL retains it
to allow for other scaffolding proteins to bind and complete the folding process. This can
also be used to explain CAL's role in mediating glycosylation. There is currently no known
sorting mechanism for glycosyltransferases which are the key enzymes in the addition of
glycans to proteins (Moremen et al., 2012). Given the ubiquitous distribution of CAL
throughout the different Golgi compartments and its potential role as a sorting molecule,
we can speculate that it is involved in the vesicular transport and sorting of
glycosyltransferases and hence mediate the glycosylation of transmembrane proteins.
A very recent paper has demonstrated that CAL interacts with the β1-AR (Koliwer et
al., 2015). This interaction with the β1-AR appears to play an important role in regulating
the internalization and recycling of the β1-AR and is proposed that this occurs as the
consequence of an effect of CAL on the endosomal degradation of the receptor following
endocytosis (Koliwer et al., 2015). The authors also demonstrate that β1-AR expression
levels are decreased in the hippocampus of CAL knockout mice. Therefore, based on this
study and our own data showing that CAL is predominantly localized to the Golgi
apparatus, we propose that CAL may mediate its effects on GPCR function by serving as
a GPCR sorting protein via two distinct mechanisms. Specifically, by acting as a regulator
of post-translational GPCR modifications involved in receptor glycosylation, as well as
functioning as a regulator of endosomal degradation.
Our data show that CAL overexpression can block agonist-stimulated endocytosis. We
are suggesting that CAL can mediate post-translational modifications and we have
provided evidence for it regulating the glycosylation of CRFR1. We can speculate that it
can mediate other modifications that might be important for receptor internalization like
phosphorylation. In addition, other PDZ proteins were shown to regulate the recruitment
of β-arrestin to GPCRs which is a key step in receptor endocytosis (Dunn and Ferguson,
2015). It has been shown that NHERF1 can enhance β-arrestin recruitment to the
chemokine receptor CCR5 (Hammad et al., 2010) while PSD95 blocks β-arrestin
recruitment to 5-HT2AR (Schmid and Bohn, 2010). Therefore, it is possible that CAL
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interferes with β-arrestin recruitment to the receptor and further studies are needed to
investigate those mechanisms.
In addition to its role in CRFR1 trafficking, we find that CAL overexpression affects
CRFR1-dependent activation of the ERK1/2 signaling pathway. Specifically, CAL
expression significantly attenuates CRFR1- mediated ERK1/2 phosphorylation in a
manner that is dependent upon an intact CRFR1 PDZ-binding motif. Similar results have
been observed for mGluR1a, where CAL overexpression reduces mGluR1a-stimulated
ERK1/2 phosphorylation (Zhang et al., 2008). Thus, it will be important in the future to
examine the role of CAL interactions with CRFR1 and other GPCRs that encode PDZbinding motifs in the central nervous system. PCR analysis of mouse tissue revealed that
CAL is ubiquitously distributed in many different regions of the brain (cerebellum, cortex,
hippocampus and hypothalamus) as well as the heart, kidney, lungs, testis and spinal cord
(Duvernay et al., 2005). CAL-deficient mice are infertile so it has been suggested that CAL
is important in the early stages of development.
We have reported previously that other PDZ proteins, SAP97 and PDZK1 are also
important for the regulation of CRFR-mediated activation of the ERK1/2 signal
transduction pathway. Unlike CAL, both SAP97 and PDZK1 facilitate CRFR1-mediated
ERK1/2 phosphorylation and SAP97 contributes to GPCR-mediated ERK1/2 activation in
the absence of PDZ binding motif interactions (Dunn et al., 2013; Dunn et al., 2014;
Walther et al., 2015). Thus, CAL functions differently than both SAP97 and PDZK1 to
antagonize CRFR1-mediated activation of ERK1/2 signaling and CAL siRNA increases
CRFR1-stimulated ERK1/2 phosphorylation. Thus, it appears that, while a number of PDZ
proteins contribute to the regulation of CRFR1 ERK1/2 signaling they have opposing
effects and mediate their actions by distinct mechanisms. The precise mechanism by which
CAL regulates the activation of the ERK1/2 pathway remains to be determined, but it does
not appear to involve reduced cell surface expression of CRFR1, as cAMP formation is not
altered following CAL overexpression.
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2.5 Conclusion
In conclusion, we find that CAL regulates N-glycosylation and cell surface
expression of CRFR1 as well as negatively regulates CRFR1- mediated ERK1/2
phosphorylation. This adds CRFR1 to a growing list of CAL-interacting GPCRs. The
effects of CAL on CRFR1 glycosylation, cell surface expression and ERK1/2 signaling are
all dependent upon an intact PDZ binding motif. Taken together, these observations and
previous studies examining CAL function suggest that CAL represents another important
PDZ domain containing protein that contributes to distinct aspects of GPCR trafficking
and signaling.

79

2.6 References
Arzt, E., Holsboer, F., (2006). CRF signaling: molecular specificity for drug targeting in
the CNS. Trends Pharmacol. Sci. 27 , 531-538.
Assil, I.Q., Abou-Samra, A.B., (2001). N-glycosylation of CRF receptor type 1 is important
for its ligand-specific interaction. Am. J. Physiol. Endocrinol. Metab. 281 , E1015-21.
Balasubramanian, S., Fam, S.R., and Hall, R.A., (2007). GABAB receptor association with
the PDZ scaffold Mupp1 alters receptor stability and function. J. Biol. Chem. 282 , 41624171.
Barak, L.S., Salahpour, A., Zhang, X., Masri, B., Sotnikova, T.D., Ramsey, A.J., Violin,
J.D., Lefkowitz, R.J., Caron, M.G., and Gainetdinov, R.R., (2008). Pharmacological
characterization of membrane-expressed human trace amine-associated receptor 1
(TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol.
Pharmacol. 74 , 585-594.
Bauch, C., Koliwer, J., Buck, F., Honck, H.H., and Kreienkamp, H.J., (2014). Subcellular
sorting of the G-protein coupled mouse somatostatin receptor 5 by a network of PDZdomain containing proteins. PLoS One 9 , e88529.
Behan, D.P., Grigoriadis, D.E., Lovenberg, T., Chalmers, D., Heinrichs, S., Liaw, C., and
De Souza, E.B., (1996). Neurobiology of corticotropin releasing factor (CRF) receptors
and CRF-binding protein: implications for the treatment of CNS disorders. Mol. Psychiatry
1 , 265-277.
Chalmers, D.T., Lovenberg, T.W., and De Souza, E.B., (1995). Localization of novel
corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical
nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15 ,
6340-6350.
Chalmers, D.T., Lovenberg, T.W., Grigoriadis, D.E., Behan, D.P., and De Souza, E.B.,
(1996). Corticotrophin-releasing factor receptors: from molecular biology to drug design.
Trends Pharmacol. Sci. 17 , 166-172.
Charest, A., Lane, K., McMahon, K., and Housman, D.E., (2001). Association of a novel
PDZ domain-containing peripheral Golgi protein with the Q-SNARE (Q-soluble Nethylmaleimide-sensitive fusion protein (NSF) attachment protein receptor) protein
syntaxin 6. J. Biol. Chem. 276 , 29456-29465.
Cheng, J., Cebotaru, V., Cebotaru, L., and Guggino, W.B., (2010). Syntaxin 6 and CAL
mediate the degradation of the cystic fibrosis transmembrane conductance regulator. Mol.
Biol. Cell 21 , 1178-1187.
Cheng, J., Moyer, B.D., Milewski, M., Loffing, J., Ikeda, M., Mickle, J.E., Cutting, G.R.,
Li, M., Stanton, B.A., and Guggino, W.B., (2002). A Golgi-associated PDZ domain protein

80

modulates cystic fibrosis transmembrane regulator plasma membrane expression. J. Biol.
Chem. 277 , 3520-3529.
Cheng, S., Zhang, J., Zhu, P., Ma, Y., Xiong, Y., Sun, L., Xu, J., Zhang, H., and He, J.,
(2010). The PDZ domain protein CAL interacts with mGluR5a and modulates receptor
expression. J. Neurochem. 112 , 588-598.
Dunn, H.A., Ferguson, S.S., (2015). PDZ Protein Regulation of G Protein-Coupled
Receptor Trafficking and Signaling Pathways. Mol. Pharmacol. 88 , 624-639.
Dunn, H.A., Walther, C., Godin, C.M., Hall, R.A., and Ferguson, S.S., (2013). Role of
SAP97 protein in the regulation of corticotropin-releasing factor receptor 1 endocytosis
and extracellular signal-regulated kinase 1/2 signaling. J. Biol. Chem. 288 , 15023-15034.
Dunn, H.A., Walther, C., Yuan, G.Y., Caetano, F.A., Godin, C.M., and Ferguson, S.S.,
(2014). Role of SAP97 in the regulation of 5-HT2AR endocytosis and signaling. Mol.
Pharmacol. 86 , 275-283.
Duvernay, M.T., Filipeanu, C.M., and Wu, G., (2005). The regulatory mechanisms of
export trafficking of G protein-coupled receptors. Cell. Signal. 17 , 1457-1465.
Guillaume, J.L., Daulat, A.M., Maurice, P., Levoye, A., Migaud, M., Brydon, L., Malpaux,
B., Borg-Capra, C., and Jockers, R., (2008). The PDZ protein mupp1 promotes Gi coupling
and signaling of the Mt1 melatonin receptor. J. Biol. Chem. 283 , 16762-16771.
Hammad, M.M., Kuang, Y.Q., Yan, R., Allen, H., and Dupre, D.J., (2010). Na+/H+
exchanger regulatory factor-1 is involved in chemokine receptor homodimer CCR5
internalization and signal transduction but does not affect CXCR4 homodimer or CXCR4CCR5 heterodimer. J. Biol. Chem. 285 , 34653-34664.
Harris, B.Z., Lim, W.A., (2001). Mechanism and role of PDZ domains in signaling
complex assembly. J. Cell. Sci. 114 , 3219-3231.
He, J., Bellini, M., Xu, J., Castleberry, A.M., and Hall, R.A., (2004). Interaction with cystic
fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits beta1adrenergic receptor surface expression. J. Biol. Chem. 279 , 50190-50196.
He, J., Bellini, M., Inuzuka, H., Xu, J., Xiong, Y., Yang, X., Castleberry, A.M., and Hall,
R.A., (2006). Proteomic analysis of beta1-adrenergic receptor interactions with PDZ
scaffold proteins. J. Biol. Chem. 281 , 2820-2827.
Herrmann, S., Ninkovic, M., Kohl, T., and Pardo, L.A., (2013). PIST (GOPC) modulates
the oncogenic voltage-gated potassium channel KV10.1. Front. Physiol. 4 , 201.
Holmes, K.D., Babwah, A.V., Dale, L.B., Poulter, M.O., and Ferguson, S.S., (2006).
Differential regulation of corticotropin releasing factor 1alpha receptor endocytosis and
trafficking by beta-arrestins and Rab GTPases. J. Neurochem. 96 , 934-949.

81

Hu, L.A., Tang, Y., Miller, W.E., Cong, M., Lau, A.G., Lefkowitz, R.J., and Hall, R.A.,
(2000). beta 1-adrenergic receptor association with PSD-95. Inhibition of receptor
internalization and facilitation of beta 1-adrenergic receptor interaction with N-methyl-Daspartate receptors. J. Biol. Chem. 275 , 38659-38666.
Kageyama, K., Hanada, K., Moriyama, T., Imaizumi, T., Satoh, K., and Suda, T., (2007).
Differential regulation of CREB and ERK phosphorylation through corticotropin-releasing
factor receptors type 1 and 2 in AtT-20 and A7r5 cells. Mol. Cell. Endocrinol. 263 , 90102.
Koliwer, J., Park, M., Bauch, C., von Zastrow, M., and Kreienkamp, H.J., (2015). The
golgi-associated PDZ domain protein PIST/GOPC stabilizes the beta1-adrenergic receptor
in intracellular compartments after internalization. J. Biol. Chem. 290 , 6120-6129.
Lanfumey, L., Mongeau, R., Cohen-Salmon, C., and Hamon, M., (2008). Corticosteroidserotonin interactions in the neurobiological mechanisms of stress-related disorders.
Neurosci. Biobehav. Rev. 32 , 1174-1184.
Lee, H.J., Zheng, J.J., (2010). PDZ domains and their binding partners: structure,
specificity, and modification. Cell. Commun. Signal. 8 , 8-811X-8-8.
Magalhaes, A.C., Dunn, H., and Ferguson, S.S., (2012). Regulation of GPCR activity,
trafficking and localization by GPCR-interacting proteins. Br. J. Pharmacol. 165 , 17171736.
Magalhaes, A.C., Holmes, K.D., Dale, L.B., Comps-Agrar, L., Lee, D., Yadav, P.N.,
Drysdale, L., Poulter, M.O., Roth, B.L., Pin, J.P., Anisman, H., and Ferguson, S.S., (2010).
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.
Nat. Neurosci. 13 , 622-629.
Mahon, M.J., Donowitz, M., Yun, C.C., and Segre, G.V., (2002). Na(+)/H(+ ) exchanger
regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 417 , 858861.
Moremen, K.W., Tiemeyer, M., and Nairn, A.V., (2012). Vertebrate protein glycosylation:
diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13 , 448-462.
Palchaudhuri, M.R., Wille, S., Mevenkamp, G., Spiess, J., Fuchs, E., and Dautzenberg,
F.M., (1998). Corticotropin-releasing factor receptor type 1 from Tupaia belangeri-cloning, functional expression and tissue distribution. Eur. J. Biochem. 258 , 78-84.
Parker, L.L., Backstrom, J.R., Sanders-Bush, E., and Shieh, B.H., (2003). Agonist-induced
phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple
PDZ protein 1. J. Biol. Chem. 278 , 21576-21583.
Romero, G., von Zastrow, M., and Friedman, P.A., (2011). Role of PDZ proteins in
regulating trafficking, signaling, and function of GPCRs: means, motif, and opportunity.
Adv. Pharmacol. 62 , 279-314.

82

Schmid, C.L., Bohn, L.M., (2010). Serotonin, but not N-methyltryptamines, activates the
serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. J. Neurosci. 30
, 13513-13524.
Vale, W., Spiess, J., Rivier, C., and Rivier, J., (1981). Characterization of a 41-residue
ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.
Science 213 , 1394-1397.
Walther, C., Caetano, F.A., Dunn, H.A., and Ferguson, S.S., (2015). PDZK1/NHERF3
differentially regulates corticotropin-releasing factor receptor 1 and serotonin 2A receptor
signaling and endocytosis. Cell. Signal. 27 , 519-531.
Wang, B., Bisello, A., Yang, Y., Romero, G.G., and Friedman, P.A., (2007). NHERF1
regulates parathyroid hormone receptor membrane retention without affecting recycling. J.
Biol. Chem. 282 , 36214-36222.
Wente, W., Stroh, T., Beaudet, A., Richter, D., and Kreienkamp, H.J., (2005). Interactions
with PDZ domain proteins PIST/GOPC and PDZK1 regulate intracellular sorting of the
somatostatin receptor subtype 5. J. Biol. Chem. 280 , 32419-32425.
Wheatley, M., Hawtin, S.R., (1999). Glycosylation of G-protein-coupled receptors for
hormones central to normal reproductive functioning: its occurrence and role. Hum.
Reprod. Update 5 , 356-364.
Xu, J., Paquet, M., Lau, A.G., Wood, J.D., Ross, C.A., and Hall, R.A., (2001). beta 1adrenergic receptor association with the synaptic scaffolding protein membrane-associated
guanylate kinase inverted-2 (MAGI-2). Differential regulation of receptor internalization
by MAGI-2 and PSD-95. J. Biol. Chem. 276 , 41310-41317.
Yao, R., Maeda, T., Takada, S., and Noda, T., (2001). Identification of a PDZ domain
containing Golgi protein, GOPC, as an interaction partner of frizzled. Biochem. Biophys.
Res. Commun. 286 , 771-778.
Zhang, J., Cheng, S., Xiong, Y., Ma, Y., Luo, D., Jeromin, A., Zhang, H., and He, J.,
(2008). A novel association of mGluR1a with the PDZ scaffold protein CAL modulates
receptor activity. FEBS Lett. 582 , 4117-4124.

83

Chapter 3

3

Role of MAGI proteins in regulating CRFR1 activity

A version of this chapter has been accepted for publication in the Journal of Molecular
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and signaling of corticotropin-releasing factor receptor 1 via a compensatory mechanism
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3.1

Introduction
Membrane-associated guanylate kinase (MAGUK) family proteins are synaptic

scaffolding proteins within a structured protein network responsible for the spatial
organization of the presynaptic and postsynaptic compartments. They play a crucial role in
the formation and function of synapses in the central nervous system (CNS) by regulating
multiple aspects of synapse physiology such as synaptogenesis, receptor trafficking,
synaptic function, and plasticity (Funke et al., 2005; Feng and Zhang, 2009; Yamagata and
Sanes, 2010). MAGUKs are well-conserved throughout evolution and are widelyexpressed in the brain and periphery. They include multiple subfamilies including
membrane palmitoylated proteins (MPPs), zona occludens (ZO), caspase recruitment
domain-containing MAGUK protein (CARMA), discs large (DLGs) and MAGUK with
inverted orientation PSD-95/Disc Large/Zona Occludens (PDZ) (MAGIs) proteins (Oliva
et al., 2012). Generally, these proteins contain multiple domains that control their function
and facilitate their interactions with their targets. The two common domains among all
members are PDZ domains and the guanylate kinase (GK) domain. (Oliva et al., 2012). An
important target for the MAGUKs scaffolding proteins is the G protein-coupled receptors
(GPCRs) family (Dunn and Ferguson, 2015). Many GPCRs encode a short class I PDZbinding motif (S/T-x-ϕ, where ϕ is any aliphatic amino acid residue) at the end of their
carboxyl-terminal tail that is recognized by the PDZ domain of the MAGUK proteins. This
protein-protein interaction between the receptor and MAGUKs results in the regulation of
GPCR function. MAGUK proteins play a key role in mediating the subcellular localization,
trafficking, cell surface expression and signal transduction of multiple GPCRs and different
proteins have both overlapping and distinct roles in the regulation of GPCR activity (Harris
and Lim, 2001; Lee and Zheng, 2010; Romero et al., 2011; Magalhaes et al., 2012). One
of the important subfamilies of MAGUKs is the membrane-associated guanylate kinase
with inverted orientation (MAGI) protein subfamily (Dunn and Ferguson, 2015), which
consists of three members; MAGI-1, MAGI-2 and MAGI-3. All three proteins share a
similar structure containing one guanylate kinase-like (GK) domain, two tryptophan
tryptophan (WW) domains and six PDZ domains. MAGI proteins, particularly MAGI-2
and MAGI-3, have been shown to regulate the trafficking and signaling of multiple GPCRs.
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MAGI-1, also known as BAP-1 (BAI-1-associated protein 1), has 7 isoforms that
are widely expressed in different tissues. Isoform 1, isoform 2 and isoform 6 are highly
expressed in colon, kidney, lung, liver, and pancreas. Isoform 5 is predominantly expressed
in brain and heart. Isoform 3 and isoform 4 are highly expressed in pancreas and brain
(Dobrosotskaya et al., 1997; Laura et al., 2002). MAGI-1 interacts with BAI-1 (brainspecific angiogenesis inhibitor-1), a family B GPCR that functions as an adhesion
molecule. Therefore, it is suggested that MAGI-1 might play an important role in the
organization of membrane proteins and cytoskeleton by transmitting signals related to cellcell or cell- matrix interactions through BAI-1 (Shiratsuchi et al., 1998; Stetak et al., 2009;
Stephenson et al., 2014). MAGI-1 also regulates AMPA receptor activity and modulate
behavioral plasticity (Emtage et al., 2009).
MAGI-2, also known as S-SCAM (synaptic scaffolding molecule), is specifically
expressed in the brain and has 2 isoforms (Wood et al., 1998). A previous study has
illustrated an association between MAGI-2 and β1-AR that is enhanced upon agonist
stimulation (Xu et al., 2001). The study also reports an increase in agonist-induced
internalization of β1-AR when MAGI-2 is co-expressed, but no effect on cAMP generation
induced by isoproterenol stimulation. In contrast, MAGI-2 has been shown to inhibit both
vasoactive intestinal polypeptide type 1 (VPAC1) receptor-mediated cAMP production and
internalization (Gee et al., 2009).
MAGI-3 is also widely expressed in different tissues. It has been shown to interact
with β2-AR and reduce signaling via the extracellular signal-regulated kinase 1 and 2
(ERK1/2) pathway (Yang et al., 2010). MAGI-3 also associates with lysophosphatidic
acid-activated receptor subtype-2 (LPA2R) and opposite to the effect that is observed for
the β2-AR, knockdown of MAGI-3 results in a decrease in LPA2R-mediated ERK 1/2
signaling (Zhang et al., 2007). The study also reports a significant reduction in Rho
activation upon knockdown of MAGI-3.
The corticotropin releasing factor receptor 1 (CRFR1) is activated by corticotropinreleasing factor (CRF), a 41 amino acid neuropeptide secreted from the paraventricular
nucleus of the hypothalamus in response to stress. Release of CRF can lead to the activation
of the hypothalamic-pituitary-adrenal axis (HPA axis) (Vale et al., 1981; Arzt and
Holsboer, 2006). CRF can also bind to and activate CRFR2, however the affinity of CRF

86

for CRFR1 is much higher than that for CRFR2. Both CRF receptors are widely expressed
in the brain (neocortex and cerebellum) and pituitary (Chalmers et al., 1995; Palchaudhuri
et al., 1998). A number of studies have elucidated a link between the pathophysiological
changes in the CRF system and various neuropsychiatric disorders such as major
depression, panic disorder, anorexia nervosa, and Alzheimer's disease (Behan et al., 1996;
Lanfumey et al., 2008). CRFRs can primarily couple to Gαs for the activation of adenylyl
cyclase leading to the formation of cyclic adenosine monophosphate (cAMP) (Chalmers et
al., 1996) as well as the activation of the mitogen-activated protein kinase (MAPK)
signaling pathway (Kageyama et al., 2007). CRFR1 encodes a PDZ-binding motif at the
carboxyl-terminal tail presented by the last three amino acids, threonine - alanine - valine
(TAV). Our laboratory has reports of the interaction between CRFR1 and multiple PDZ
domain-containing proteins including SAP97, PSD-95, CAL and PDZK1. These studies
showed that both SAP97 and CAL function to antagonize the internalization of CRFR1
(Dunn et al., 2013; Hammad et al., 2015). Interestingly, the two proteins had opposite
effects on CRF-stimulated ERK1/2 signaling where knockdown of SAP97 suppressed
ERK activation while knockdown of CAL resulted in a significant enhancement of this
activation. CAL, a Golgi PDZ protein, seems to regulate CRFR1 function via mediating
the post-translational modifications since it prevents the glycosylation of the receptor in
the Golgi. On the other hand, SAP97 regulation of ERK signaling is a general regulatory
mechanism that is independent from the receptor-PDZ protein interaction. This only further
confirms the distinct functions of PDZ proteins depending on the particular GPCR with
which they are associated. PDZK1 had no significant effect on the endocytosis of CRFR1
but enhanced ERK1/2 signaling (Walther et al., 2015).
A PDZ overlay assay previously performed utilizing the carboxyl-terminal tail of
the CRFR1 suggests an interaction between the first PDZ domain of all three MAGI
proteins with the receptor (Dunn et al., 2013). Therefore, we have further investigated these
interactions and examined the effects of the MAGI family members on CRFR1 signaling
and trafficking. We find that all three MAGI proteins as MAGUK proteins can interact
with CRFR1 via the class I PDZ-binding motif. We find that MAGI proteins can regulate
the endocytosis of CRFR1 by mediating β-arrestin recruitment upon stimulation with CRF.
We also demonstrate that siRNA knockdown of MAGI proteins can result in an
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enhancement in ERK1/2 signaling. Furthermore, we show that knocking down one of the
MAGI proteins results in the upregulation of the expression levels of the other members of
the MAGI subfamily suggesting a compensatory mechanism for regulation. Taken
together, our results indicate that MAGI proteins interactions with CRFR1 play an
important role in regulating CRFR1 function.
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3.2
3.2.1

Materials and Methods
Materials

Protein G beads were purchased from GE Healthcare (Oakville, ON, Canada). CRF was
purchased from R&D Systems (Minneapolis, MN). HA peroxidase high affinity antibody
was purchased from Roche (Mississauga, ON, Canada). Rabbit anti-GFP antibody was
obtained from Invitrogen/Life Technologies (Burlington, ON, Canada). MAGI-1, MAGI2 and MAGI-3 antibodies were purchased from Thermo Fisher (Burlington, ON, Canada).
ECL Western blotting detection reagents were purchased from Biorad (Mississauga, ON,
Canada). Mouse anti-HA antibody and all other biochemical reagents were purchased from
Sigma-Aldrich (Oakville, ON, Canada).

3.2.2

Plasmids

HA-CRFR1, CRFR1-YFP and HA-CRFR1-ΔTAV were described previously (Holmes et
al., 2006; Magalhaes et al., 2010). His-MAGI-1, HA-MAGI-2 and His-MAGI-3 were
kindly provided by Dr. Randy Hall (Emory University, School of Medicine). MAGI-1
siRNA, MAGI-2 siRNA and MAGI-3 siRNA were purchased from Thermo Fisher
(Burlington, ON, Canada). For the negative control, we used Silencer Negative Control #1
AM4635 AGUACUGCUUACGAUACGGTT from Thermo Fisher (Burlington, ON,
Canada). The exchange proteins directly activated by cAMP biosensor (EPAC) was a gift
from Drs. Ali Salahpour (University of Toronto) and Marc Caron (Duke University) (Barak
et al., 2008).

3.2.3

Cell Culture and Transfection

Human embryonic kidney (HEK 293) cells were cultured in Eagle’s minimal essential
medium supplemented with 10% fetal bovine serum. Cells were plated on 10-cm dishes
24h prior to transfection. All experiments were performed on 75-80% confluent plates.
Transfections were performed using calcium phosphate protocol except for siRNA
transfections which were performed using Lipofectamine 2000 following manufacturer’s
instructions. Transfections were performed with 1 µg of each construct. Empty pcDNA3.1
vector was used to equalize the total amount of plasmid cDNA used to transfect cells. 18h
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post-transfection, cells were washed with phosphate-buffered saline (PBS) and
resuspended with trypsin, 0.25% EDTA. Experiments were performed approximately 48h
after transfection except for knockdown experiments which were performed 72h post
transfection since this protocol resulted in the maximum knockdown of the different MAGI
proteins.

3.2.4

Co-immunoprecipitation

24h after transfection, HEK 293 cells were seeded onto 10-cm dishes. Cells were starved
with HBSS for 1h at 37°C then stimulated with 100 nM CRF agonist for 30 min. Cells
were then lysed in 500 µL lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1%
Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 µg/ml leupeptin, and 2.5
µg/ml aprotinin) for 20 min on a rocking platform at 4°C. Samples were collected into 1.5
ml Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4°C to pellet insoluble
material. A Bradford protein assay was performed and 300 µg of protein was incubated
overnight at 4°C with protein G-Sepharose and mouse anti-HA antibody (1:50). Beads
were washed three times with cold lysis buffer and incubated overnight at room
temperature in 3xSDS loading buffer containing 2-mercaptoethanol. Samples were
separated by SDS-PAGE, transferred to a nitrocellulose membrane, and western blots were
then performed with the indicated antibodies (rabbit anti-GFP, 1:10000), (HA-POD,
1:1000), (rabbit anti-MAGI-3, 1:1000), (rabbit anti-V5, 1:1000).

3.2.5

Bioluminescent Resonance Energy Transfer-based biosensor
cAMP Assay

HEK 293 cells were co-transfected with 1 µg HA-CRFR1 (WT or ΔTAV) and either 1µg
pcDNA3.1, MAGI-1, MAGI-2, MAGI-3, 80 pmoles scrambled (SCR) siRNA or siRNA
against MAGI-1, MAGI-2 or MAGI-3 as well as 2 µg of an EPAC (exchange proteins
directly activated by cAMP) construct in 10-cm dishes. 24h post-transfection, cells were
reseeded into 96-well plate (~10,000 cells/well) and left for another 24h. On the following
day, cells were serum-starved for 1h in induction buffer (200 μM isobutyl-1methylxanthine (IBMX) in HBSS). Coelenterazine was then added to the wells at a final
concentration of 5 µM. Cells were then stimulated with increasing concentrations of CRF
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peptide for 10 min. The plate was then read by a Victor Plate Reader (Perkin-Elmer) and
the BRET signal was determined by calculating the ratio of the light emitted at 505 to 555
nm to the light emitted at 465 to 505 nm.

3.2.6

Receptor Endocytosis

Following transfection, HEK 293 cells were re-seeded into 12-well plates. Cells were
serum-starved in HBSS for 1h at 37°C then stimulated for 0 or 30 min with 500 nM CRF
in HBSS at 37 °C. Cells were washed with cold HBSS and incubated with mouse anti-HA
antibody (1:1000) for 1h on ice. Cells were washed with cold HBSS then labeled with
Alexa Fluor 647 donkey anti-mouse IgG (1:1000) for 1h on ice in the dark. Cells were
washed with cold HBSS and treated with 5mM EDTA in PBS for 5 min on ice. Cells were
collected and transferred to flow cytometry tubes containing 4% formaldehyde in PBS.
Samples were run on a FACS Calibur cytometer using BD Cell Quest Pro software (BD
Biosciences, Mississauga, ON) until 10,000 cells were counted. The geometric mean of
fluorescence was determined using Flow Jo analysis software and was representative of
the expression levels of the receptor on the plasma membrane (BD Biosciences,
Mississauga, ON).

3.2.7

Western Blot Analysis

75-90 μl of the samples from the different assays which is equivalent to about 50-70 μg of
protein was diluted in β-mercaptoethanol-containing 3xSDS loading buffer and then
applied to 10% SDS-PAGE (30% acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10%
ammonium persulfate and TEMED). Separated proteins were then transferred to
nitrocellulose membranes and membranes were then blocked in 10% milk in TBS for 1h.
Membranes were then blotted overnight by incubation with the appropriate antibody at
4°C. 24h later, membranes were washed at least three times with 1X TBS with 0.05%
Tween 20, and then incubated with a horseradish peroxidase-conjugated secondary
antibody (1:10000) for 1h. Membranes were finally washed again with 1X TBS with 0.05%
Tween 20 three times before being developed using a BioRad chemiluminescence system.
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3.2.8

Bioluminescent Resonance Energy Transfer

Cells were co-transfected with the indicated cDNA using Lipofictamine 2000. β-arrestin
was tagged with Renilla luciferase (Rluc) and used as the energy donor while CRFR1 was
tagged with YFP and used as the energy acceptor. 72h after transfection, cells were starved
with HBSS for 1h at 37°C. The reaction was then started by the addition of Coelenterazine
at a final concentration of 5 μM followed by increasing concentrations of CRF. Signal was
collected on a Synergy Neo2 plate reader (Thermo Fisher) using 460/40-nm (luciferase)
and 540/25-nm (YFP) band pass filters. Whether or not BRET occurred was determined
by calculating the ratio of the light passed by the 540/25 filter to that passed by the 460/40
filter. This ratio is referred to as the BRET ratio.

3.2.9

Statistical Analysis

All measurements are represented as mean ± SEM. Comparisons were performed using
one way analysis of variance test (ANOVA) followed by Bonferroni’s or Dunn’s Multiple
comparisons test to determine significance. * indicate P values less than 0.05 and is
considered to be significant.
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3.3
3.3.1

Results
MAGI proteins interact with CRFR1 via the PDZ-binding motif
independent of CRF activation

The different members of the MAGI subfamily of proteins were previously shown to
interact with different GPCRs. MAGI-2 was shown to interact with β1-AR, mGluR1a and
VPAC1 while MAGI-3 was shown to interact with β1-AR, β2-AR, BAI-1 and LPA2R. We
previously identified the first PDZ domains of MAGI-1, MAGI-2 and MAGI-3 as positive
hits among several PDZ domains that interact with a GST fusion of the CRFR1 carboxylterminal tail (Dunn et al., 2013). To further validate this interaction between MAGI
proteins and CRFR1, we performed co-immunoprecipitation experiments with His-MAGI1 or His-MAGI-3 and either wild-type HA-tagged CRFR1 (HA-CRFR1) or HA-tagged
CRFR1 mutant that lacked the PDZ-binding motif (HA-CRFR1-TAV) in transiently
transfected HEK 293 cells. We found that His-MAGI-1 and His-MAGI-3 coimmunoprecipitated with HA-CRFR1 but not CRFR1-TAV (Fig. 3.1A and 3.1C) and that
the interaction with HA-CRFR1 was not altered following agonist treatment with 100 nM
CRF for 30 min (Fig. 3.1B and 3.1D). Similarly, MAGI-2 was previously shown to interact
with CRFR1 via the carboxyl terminal tail by another group (Bender et al., 2015).

3.3.2

Effect of MAGI proteins expression on cAMP signaling

PDZ domain-containing proteins were previously shown to have the potential to regulate
cAMP signaling of some GPCRs (Magalhaes et al., 2012; Dunn and Ferguson, 2015) and
MAGI-2 in particular was shown to reduce cAMP formation upon activation of VPAC1
(Gee et al., 2009). Therefore, we tested whether MAGI proteins contributed to the
regulation of CRFR1-mediated cAMP formation. In HEK 293 cells transfected with either
HA-CRFR1 or HA-CRFR1-TAV, with or without MAGI-1, MAGI-2 or MAGI-3, there
were no significant changes in the maximum efficacy for cAMP signaling in response to
treatment with increasing concentrations of CRF for 10 min (Fig. 3.2A-C). In addition, we
examined whether the attenuation of MAGI proteins expression could alter CRFR1mediated cAMP signaling. We found that transfection of HEK 293 cells with siRNA
directed to knockdown MAGI-1, MAGI-2 or MAGI-3 had no effect on either HA-CRFR1-
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Figure 3.1: MAGI proteins co-immunoprecipitate with HA-CRFR1 in a PDZ-binding
motif-dependent manner: HEK 293 cells were co-transfected with HA-CRFR1 (WT or
ΔTAV) and pcDNA or His-MAGI-1-V5. (A) Representative immunoblot of His-MAGI-1-V5
co-immunoprecipitated (IP) with HA-CRFR1 but not HA-CRFR1-ΔTAV which lacks the
PDZ-binding motif. SDS-PAGE was used to analyze samples and immunoblots were
performed with rabbit anti-V5. (B) Effect of CRF treatment was quantified using densitometry
and had no significant difference on the amount of MAGI-1 co-immunoprecipitated with HACRFR1. HEK 293 cells were co-transfected with HA-CRFR1 (WT or ΔTAV) and pcDNA or
His-MAGI-3. (C) Representative immunoblot of His-MAGI-3 co-immunoprecipitated (IP)
with HA-CRFR1 but not HA-CRFR1-ΔTAV which lacks the PDZ-binding motif. SDS-PAGE
was used to analyze samples and immunoblots were performed with rabbit anti-MAGI-3. (D)
Effect of CRF treatment was quantified using densitometry and had no significant difference
on the amount of His-MAGI-3 co-immunoprecipitated with HA-CRFR1. Data are
representative of three independent experiments.
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Figure 3.2: MAGI proteins do not regulate CRFR1-mediated cAMP formation: Dose
response for CRF-stimulated cAMP formation assessed using a BRET-based cAMP biosensor
assay. CRFR1- and CRFR1-ΔTAV- mediated cAMP formation in either plasmid vector or
MAGI-1 (A), MAGI-2 (B) or MAGI-3 (C) transfected HEK 293 cells. CRFR1- and CRFR1ΔTAV- mediated cAMP formation in either MAGI-1 siRNA (D), MAGI-2 siRNA (E) or
MAGI-3 siRNA (F) transfected HEK 293 cells. Shown are representative immunoblots
showing siRNA knockdown of (G) MAGI-1, (H) MAGI-2, and (I) MAGI-3 with 80 pmol
siRNA for 72 hours. The data represent the mean ± SEM of at least three independent
experiments.
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or HA-CRFR1-TAV- stimulated cAMP signaling in response to treatment with
increasing concentrations of CRF for 10 min (Fig. 3.2D-F). These results suggested that
MAGI proteins did not contribute to the regulation of CRFR1 activation of the cAMP
pathway. We validated the knockdown of MAGI proteins by co-transfecting HEK 293 cells
with MAGI proteins cDNA (MAGI-1, MAGI-2 or MAGI-3) and 80 pmoles of either SCR
siRNA or MAGI-siRNA. We observed 90% knockdown with MAGI-1 siRNA (Fig. 3.2G),
50% knockdown with MAGI-2 siRNA (Fig. 3.2H) and 65% knockdown with MAGI-3
siRNA (Fig. 3.2I).

3.3.3

Effect of MAGI proteins on cell surface expression

A previous study from our laboratory illustrated an effect of CAL, a Golgi PDZ protein,
on cell surface expression of CRFR1 (Hammad et al., 2015). Therefore, we used flow
cytometry to measure the plasma membrane expression of CRFR1 upon overexpression as
well as knockdown of MAGI proteins. While overexpression of MAGI proteins had no
effect on receptor expression levels (Fig. 3.3A-C), knockdown of certain MAGI proteins
altered CRFR1 membrane expression. Our data show that knockdown of MAGI-1 resulted
in an enhancement in CRFR1 expression at the plasma membrane (Fig. 3.3D). Knockdown
of MAGI-2 and MAGI-3 on the hand had no effect on CRFR1 expression levels (Fig. 3.3EF). This illustrated the importance of MAGI proteins in regulating receptor expression and
reflects distinguished effects among the members of the subfamily.

3.3.4

Effect of MAGI proteins on CRF-mediated ERK1/2 signaling

MAGI-3 was previously shown to regulate ERK1/2 signaling of other GPCRs in a
distinctive manner as it was shown to enhance ERK1/2 activation in the case of LPA2R
and BAI-1 and inhibit β-AR-stimulated ERK1/2 phosphorylation (He et al., 2006; Zhang
et al., 2007). Since CRFR1 was shown to have the ability to activate the MAPK cascade,
we assessed the effects of MAGI proteins overexpression on CRFR1-mediated ERK1/2
phosphorylation. We found that the overexpression of MAGI-1, MAGI-2 and MAGI-3 did
not have an effect on ERK1/2 phosphorylation (Fig. 3.4). Interestingly, when we
knockdown endogenous expression of MAGI-1, MAGI-2 or MAGI-3, we observed a
significant increase in ERK1/2 phosphorylation in response to stimulation of CRFR1
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Figure 3.3: Effect of MAGI proteins on cell surface expression: Cell surface expression
in HEK 293 cells expressing either HA-CRFR1 or HA-CRFR1-ΔTAV along with MAGI-1
(A), MAGI-2 (B), MAGI-3 (C), MAGI-1 siRNA (D), MAGI-2 siRNA (E) or MAGI-3 siRNA
(F) expressed as measured by flow cytometry. Data is normalized to HA-CRFR1 expression
in the control pcDNA or SCR siRNA. The data represent the mean ± SEM of four independent
experiments. * P < 0.05 versus HA-CRFR1 cell surface expression.
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Figure 3.4: Effect of MAGI proteins overexpression on CRFR1-mediated ERK1/2
signaling: (A) Representative immunoblot showing ERK1/2 phosphorylation in response to
500 nM CRF treatment for 0, 2, 5, and 15 min in non-transfected (NT) HEK 293 cells, and
HEK 293 cells transfected with HA-CRFR1 along with either pcDNA or His-MAGI-1. Also
shown are corresponding immunoblots for total ERK1/2, MAGI-1 and HA-CRFR1 protein
expression. (B) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 2, 5, and 15 min. The data represent the mean ± SEM of four independent
experiments. (C) Representative immunoblot showing ERK1/2 phosphorylation in response to
500 nM CRF treatment for 0, 2, 5, and 15 min in non-transfected (NT) HEK 293 cells, and
HEK 293 cells transfected with HA-CRFR1 along with either pcDNA or MAGI-2. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-2 and HA-CRFR1 protein
expression. (D) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 2, 5, and 15 min. The data represent the mean ± SEM of six independent
experiments. (E) Representative immunoblot showing ERK1/2 phosphorylation in response to
500 nM CRF treatment for 0, 2, 5, and 15 min in non-transfected (NT) HEK 293 cells, and
HEK 293 cells transfected with HA-CRFR1 along with either pcDNA or MAGI-3. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-3 and HA-CRFR1 protein
expression. (F) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 2, 5, and 15 min. The data represent the mean ± SEM of six independent
experiments.
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Figure 3.5: Effect of MAGI proteins knockdown on CRF-mediated ERK1/2 signaling:
(A) Representative immunoblot showing ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells
transfected with HA-CRFR1 along with either SCR siRNA or MAGI-1 siRNA. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-1 and HA-CRFR1 protein
expression. (B) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 5, and 15 min. The data represent the mean ± SEM of four independent
experiments. (C) Representative immunoblot showing ERK1/2 phosphorylation in response to
500 nM CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK
293 cells transfected with HA-CRFR1 along with either SCR siRNA or MAGI-2 siRNA. Also
shown are corresponding immunoblots for total ERK1/2 and HA-CRFR1 protein expression.
The antibody was not sensitive enough to blot for endogenous MAGI-2. (D) Densitometric
analysis of ERK1/2 phosphorylation in response to 500 nM CRF treatment for 0, 5, and 15
min. (E) Representative immunoblot showing ERK1/2 phosphorylation in response to 500 nM
CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells
transfected with HA-CRFR1 along with either SCR siRNA or MAGI-3 siRNA. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-3 and HA-CRFR1 protein
expression. (F) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF
treatment for 0, 5, and 15 min. The data represent the mean ± SEM of four independent
experiments. * P < 0.05 versus SCR siRNA control.
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with 500 nM CRF for 5 or 15 minutes (Fig. 3.5).

3.3.5

Effect of MAGI proteins expression on agonist-stimulated
CRFR1 endocytosis

Our laboratory previously reported that other members of the MAGUK family such as
SAP97 and PSD-95, as well as the Golgi PDZ protein CAL could regulate CRF-induced
CRFR1 internalization (Dunn et al., 2013; Hammad et al., 2015; Dunn et al., 2016). To
determine whether MAGI proteins also contributed to the regulation of CRFR1
endocytosis, we utilized flow cytometry to assess the loss of cell surface HA-CRFR1 by
immunofluorescence. We found that the overexpression of MAGI-1, MAGI-2 and MAGI3 each attenuated agonist-stimulated HA-CRFR1 internalization following treatment with
500 nM CRF for 30 min (Fig. 3.6A-C). However, although the internalization of the mutant
HA-CRFR1-TAV was not altered by either MAGI-2 or MAGI-3, the overexpression of
MAGI-1 significantly reduced HA-CRFR1-TAV (Fig. 3.6A-C). In addition, we assessed
the effect of knockdown of endogenous MAGI proteins on agonist-stimulated CRFR1
internalization. We observe that all MAGI siRNAs attenuated the internalization of CRFR1
(Fig. 3.6D-F) and that MAGI-1 siRNA had the same effect on CRFR1-TAV
internalization (Fig. 3.6D). Thus, MAGI proteins could regulate CRFR1 endocytosis.

3.3.6

MAGI proteins can regulate CRFR1 endocytosis by mediating
β-arrestin recruitment to the receptor

The primary pathway contributing to CRFR1 internalization was previously shown to be
β-arrestin-dependent (Holmes et al., 2006). Because of the effect of MAGI proteins on the
regulation of CRFR1 endocytosis observed in Fig. 3.6, we decided to study the effect of
MAGI proteins on β-arrestin recruitment to CRFR1. To do this, we employed a BRET
assay to investigate this interaction between rLuc-tagged β-arrestin2 and YFP-tagged
CRFR1. The overexpression of all MAGI proteins resulted in a right-ward shift in the CRF
dose response curve for -arrestin2 recruitment (Fig. 3.7A). There was also a significant
reduction in the maximal response for β-arrestin recruitment at 500 nM CRF with time
(Fig. 3.7B). We also examined the effect of knockdown of MAGI proteins on β-arrestin2
recruitment and similar results were observed, with a right-ward shift in the does response
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Figure 3.6: Effect of MAGI proteins expression on agonist-stimulated CRFR1
endocytosis: Agonist-stimulated internalization of either HA-CRFR1 or HA-CRFR1ΔTAV following 500 nM CRF treatment for 30 min in the presence of either MAGI-1 (A),
MAGI-2 (B), MAGI-3 (C), MAGI-1 siRNA (D), MAGI-2 siRNA (E), or MAGI-3 siRNA
(F). The data represent the mean ± SEM of at least three independent experiments. * P <
0.05 versus empty vector or SCR siRNA control.
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Figure 3.7: Effect of MAGI proteins expression on β-arrestin recruitment to CRFR1:
BRET assays measured between β-arrestin-rLuc and CRFR1-YFP in the presence of
MAGI-1, MAGI-2 or MAGI-3 (A, B) or MAGI-1 siRNA, MAGI-2 siRNA or MAGI-3
siRNA (C, D). A and C show dose responses of the interaction while B and D show the
interaction as a function of time upon stimulation with 500 nM CRF.
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curve and significant reduction in the maximal response, with MAGI-3 exhibiting the most
prominent effect (Fig. 3.7C and 3.7D). Taken together, these data suggested that MAGI
proteins are regulating CRFR1 endocytosis by mediating β-arrestin recruitment to CRFR1.

3.3.7

Knockdown of one MAGI proteins can lead to the upregulation
in the expression level of the others

The results we obtained from our internalization assays and β-arrestin recruitment assays
were surprising in terms of having similar effects upon overexpression and knockdown of
MAGI proteins. Therefore, we hypothesized that the expression levels of different
members of the MAGI subfamily of proteins might be changing to compensate for the loss
of another family member. In order to test this, we assessed the expression levels of each
MAGI protein upon knockdown of the other MAGI proteins. We observed a significant
up-regulation of MAGI-1 expression levels upon knockdown of MAGI-3 (Fig. 3.8A).
Similarly, there was a significant up-regulation of MAGI-3 expression levels when MAGI1 is knocked down (Fig. 3.8B). This suggested a compensatory effect between MAGI-1
and MAGI-3 that could explain the similar results observed for CRFR1 internalization and
-arrestin2 recruitment following either MAGI protein overexpression or knockdown.
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Figure 3.8: Knockdown of one MAGI protein results in an increase of expression of
the other MAGI proteins: (A) Representative immunoblot showing the levels of MAGI1 in HEK 293 cells transfected with siRNA combinations as labeled. Densitometric
analysis shows MAGI-1 levels after normalization to actin as a loading control. (B)
Representative immunoblot showing the levels of MAGI-3 in HEK 293 cells transfected
with siRNA combinations as labeled. Densitometric analysis shows MAGI-3 levels after
normalization to actin as a loading control. The data represent the mean ± SEM of at least
eight independent experiments. * P < 0.05 versus SCR siRNA control.
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3.4

Discussion
We have previously identified all three members of the MAGI subfamily as

CRFR1-interacting PDZ proteins in the PDZ overlay assay (Dunn et al., 2013). Despite
similarities in their molecular topology, the members of the MAGI subfamily, specifically
MAGI-2 and MAGI-3, are known to have distinct function with respect to their functional
regulation of different GPCRs, but their role in regulating CRFR1 activity has not been
investigated (Xu et al., 2001; Sugi et al., 2007; Zhang et al., 2007; Gee et al., 2009; Yang
et al., 2010). We find that all three MAGI proteins are co-immunoprecipitated with CRFR1
in a PDZ motif dependent manner and that either overexpression or knockdown of each of
the MAGI proteins is able to negatively regulate CRFR1 endocytosis with MAGI-1
overexpression or knockdown negatively regulating CRFR1 endocytosis in a PDZ motifindependent manner. This antagonism of CRFR1 endocytosis that is mediated by either
MAGI protein overexpression or knockdown appears to involve the antagonism of arrestin recruitment to the receptor. In the case of siRNA-mediated knockdown of
individual MAGI proteins there appears to be a compensatory up-regulation of the
expression of other MAGI protein subtypes. In addition we find that while the
overexpression of each of the MAGI proteins does not influence CRFR1-stimulated
ERK1/2 phosphorylation, siRNA knockdown of each of the MAGIs results in a significant
increase in CRFR1-mediated ERK1/2 phosphorylation. Taken together, our results indicate
that MAGI protein interactions with CRFR1 play an important role in regulating CRFR1
function.
MAGUK proteins comprise a subfamily of scaffolding proteins that are defined by
having PDZ, SH3 and GK domains with an emerging role in synapse formation and
function. DLG (discs large) subfamily (mainly SAP97 and PSD-95) have been the focus
of many studies and are shown to play key roles in synaptogensis, the creation of neural
circuits, synaptic transmission, memory and learning, as well as glutamate receptor
clustering and trafficking (Stetak et al., 2009). On the other hand, few studies have looked
at the MAGI subfamily of MAGUK proteins, although they are abundantly expressed in
the brain. Current understanding of MAGI protein function in the brain suggests a role on
memory and learning, but the mechanism is still unknown (Funke et al., 2005; Stetak et al.,
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2009; Oliva et al., 2012). In terms of the MAGUKs role in regulating GPCRs function,
studies from our laboratory illustrate distinct roles for SAP97 and PSD-95 in regulating
CRFR1 trafficking and signaling (Dunn et al., 2013; Dunn et al., 2016). This is an
intriguing observation because of the overlapping sequence and structural similarities of
SAP97 and PSD-95. This lead to the hypothesis that MAGI proteins would also elicit
diverse effects on receptor physiology. Although previous studies have looked at the effects
of MAGI proteins on regulating GPCRs function, none of these previous reports have
compared the relative function of all three MAGI proteins in regulating the activity of an
individual GPCR, despite evidence that many GPCRs interact with all three MAGIs (Xu
et al., 2001; He et al., 2006; Sugi et al., 2007; Zhang et al., 2007; Gee et al., 2009; Yang et
al., 2010; Dunn and Ferguson, 2015). For example, MAGI-2 interacts with the β1-AR and
enhances its internalization, whereas it also interacts with VPAC1 to regulate its
intracellular localization in epithelial cells and inhibit agonist-induced internalization (Xu
et al., 2001; He et al., 2006; Gee et al., 2009). MAGI-3 on the other hand is found to
antagonize ERK1/2 activation by both the β1-AR and the β2-AR (Zhang et al., 2007; Yang
et al., 2010; He et al., 2006). We find here that the overexpression of any of the MAGI
proteins reduces CRF-stimulated CRFR1 internalization, which is similar to what is
observed for VPAC1, but opposite to what is observed for the β1-AR. Interestingly, this
effect is dependent on an intact CRFR1 PDZ-binding motif for MAGI-2 and MAGI-3, but
not MAGI-1. This suggests that MAGI-1 may associate with CRFR1 via other interactions
than those mediated by the PDZ domain. An alternative possibility would be that MAGI-1
is antagonizing the formation of protein complexes required for GPCR endocytosis.
Further studies on receptors that do not harbor a PDZ-binding motif such as CRFR2 would
be required to further investigate this role of MAGI-1. It will also be important to study the
effect of MAGI-1 on the ESCRT complex and its components.
As is the case for many GPCRs, the primary internalization pathway utilized by the
CRFR1 involves β-arrestin-dependent endocytosis via clathrin-coated pits (Ferguson et al.,
1998; Ferguson, 2001; Holmes et al., 2006; von Zastrow and Williams, 2012). The
observation that each of the MAGI proteins antagonize CRFR1 endocytosis suggested the
possibility that MAGI proteins may play a role in regulating β-arrestin recruitment to the
receptor. Consistent with this hypothesis, the overexpression of all of the MAGIs resulted
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in the antagonism of -arrestin2 recruitment to the receptor as measured by BRET assay
as assessed by a right-ward shift in the CRF dose response curve and a blunting of the
maximal translocation response. Surprisingly, when the same assay is repeated with siRNA
against MAGI-1, MAGI-2 or MAGI-3 to knockdown the endogenous proteins, we still
observe a right-ward shift in the dose response curve and an even more prominent reduction
in the maximal response. This result is opposite to what we had anticipated. Therefore, we
investigated whether changes in the expression levels of other MAGI protein subtypes is
compensating for the loss of expression of the MAGI protein knocked down by siRNA.
This concept of compensation is not entirely novel to the field of PDZ domain- containing
proteins, as it is suggested that PSD-95 and PSD-93 can replace one another to regulate
GPCR function in a similar manner (Sun and Turrigiano, 2011). Interestingly, we observe
a compensatory up-regulation of MAGI-1 expression upon MAGI-3 knockdown and an
up-regulation of MAGI-3 expression following MAGI-1 protein knockdown. Thus,
compensatory MAGI protein expression provides a plausible mechanism by which
knocking down individual MAGI proteins attenuates CRFR1 endocytosis and impairs arrestin2 recruitment. However, this mechanism may not be entirely sufficient to explain
our results, as although MAGI-2 knockdown resulted in increased MAGI-1 and MAGI-3
protein expression in the representative blots shown in Fig. 3.8, this result is not reliably
reproduced when compared to MAGI-1 and MAGI-3 knockdown. Additional work would
be necessary to further assess this interplay between the MAGI subfamily members.
We have previously reported the interaction of other PDZ domain- containing
proteins with CRFR1 and the consequences of that on receptor endocytosis. We have
shown that the overexpression of SAP97 antagonizes agonist-stimulated CRFR1
internalization, whereas single hairpin (shRNA) knockdown of endogenous SAP97 in
HEK 293 cells results in increased agonist-stimulated CRFR1 endocytosis and that PSD95 elicits the same effects on CRFR1 endocytosis (Dunn et al., 2015; Dunn et al., 2016).
Similarly, we also find that CAL negatively regulates CRFR1 endocytosis when
overexpressed (Hammad et al., 2015). Despite seemingly having similar effects, the
mechanism of GPCR regulation by these PDZ proteins is vastly different. SAP97 and PSD95 are suggested to regulate the internalization by affecting β-arrestin recruitment to
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CRFR1, while CAL acts as a major sorting protein at different subcellular levels and by
modifying the post-translational modifications that the receptor undergoes at the Golgi.
Thus, the MAGI proteins employ a similar “MAGUK-like” mechanism to regulate CRFR1
endocytosis via the attenuation of β-arrestin recruitment. However, their collective function
is further complicated by a compensatory mechanism involving changes in protein
expression of other subtypes. Future studies will examine this potential phenomenon and
how it may affect other GPCRs function.
In addition to the role that MAGI proteins play in regulating the trafficking of
CRFR1, we find that they have an important effect on the regulation of CRFR1 signaling,
specifically via the MAPK pathway, but not G protein-mediated cAMP formation. While
the overexpression of each of the MAGI proteins has no effect on CRFR1-mediated
ERK1/2 phosphorylation, siRNA knockdown of all of the MAGIs results in a significant
increase in the extent of ERK1/2 phosphorylation induced by CRFR1 activation.
Interestingly, a study on LPA2R showed opposite effects on ERK1/2 activation where
MAGI-3 knockdown reduced the signal. However, similar to our study, the LPA2R study
which was performed on SW480 cells reported no difference in ERK activity upon
overexpression of MAGI-3 suggesting that different tissues and cell lines express
endogenous MAGI proteins in high levels. Previous experiments examining the regulation
of CRFR1-mediated ERK1/2 activation by two other MAGUK family members, SAP97
and PSD-95 yielded different results (Dunn et al., 2013; Dunn et al., 2016). Whereas,
SAP97 expression significantly enhanced CRFR1-stimulated ERK1/2 phosphorylation,
PSD-95 overexpression had no effect on ERK1/2 phosphorylation induced by CRFR1
activation. In contrast, the observed increase in CRFR1-mediated ERK1/2 phosphorylation
following siRNA knockdown of each of the MAGI proteins is similar to what we have
previously observed following siRNA knockdown of PDZK1 (Walther et al., 2015). The
mechanism by which siRNA knockdown of an individual MAGI protein results in
compensatory changes in the expression levels of other MAGI proteins to attenuate CRFR1
endocytosis without compensating for CRFR1-mediated ERK1/2 activation is unclear.
However, these results might suggest that the observed increase in ERK1/2
phosphorylation is mediated by a -arrestin-independent pathway as CRFR1/-arrestin
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interactions are predominantly regulated by GRK5 phosphorylation, which is thought to
preferentially allow activation of ERK1/2 via the -arrestin-mediated pathway (Holmes et
al., 2006; Zidar et al., 2009).
Now that we have a better understanding for the role of MAGI proteins in
regulating CRFR1 function in HEK293 cells, the next step would be to asses these
interactions in vivo. RT-PCR in mouse tissue showed that the MAGI proteins are expressed
in different regions of the brain including the cortex, thalamus and cerebellum (Sugnet et
al., 2006). We would predict that MAGI proteins are expressed in CRF-containing neurons
and would regulate CRFR1 physiology. Some knockout mouse models of MAGI proteins
are available (MAGI-1 and MAGI-2) and have exhibited some renal deficits (Ihara et al.,
2014). This reflects the importance of MAGI proteins in periphery. In addition, MAGI-2
knockout mice show abnormal elongation of dendritic spines indicating a possible role for
MAGI-2 during morphogenesis of neurons. (Iida et al., 2007). Furthermore, studies on C.
elegans demonstrate a role for MAGI-1 in regulating the clustering of ionotropic glutamate
receptors in certain neurons that are associated with learning and memory (Stetak et al.,
2009). Therefore, further characterization of MAGI proteins knockout models is required
to determine the role of this subfamily in the CNS.
In summary, the current study completes a series of investigations examining the
role of PDZ proteins in regulating the expression, trafficking and signaling of CRFR1. We
find that PDZ proteins play an overlapping but distinguishable role in regulating the posttranslation modification, ER-Golgi trafficking, endocytosis and signaling of CRFR1 (Dunn
et al., 2013; Hammad et al., 2015; Walther et al., 2015; Dunn et al., 2016). Although each
of these proteins had a similar effect on CRFR1 endocytosis, as they each, with the
exception of PDZK1, function to antagonize CRFR1 internalization, they exhibit
pleiotropic effects on the regulation of CRFR1-mediated ERK1/2 activity. These
observations indicate that there is likely no redundancy of function for PDZ proteins in the
regulation of GPCR activity in vivo, and suggest that in a cellular context these proteins
may interchangeably interact with GPCRs to differentially regulate the recruitment of
signaling complexes required for their activation of mitogenic signaling pathways.
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3.5

Conclusion
In conclusion, our data demonstrate an interaction between all three MAGI

proteins, MAGI-1, MAGI-2 and MAGI-3 with CRFR1 that leads to the regulation of
receptor activity. We illustrate that all MAGI proteins can regulate the internalization of
the receptor by mediating β-arrestin recruitment. We also provide evidence that MAGI
proteins can regulate CRFR1 signaling via the MAPK pathway but not the G proteindependent pathways presented by cAMP formation. We also suggest a compensatory effect
of regulation among the members of the MAGI subfamily. Taken together, these
observations along with our previous studies on CRFR1 confirm the distinctive functions
of PDZ domain-containing proteins in regulating GPCRs function.
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4.1 Introduction
The family of serotonin receptors (5-HTRs) consists of 7 receptor types and 15
subtypes that belong to Class A G protein-coupled receptors (GPCRs), except for 5-HT3Rs
which are ligand-gated ion channels (Gray and Roth, 2001; Lanfumey et al., 2008). 5-HTRs
contribute to the modulation of various biological processes including sleep-wake cycles,
appetite, mood, memory, breathing, cognition and sexual behavior (McCorvy and Roth,
2015). Serotonin has been the focus of many pharmacological studies for the treatment of
neuropsychiatric disorders with drugs that target either the serotonin receptors or serotonin
uptake (Kroeze and Roth, 1998; Roth et al., 2004). Examples include SSRIs (serotoninselective reuptake inhibitors), SNRIs (dual serotonin-norepinephrine reuptake inhibitors)
and partial agonists or antagonists for the 5-HTRs. Among the different serotonin receptor
subtypes, the most ubiquitous and extensively studied 5-HTRs in the human brain are the
5-HT1AR and 5-HT2AR. These receptors have been shown to have potential roles in
different neuropsychiatric diseases such as Alzheimer’s disease, schizophrenia, depression
and suicide (Burnet et al., 1995; Roth et al., 2004).
The 5-HT2R subfamily consists of three subtypes: 5-HT2A, 5-HT2B and 5-HT2C. The
family is primarily coupled to Gq leading to the activation of phospholipase Cβ (PLCβ)
which hydrolyzes the phosphatidylinositol diphosphate (PIP2) to release diacylglycerol
(DAG) and inositol triphosphate (IP3) (Gray and Roth, 2001; Roth et al., 2004). 5-HT2R
coupling to Gq ultimately culminates in the release of Ca2+ from intracellular stores and
the subsequent activation of protein kinase C. In addition to activating Gq-dependent cell
signaling, 5-HTRs can activate the MAPK pathway resulting in the extracellular signalregulated kinase 1 and 2 (ERK1/2) phosphorylation. 5-HT2AR also encodes a class I PDZbinding motif at the distal end of its carboxyl-terminal tail that consists of three amino
acids; serine, cysteine and valine (SCV). It was shown to be regulated by multiple PSD95/Disc Large/Zona Occludens (PDZ) domain-containing proteins such as SAP97, PSD95, PDZK1 and MUPP1 (Xia et al., 2003; Jones et al., 2009; Jones et al., 2009; Dunn et
al., 2014; Walther et al., 2015). SAP97 and PSD-95 belong to the membrane associated
guanylate kinase (MAGUK) subfamily of PDZ proteins (Funke et al., 2005; te Velthuis et
al., 2007; Oliva et al., 2012).
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The MAGUK family of proteins are synaptic scaffolding proteins that belong to a
protein network responsible for the spatial organization of the presynaptic and postsynaptic
compartments. One of their primary functions is to regulate the formation of synapses in
the central nervous system (Funke et al., 2005; Zhang et al., 2009; Yamagata and Sanes,
2010). MAGUKs are widely-expressed in the brain and periphery and they consist of
multiple subfamilies including membrane palmitoylated proteins (MPPs), zona occludens
(ZO), caspase recruitment domain containing MAGUK protein (CARMA), discs larges
(DLGs) and MAGUK with inverted orientation PDZ proteins (MAGIs) (Oliva et al., 2012).
As scaffolding proteins, they contain multiple domains to control their function and
facilitate their interactions with their targets. The two common domains among all
members are PDZ domains and guanylate kinase (GK) domains (Oliva et al., 2012). One
of the important targets for MAGUKs are GPCRs (Dunn and Ferguson, 2015). The proteinprotein interaction between GPCRs and MAGUKs have crucial effects on the regulation
of GPCR activity (reviewed by Dunn and Ferguson, 2015). MAGUK proteins play a central
role in mediating the subcellular localization, trafficking, cell surface expression and signal
transduction of multiple GPCRs and different proteins have both overlapping and distinct
roles in the regulation of GPCR activity (Harris and Lim, 2001; Lee and Zheng, 2010;
Romero et al., 2011; Magalhaes et al., 2012). MAGI protein represent an important
subfamily of MAGUK proteins and is comprised of three members: MAGI-1, MAGI-2 and
MAGI-3. All three proteins share a similar structure containing one guanylate kinase-like
(GK) domain, two tryptophan tryptophan (WW) domains and six PDZ domains (te
Velthuis et al., 2007; Oliva et al., 2012; Dunn and Ferguson, 2015).
MAGI-1 is also called BAP-1 (BAI-1-associated protein 1) and has 7 different
splice variants that exhibit distinct but overlapping tissue distributions (Dobrosotskaya et
al., 1997; Laura et al., 2002). MAGI-2 or S-SCAM (synaptic scaffolding molecule) has
two alternative splice variants and is brain-specific, whereas MAGI-3 exhibits a
widespread expression pattern. MAGI-1 through its interaction with the brain-specific
angiogenesis inhibitor-1 (BAI-1) is proposed to contribute to regulating the cytoskeletal
organization and membrane protein distribution, likely by relaying signals via BAI-1 that
control both cell- cell and cell- matrix interactions (Shiratsuchi et al., 1998; Stetak et al.,
2009; Stephenson et al., 2013). MAGI-2 interacts with β1-AR in an agonist-dependent
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manner to facilitate β1-AR endocytosis without altering cAMP responses (Xu et al., 2001)
In contrast, MAGI-2 negatively regulates the internalization and Gs-coupling of the
vasoactive intestinal polypeptide type 1 receptor (VPAC1R) (Gee et al., 2009). MAGI-3
overexpression inhibits β2-AR-mediated signaling via the extracellular signal-regulated
kinase 1 and 2 (ERK1/2) pathway, whereas a loss of MAGI-3 expression antagonizes
lysophosphatidic

acid-activated

receptor

subtype-2

(LPA2R)-stimulated

ERK1/2

phosphorylation (Yang et al., 2010). We previously identified all three MAGI protein
subtypes as 5-HT2AR-interacting proteins using a 96 well PDZ protein array. In the present
study we confirm the interaction of each of the MAGI proteins with 5-HT2AR and
investigate their role in regulating 5-HT2AR cell surface expression, trafficking and
signaling.
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4.2 Materials and Methods
4.2.1

Materials

MAGI-1, MAGI-2 and MAGI-3 antibodies were purchased from Thermo Fisher
(Burlington, ON, Canada). Rabbit anti-phospho-p44/42 MAPK (Thr-202/Tyr-402) and
rabbit anti-p44/42 MAPK antibodies were obtained from Cell Signaling Technology
(Pickering, ON, Canada). Rabbit anti-PLCβ3 was purchased from abcam (Toronto, ON,
Canada). ECL Western blotting detection reagents were purchased from Biorad
(Mississauga, ON, Canada). Rabbit anti-Flag antibody and all other biochemical reagents
were purchased from Sigma-Aldrich (Oakville, ON, Canada).

4.2.2

Plasmids

FLAG-tagged 5-HT2AR and 5-HT2AR-ΔSCV constructs were described previously
(Magalhaes et al., 2010). His-MAGI-1, HA-MAGI-2 and His-MAGI-3 were kindly
provided by Dr. Randy Hall (Emory University, School of Medicine). PLCβ3 was kindly
provided by Dr. Alan Smrcka (University of Rochester Medical Center). MAGI-1 siRNA,
MAGI-2 siRNA and MAGI-3 siRNA were purchased from Thermo Fisher (Burlington,
ON, Canada). For the negative controls, we used Silencer Negative Control #1 AM4635
AGUACUGCUUACGAUACGGTT from Invitrogen (Burlington, ON, Canada).

4.2.3

Cell Culture and Transfection

Human embryonic kidney (HEK 293) cells were grown in Eagle’s minimal essential
medium supplemented with 10% fetal bovine serum. Cells were plated on 10-cm dishes
24h prior to transfection. All experiments were performed on 75-80% confluent plates.
Transfections were performed using calcium phosphate protocol except for siRNA
transfections which were performed using Lipofictamine 2000 following manufacturer’s
instructions. Transfections were performed with 2 g of each construct. Empty pcDNA3.1
vector was used to equalize the total amount of plasmid cDNA used to transfect cells. 18h
post-transfection, cells were washed with phosphate-buffered saline (PBS) and
resuspended with trypsin, 0.25% EDTA. Experiments were performed approximately 48h
after transfection except for knockdown experiments which were performed 72h post
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transfection since this protocol resulted in the maximum knockdown of the different MAGI
proteins.

4.2.4

Co-immunoprecipitation

24h after transfection, HEK 293 cells were seeded onto 10-cm dishes. Cells were starved
in HBSS lacking serum for 1h at 37°C then stimulated with 10 µM 5-HT for 30 mins. Cells
were then lysed in 500 L lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1%
Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 g/ml leupeptin, and 2.5
g/ml aprotinin) for 20 min on a rocking platform at 4°C. Samples were collected into 1.5
ml Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4°C to pellet insoluble
material. A Bradford protein assay was performed and 300 µg of protein was incubated
overnight at 4°C with 40 µl Flag-immunoprecipitation beads. Beads were washed three
times with cold lysis buffer and incubated overnight at room temperature in 3xSDS loading
buffer containing 2-mercaptoethanol. Samples were separated by SDS-PAGE, transferred
to a nitrocellulose membrane, and western blots were then performed with the indicated
antibodies (rabbit anti- Flag, 1:1000), (rabbit anti-MAGI-2, 1:1000), (rabbit anti-MAGI-3,
1:1000), (rabbit anti- V5, 1:1000), (rabbit anti-PLCβ3, 1:1000).

4.2.5

Measurement of Inositol Phosphate Formation

HEK 293 cells were transiently co-transfected with 2 μg Flag-5-HT2AR or Flag-5-HT2ARΔSCV with 2 µg of MAGI-1, MAGI-2 or MAGI-3. 48h post-transfection cells were
incubated overnight in inositol-free Dulbecco’s modified Eagle’s medium with 1 μCi/ml
myo-[3H]-Inositol. For all experiments cells were incubated for 1h in warm HBSS and were
then incubated with 10 mM LiCl alone for 10 minutes followed by increasing doses of 5HT in LiCl for 30 minutes. Cells were placed on ice and the reaction was stopped with 500
μl of perchloric acid and was neutralized with 400 μl of 0.72 M KOH, 0.6 M KHCO3. Total
cellular [3H] inositol incorporation was determined in 50 μl of cell lysate. Total inositol
phosphate was purified by anion exchange chromatography using Dowex 1-X8 (formate
form) 200–400 mesh anion exchange resin and [3H] inositol phosphate formation was
determined by liquid scintillation using a Beckman LS 6500 scintillation system.
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Alternatively for siRNA experiments, HEK 293 cells were transiently transfected with 2
μg Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV with either MAGI-1, MAGI-2 or MAGI-3
siRNA as described in the figure legends. 24h post-transfection, cells were reseeded into
96-well poly-lysine coated plates. Cells were left to recover for another 24h and were then
incubated overnight in inositol-free Dulbecco’s modified Eagle’s medium with 1 μCi/well
myo-[3H]-Inositol. On the next day, cells were incubated for 1h in HBSS and were then
incubated with 15 mM LiCl for 15 minutes followed by increasing doses of 5-HT in LiCl
for 30 minutes. Cells were then lysed with 50 mM formic acid. 30 μl of cell lysates were
mixed with 75 μl of 2.67 mg/ml of SPA beads diluted in water (RNA binding YSi beads,
GE Healthcare) in a 96-well/plate and agitated at 4°C for 3h. The radioactivity was counted
with a Wallac MicroBeta luminescence counter (PerkinElmer).

4.2.6

Receptor Endocytosis

Following transfection, HEK 293 cells were re-seeded into 12-well plates. Cells were
serum-starved in HBSS lacking serum for 1h at 37°C then stimulated for 0 or 30 min with
10 µM 5-HT in HBSS at 37 °C. Cells were washed with cold HBSS and incubated with
mouse anti-Flag antibody (1:1000) for 1h on ice. Cells were washed with cold HBSS then
labeled with Alexa Fluor 647 donkey anti-mouse IgG (1:1000) for 1h on ice in the dark.
Cells were washed with cold HBSS and treated with 5 mM EDTA in PBS for 5 min on ice.
Cells were collected and transferred to flow cytometry tubes containing 4% formaldehyde
in PBS. Samples were run on a FACS Calibur cytometer using BD Cell Quest Pro software
(BD Biosciences, Mississauga, ON) until 10,000 cells were counted. The geometric mean
of fluorescence was determined using Flow Jo analysis software and was representative of
the expression levels of the receptor on the plasma membrane (BD Biosciences,
Mississauga, ON).

4.2.7

Western Blot Analysis

75-90 μl of the samples from the different assays which is equivalent to about 50-70 μg of
protein was diluted in β-mercaptoethanol-containing 3xSDS loading buffer and then
applied to 10% SDS-PAGE (30% acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10%
ammonium persulfate and TEMED). Separated proteins were then transferred to
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nitrocellulose membranes and membranes were then blocked in 10% milk in TBS for 1h.
Membranes were then blotted overnight by incubation with the appropriate antibody at
4°C. 24h later membranes were washed at least three times with 1X TBS with 0.05%
Tween 20, and then incubated with a horseradish peroxidase- conjugated secondary
antibody (1:10,000) for 1h. Membranes were finally washed again with 1X TBS with
0.05% Tween 20 three times before being developed using a BioRad chemiluminescence
system.

4.2.8

ERK Phosphorylation

Following 48h of transfection, HEK 293 cells were re-seeded into 6-well plates. Cells were
serum starved overnight in DMEM. On the day of the experiment, cells were starved for
1h at 37°C in HBSS and then stimulated with 10 µM 5-HT agonist for 0, 5 and 10 min.
Cells were lysed with lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 1% Triton X100) containing protease inhibitors (1 mM AEBSF, 10 μg/ml leupeptin, and 2.5 μg/ml
aprotinin) and phosphatase inhibitors (10 mM NaF and 500 μM Na3VO₄) for 20 min on a
rocking platform at 4°C. Samples were collected into 1.5 ml Eppendorf tubes and
centrifuged at 15,000 g for 15 min at 4°C to pellet insoluble material. A Bradford protein
assay was performed, and 30–50 μg of protein was incubated overnight at room
temperature in 3xSDS loading buffer containing 2-mercaptoethanol. Samples were
separated by SDS-PAGE, transferred to a nitrocellulose membrane, and western blot
analysis was performed for ERK1/2 (rabbit anti-p44/42 MAPK, 1:1000), phospho-ERK1/2
(rabbit anti-phospho-p44/42 MAPK, 1:1000), MAGI antibodies (1:1000), Flag-5-HT2AR
(rabbit anti-Flag, 1:1000).

4.2.9

Statistical Analysis

All measurements are represented as mean ± SEM. Comparisons were performed using
one way analysis of variance test (ANOVA) followed by Bonferroni’s or Dunn’s Multiple
comparisons test to determine significance. * indicate P values less than 0.05 and is
considered to be significant.
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4.3 Results
4.3.1

MAGI proteins co-immunoprecipitate with Flag-5-HT2AR

All the MAGI subfamily proteins (MAGI-1, 2 and 3) were identified using a PDZ domain
proteomic array as potential 5-HT2AR-interacting proteins (unpublished data). To validate
this interaction we assessed whether V5-His-MAGI-1, HA-MAGI-2 and V5-His-MAGI-3
were co-immunoprecipitated with either Flag-tagged 5-HT2AR (Flag-5-HT2AR) or a Flag5-HT2AR construct lacking the PDZ binding motif (Flag-5-HT2AR-ΔSCV). We found that
all of the MAGI proteins were effectively co-immunopreciptated with Flag-5-HT2AR, but
not Flag-5-HT2AR-ΔSCV (Fig. 4.1A-C). However, the interaction between Flag-5-HT2AR
and each of the MAGI proteins was not altered by agonist activation of the receptor (Fig.
4.1D).

4.3.2

Effect of MAGI proteins on agonist-stimulated 5-HT2AR
endocytosis

MAGI proteins were previously shown to regulate the endocytosis of other GPCRs, such
as VPAC1 and β1-AR (Xu et al., 2001; Gee et al., 2009). In addition, the internalization of
both CRFR1 and 5-HT2AR was shown to be mediated by the MAGUK protein SAP97
(Dunn et al., 2013; Dunn et al., 2014). Therefore, we assessed the effects of MAGI protein
overexpression and knockdown on both Flag-5-HT2AR and Flag-5-HT2AR-ΔSCV
internalization by flow cytometry. We found that the overexpression of each of the MAGI
proteins had no effect on either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV internalization
following agonist treatment with 10 µM 5-HT for 30 min (Fig. 4.2A-C). In contrast, while
MAGI-2 siRNA knockdown did not alter either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV
endocytosis, MAGI-3 knockdown significantly decreased Flag-5-HT2AR internalization
(Fig 4.2D and 4.2E). Thus, MAGI protein expression could differentially regulate 5-HT2AR
endocytosis.
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Figure 4.1: MAGI proteins co-immunoprecipitate with Flag-5-HT2AR in a PDZbinding motif-dependent manner and an agonist-independent manner: HEK 293
cells were co-transfected with Flag-5-HT2AR (WT or ΔSCV) and pcDNA3.1 along with
MAGI-1, MAGI-2 or MAGI-3. Shown are representative immunoblots for the coimmunoprecipitation (IP) of (A) MAGI-1, (B) MAGI-2, and (C) MAGI-3 with Flag-5HT2AR, but not Flag-5-HT2AR-ΔSCV which lacks the PDZ-binding motif. (D)
Densitometric quantification of changes in agonist-stimulated (10 M 5-HT) coimmunoprecipitation of MAGI-1, MAGI-2 or MAGI-3 with Flag-5-HT2AR. Data are
representative of 3-4 independent experiments. NT: non-transfected.
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Figure 4.2: Effect of MAGI proteins on 5-HT2AR endocytosis: Agonist-stimulated
internalization of Flag-5-HT2AR and Flag-5-HT2AR-SCV in response to 10 M 5-HT
for 30 min in HEK 293 cells upon overexpression of either (A) MAGI-1, (B) MAGI-2
or (C) MAGI-3. Agonist-stimulated internalization of Flag-5-HT2AR and Flag-5HT2AR-SCV in response to 10 M 5-HT for 30 min in HEK 293 cells upon siRNA
knockdown of either (D) MAGI-2 or (E) MAGI-3. SCV, Flag-5-HT2AR-SCV. * P <
0.05 versus pcDNA or scrambled siRNA peptide (SCR) control.
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4.3.3

MAGI proteins modulate 5-HT2AR-stimulated IP formation

5-HT2AR can couple to Gαq/11 protein resulting in the activation of PLC and the formation
of DAG and IP3. Both SAP97 and PSD-95 regulate 5-HT-mediated IP formation where
knockdown of SAP97 reduces IP signaling and overexpression of PSD-95 enhances it (Xia
et al., 2003; Dunn et al., 2014). Therefore, we examined whether either the overexpression
or knockdown of MAGI proteins can alter 5-HT-stimulated IP formation in either Flag-5HT2AR or Flag-5-HT2AR-SCV expressing HEK 293 cells. We found that the
overexpression of each of the MAGI proteins significantly increased the maximum
response for 5-HT-stimulated IP formation mediated by both Flag-5-HT2AR and Flag-5HT2AR-SCV, compared with cells transfected with receptor alone (Fig. 4.3A-C). In
contrast, we found that whereas siRNA knockdown of endogenous MAGI-1 or -3 had no
effect upon Flag-5-HT2AR-stimulated IP formation, knockdown of MAGI-2 resulted in a
reduction of Flag-5-HT2AR-induced IP formation significantly (Fig. 4.3D). The siRNA
knockdown of either MAGI-2, or -3 resulted in a significant reduction of Flag-5-HT2ARΔSCV-mediated IP formation (Fig. 4.3E). This suggested that this effect does not require
a direct interaction between the receptor and the MAGI proteins, because each of the MAGI
proteins did not immunoprecipitate with the truncated receptor mutant.

4.3.4

MAGI proteins can enhance cell surface trafficking of 5-HT2AR
to the plasma membrane

MAGUK proteins were previously shown to regulate the cell surface expression of the
CRFR1 (Dunn et al., 2013; Dunn et al., 2016). Therefore, we examined whether either the
overexpression or the siRNA knockdown of MAGI-1, -2 or -3 altered the cell surface
expression of 5-HT2AR. We found that the overexpression of MAGI-1 did not alter cell
surface expression of either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV (Fig. 4.4A). In
contrast, the overexpression of both MAGI-2 and MAGI-3 increased the cell surface
expression of Flag-5-HT2AR, whereas MAGI-3 also increased the plasma membrane
expression of Flag-5-HT2AR-ΔSCV (Fig. 4.4B and 4.4C). The siRNA-mediated
knockdown of both MAGI-2 and MAGI-3 did not alter the relative cell surface expression
of either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV (Fig. 4.4D and 4.4E).
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Figure 4.3: MAGI proteins regulate 5-HT2AR-stimulated IP formation in PDZ motifindependent manner: Dose response curves for 5-HT-stimulated (30 min) inositol
phosphate (IP) formation in HEK 293 cells co-transfected with either Flag-5-HT2AR or
Flag-5-HT2AR-SCV along with either (A) MAGI-1, (B) MAGI-2 or (C) MAGI-3. Inositol
phosphate formation in cells expressing either (D) Flag-5-HT2AR or (E) Flag-5-HT2ARSCV along with MAGI-1 siRNA, MAGI-2 siRNA or MAGI-3 siRNA and treated with
10 M 5-HT for 30 min. * P < 0.05 versus scramble (SCR) peptide treated control. SCV,
Flag-5-HT2AR-SCV.
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Figure 4.4: Effect of MAGI proteins on the trafficking of 5-HT2AR to the plasma
membrane: Cell surface expression of Flag-5-HT2AR and Flag-5-HT2AR-ΔSCV at basal
level following the overexpression of MAGI-1 (A) or MAGI-2 (B) or MAGI-3 (C) or the
knockdown of MAGI-2 (D) or MAGI-3 (E). SCV, Flag-5-HT2AR-ΔSCV. * P < 0.05
versus pcDNA or scrambled peptide (SCR) control.
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4.3.5

MAGI-3 can enhance the recruitment of PLCβ3 to 5-HT2AR

Overexpression of MAGI proteins appeared to significantly enhance 5-HT2AR signaling
via Gαq/11 pathway for which the key effector enzyme is PLC. It was previously reported
that MAGI-3 could interact directly with PLCβ3 to alter LPA2 receptor-stimulated IP
formation (Lee et al., 2011). Therefore, we assessed by co-immunoprecipitation whether
PLC could be co-immumoprecipitated with both Flag-5-HT2AR and Flag-5-HT2ARSCV and whether this was influenced either by agonist treatment or by MAGI-3
overexpression. We found that PLC3 could be co-immunoprecipitated with Flag-5HT2AR and that 5-HT treatment (10 M) for 30 min increased the association with the
receptor (Fig. 4.5A and 4.5B). In contrast, PLC3 co-immunoprecipitation with Flag-5HT2AR-SCV was enhanced when compared to Flag-5-HT2AR but did not exhibit agonist
regulation. Interestingly, we observe a stronger interaction between the Flag-5-HT2AR and
PLCβ3 in the presence of MAGI-3, but not Flag-5-HT2AR-SCV. This could provide
another possible mechanism to explain the enhancement in 5-HT-stimulated IP formation.

4.3.6

Effect of MAGI proteins on regulating 5-HT-mediated ERK1/2
phosphorylation

MAGI proteins were previously shown to have distinct effects on ERK1/2 signaling since
it has been reported that MAGI-3 can enhance BAI-1- and LPA2R- mediated ERK1/2
phosphorylation and attenuate the same pathway if the β1- and β2- adrenergic receptors are
stimulated (He et al., 2006; Zhang et al., 2007; Yang et al., 2010; Stephenson et al., 2013).
Therefore, we assessed whether MAGI overexpression or siRNA-mediated knockdown of
endogenous MAGI proteins would alter Flag-5-HT2AR-mediated ERK1/2 phosphorylation
in response to 10 µM 5-HT treatment for 5, 10 and 30 min. We found that the
overexpression of MAGI-1, MAGI-2 or MAGI-3 had no effect on ERK1/2 signaling (Fig.
4.6A-F). However, when siRNA was used to silence the expression of endogenous MAGI
proteins, we found a significant increase in the signal following stimulation with 10 µM 5HT for 5, 10 and 30 min for MAGI-1 (Fig. 4.6A and 4.6B), 5 and 10 min for MAGI-2 (Fig
4.6C and 4.6D), but only 5 min for MAGI-3 (Fig. 4.6E and 4.6F). When ERK1/2
phosphorylation was tested in response to Flag-5-HT2AR-SCV activation in the presence
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Figure 4.5: MAGI-3 can enhance the association of PLCβ3 with 5-HT2AR: A) HEK
293 cells were co-transfected with Flag-5-HT2AR (WT or ΔSCV) and PLCβ3 or MAGI-3
+ PLCβ3. Representative immunoblot of PLCβ3 co-immunoprecipitated (IP) with both
Flag-5-HT2AR and Flag-5-HT2AR-ΔSCV. SDS-PAGE was used to analyze samples and
immunoblots were performed with rabbit anti-PLCβ3. B) Densitometric analysis of the
effect of MAGI-3 co-transfection. Data are representative of four independent experiments.
* P < 0.05 versus 5-HT2AR + PLC.
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of overexpressed MAGI proteins no change in phosphorylation was observed (Fig.4.7AF). In contrast, siRNA knockdown of MAGI-1 increased Flag-5-HT2AR-SCV-stimulated
ERK1/2 phosphorylation following 5 and 10 min 5-HT treatment (Fig. 4.7A and 4.7B) and
MAGI-2 knockdown increased ERK1/2 phosphorylation in response to 10 min 5-HT
treatment (Fig. 4.7C and 4.7D). MAGI-3 knockdown had no effect on Flag-5-HT2ARSCV activated ERK1/2 phosphorylation (Fig. 4.7E and 4.7F).
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Figure 4.6: Effect of MAGI proteins on 5-HT2AR-mediated ERK1/2 signaling: (A)
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for
0, 5, 10, and 30 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with
Flag-5-HT2AR along with either pcDNA, MAGI-1, SCR siRNA or MAGI-1 siRNA. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-1 and Flag-5-HT2AR protein expression.
(B) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, 10,
and 30 min. The data represent the mean ± SEM of four independent experiments. (C)
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag5-HT2AR along with either pcDNA, MAGI-2, SCR siRNA or MAGI-2 siRNA. Also shown are
corresponding immunoblots for total ERK1/2, MAGI-2 and Flag-5-HT2AR protein expression. (D)
Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, and 10
min. The data represent the mean ± SEM of four independent experiments. E) Representative
immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, 10, and 30
min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag-5-HT2AR
along with either pcDNA, MAGI-3, SCR siRNA or MAGI-3 siRNA. Also shown are
corresponding immunoblots for total ERK1/2, MAGI-3 and Flag-5-HT2AR protein expression. (F)
Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, 10,
and 30 min. The data represent the mean ± SEM of four independent experiments. * P < 0.05 versus
pcDNA or scramble peptide (SCR) control.
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Figure 4.7: Effect of MAGI proteins on 5-HT2AR-SCV-mediated ERK1/2 signaling: (A)
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag5-HT2AR-SCV along with either pcDNA, MAGI-1, SCR siRNA or MAGI-1 siRNA. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-1 and Flag-5-HT2AR-SCV protein
expression. (B) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment
for 0, 5, and 10 min. The data represent the mean ± SEM of four independent experiments. (C)
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag5-HT2AR-SCV along with either pcDNA, MAGI-2, SCR siRNA or MAGI-2 siRNA. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-2 and Flag-5-HT2AR-SCV protein
expression. (D) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment
for 0, 5, and 10 min. The data represent the mean ± SEM of four independent experiments. E)
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag5-HT2AR-SCV along with either pcDNA, MAGI-3, SCR siRNA or MAGI-3 siRNA. Also shown
are corresponding immunoblots for total ERK1/2, MAGI-3 and Flag-5-HT2AR-SCV protein
expression. (F) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment
for 0, 5, and 10 min. The data represent the mean ± SEM of four independent experiments. * P <
0.05 versus pcDNA or scramble peptide (SCR) control.
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4.4 Discussion
Recent studies have illustrated the importance of PDZ domain-containing proteins
in the regulation of GPCR activity (Dunn and Ferguson, 2015). Furthermore, studies on
the 5-HT2AR demonstrated the roles of MAGUKs such as PSD-95 (Xia et al., 2003) and
SAP97 (Dunn et al., 2014) and other PDZ proteins including MUPP1 (Jones et al., 2009)
and PDZK1 (Walther et al., 2015) in mediating the trafficking and signaling of the receptor.
In a PDZ overlay assay performed in our laboratory, we found that all three MAGI proteins
can associate with the carboxyl-terminal tail of 5-HT2AR (unpublished data). Therefore, we
decided to further characterize this interaction and determine its functional consequences
on the signaling and trafficking of 5-HT2AR. Despite the similarity in sequence and domain
structure of these proteins, we hypothesized that they would exhibit distinct functions. We
find that MAGI proteins regulate both IP3 and ERK1/2 signaling downstream of the
activation of the 5-HT2AR. We propose that the observed increase in 5-HT-mediated IP3
signaling is mediated at least in part by the regulated recruitment of PLCβ to the receptor.
We also show that silencing the expression of endogenous MAGI proteins using siRNA
can enhance 5-HT-mediated ERK1/2 signaling.
MAGI-2 has been shown to play an important role in regulating the trafficking and
signaling of multiple receptors including β1-AR and VPAC1 (Xu et al., 2001; Gee et al.,
2009). In the current study, we were able to show an effect of MAGI-2 knockdown on
regulating ERK1/2 activation. This is the first report to implicate MAGI-2 with the MAPK
pathway. Our data also showed that MAGI-2 can regulate IP formation where
overexpression resulted in an enhancement of the signal and knockdown reduced it. This
is the first report of MAGI-2 regulation of a Gαq-dependent pathway as well, however
MAGI-2 was previously shown to regulate Gαs-mediated cAMP formation by VPAC1 (Gee
et al., 2009). Despite previous reports indicating an effect of MAGI-2 overexpression on
GPCR internalization where it had a positive effect on β1-AR (Xu et al., 2001) and a
negative effect on VPAC1 (Gee et al., 2009), our observations indicated that MAGI-2 did
not affect the endocytosis of 5-HT2AR. However, we observed a significant increase in
receptor expression levels upon MAGI-2 overexpression. Therefore, it seems that MAGI2 is involved in regulating both the signaling and trafficking of 5-HT2AR.
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MAGI-3 has also been shown to regulate the signaling of a number of GPCRs
including LPA2R and β-adrenergic receptors (Zhang et al., 2007; Yang et al., 2010; Lee et
al., 2011). Our current study showed that MAGI-3 can regulate both G protein-dependent
as well as G protein- independent signaling pathways. Our data demonstrated that MAGI3 can regulate IP formation in a PDZ motif-independent manner. This is illustrated by the
enhancement in IP formation mediated by both 5-HT2AR and 5-HT2AR-ΔSCV upon
overexpression of MAGI-3 and the reduction in this effect upon MAGI-3 knockdown. The
effect of MAGI-3 knockdown was statistically different only for the 5-HT2AR-ΔSCVtranfected cells despite a trend for reduction with the 5-HT2AR-transfected cells suggesting
that the assay needs to be repeated for more conclusive statistical data. Interestingly,
opposite effects were previously observed when LPA-induced IP formation was studied
where MAGI-3 overexpression resulted in a decrease in IP formation and MAGI-3
knockdown led to an enhancement in this signaling pathway (Lee et al., 2011). We showed
that MAGI-3 could also mediate the MAPK cascade. While overexpression of MAGI-3
did not have an effect on ERK1/2 activation, knockdown led to an enhancement in ERK1/2
signaling. Interestingly, this effect is opposite to what was reported with LPA2R where
MAGI-3 knockdown reduced ERK activity (Zhang et al., 2007). However, similar to our
study, the LPA2R study which was performed on SW480 cells reported no difference in
ERK activity upon overexpression of MAGI-3 suggesting that different tissues and cell
lines express endogenous MAGI-3 in high levels (Zhang et al., 2007). Nonetheless, studies
on both β1-AR and β2-AR showed that MAGI-3 overexpression could lead to a decrease in
ERK1/2 signaling (He et al., 2006; Yang et al., 2010). It is noteworthy to mention that
MAGI-3 was also shown to regulate Gα12/13-mediated RhoA activation by LPA2R (Zhang
et al., 2007). Taken together, our data and previous studies confirmed the importance of
MAGI-3 in regulating GPCR signaling via multiple pathways and the distinct effects it
elicits based on the receptor being investigated. In addition to its role on signaling, we also
illustrated a role for MAGI-3 on 5-HT2AR internalization where MAGI-3 knockdown
resulted in a significant reduction in the internalization of the receptor. This is the first
report of a role for MAGI-3 in receptor endocytosis and as mentioned previously, MAGI2 was usually the MAGI protein responsible for this regulation for other receptors (Xu et
al., 2001; Gee et al., 2009). This emphasized the importance of investigating all PDZ
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proteins that interact with a receptor to gain complete understanding of how they regulate
its function.
To our knowledge, no previous reports studied the functional role of MAGI1/GPCR interactions. MAGI-1 was first characterized as a BAI-1 (Brain-specific
angiogenesis inhibitor 1) interacting protein and has been shown to co-immunoprecipitate
with VPAC1, but more studies are required to investigate the role it plays in regulating
GPCRs. Data from our current study suggest that MAGI-1 seems to be more important for
regulation of 5-HT2AR signaling as opposed to its trafficking. We demonstrate that MAGI1 overexpression can increase IP formation, while its knockdown can enhance ERK1/2
activation.
We proposed two mechanisms of regulation for 5-HT2AR signaling by MAGI
proteins. First, the increase in receptor expression level at the plasma membrane could
partly explain the enhancement in IP formation upon overexpression. However, this would
not apply to MAGI-1 which despite enhancing IP signaling had no effect on cell surface
levels. It also does not completely explain the fact that this effect on IP formation did not
require an intact PDZ motif, while the effect on receptor expression level was PDZdependent for MAGI-2 and PDZ-independent for MAGI-3. Second, the other mechanism
we presented here involved the effect of MAGIs on PLCβ3 recruitment to the receptor. We
specifically tested MAGI-3, since it has been shown to interact with PLCβ3 (Lee et al.,
2011). We found that MAGI-3 overexpression can increase the association between 5HT2AR and PLCβ3. However, although the representative blot in Fig. 4.5A shows this
enhancement with 5-HT2AR-ΔSCV, it was not a reproducible effect and therefore, we could
not conclude that it was PDZ-independent. These mechanisms might also provide a general
MAGUK regulation of IP signaling since both SAP97 and PSD-95 were shown previously
to mediate IP formation (Xia et al., 2003; Dunn et al., 2014). Another possibility that can
be explored is to examine whether MAGI proteins can affect the coupling of Gαq to 5HT2AR in a PDZ motif-independent manner. This is particularly important because MAGI3 has been shown to associate with different G proteins and has been suggested to bias the
coupling of different G proteins to LPA2R (Lee et al., 2011).
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The mechanism of regulation of the MAPK cascade remains unknown and further
studies are required to understand it. However, one speculation would be an effect of the
MAGI proteins on the recruitment of β-arrestin to the receptor. The activation of MAP
kinase pathway by GPCRs can be mediated by both arrestin- dependent and independent
pathways and previous studies showed a role for multiple PDZ proteins in mediating βarrestin recruitment either by enhancing it or by interfering with it (Hu et al., 2002;
Hammad et al., 2010).
Now that we have demonstrated the distinct roles of MAGI proteins in regulating
the function of the 5-HT2AR in HEK 293 cells, it would be important to further examine
this association and its physiological consequences in vivo. RT-PCR in mouse tissue
revealed that MAGI proteins are expressed in different regions of the brain including the
cortex, thalamus and cerebellum (Sugnet et al., 2006). We would predict that MAGI
proteins are expressed in serotonergic neurons where they co-localize with 5-HT2AR but
their effects need to be explored. In light of the involvement of 5-HT2AR in multiple mental
disorders such as schizophrenia and anxiety, it will also be important to study how 5HT2AR- MAGIs interactions contribute to using the receptor as a pharmacological target
(Gray and Roth, 2001; Roth et al., 2004). In fact, a study showed that PSD-95, another
MAGUK protein, is essential for the actions of atypical antipsychotics on 5-HT2Rs.
Therefore, a better understanding of PDZ protein regulation of 5-HT2AR function in vivo
is vital.
In conclusion, in this study, we compare the function of three PDZ proteins in
regulating 5-HT2AR activity. This is unique because previous studies have focused on one
MAGI protein based on the strength of interaction or tissue distribution despite reporting
the interaction with at least two of the MAGI proteins (Xu et al., 2001; Zhang et al., 2007;
Gee et al., 2009). It will be important to further investigate the dynamics between the three
MAGI proteins to determine if they have synergistic or competitive effects with one
another and one way to do so could be simultaneous overexpression and knockdown of the
MAGI proteins followed by an assessment of the receptor function.
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Chapter 5

5

Discussion

5.1 Summary
Previous research from our laboratory illustrated a crosstalk between CRFR1 and
5-HT2AR (Magalhaes et al., 2010). Magalhaes et. al showed that the activation of CRFR1
mediates the signaling of 5-HT2AR since pretreatment with CRF enhances 5-HT2ARmediated inositol phosphate formation. This effect was abolished when mutant forms of
the receptors that lack the PDZ motif are used indicating that intact PDZ motifs are required
for the crosstalk to occur and suggested a role for PDZ proteins in regulating the process.
They also reported that this effect was dependent on receptor internalization and recycling
by showing that using dominant negative forms of Rab4, Rab5 or dynamin could lead to
blockade of the crosstalk. Moreover, infusion of CRF peptide (1.5 μg) into the medial
prefrontal cortex of mice followed by the intraperitoneal administration of the 5-HT2Rselective agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) (0.15 mg/kg) results in
enhanced 5-HT2 receptor-stimulated anxiety-related behaviors. Our hypothesis was that a
PDZ-binding protein was recruited for the CRFR1-mediated sensitization of 5-HT2AR
signaling and it could enhance the expression of both receptors by regulating the
internalization and recycling of CRFR1/5-HT2AR complexes. To better understand the
molecular mechanism behind this crosstalk between receptors and to be able to use this
phenomenon in the development of therapeutic agents, the overall objective of this study
was to determine the PDZ protein responsible for CRFR1-mediated sensitization of 5-HT2A
receptor signaling.
In order to find PDZ domain-containing proteins that would be good candidates for
this regulation, a screen of 96 PDZ domains with the carboxyl-terminal tails of 5-HT2AR
and CRFR1 was performed (Dunn et al., 2013). This resulted in a sub-group of common
PDZ proteins that interacts with both receptors. These were SAP97, PDS-95, MAGI-1
MAGI-2, MAGI-3, CAL, PDZK1, MUPP1 and PTPN13. The proteins I chose to work
with for my thesis projects were CAL, MAGI-1, MAGI-2 and MAGI-3. These proteins
have been previously shown to regulate the trafficking and signaling of some members of
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the GPCRs family (Dunn and Ferguson, 2015). However, their role in regulating CRFR1
and 5-HT2AR was yet to be determined. It was essential to characterize the functional roles
of the interaction between the PDZ proteins and the two receptors separately before we
could assess the effects on the crosstalk regulation. Therefore, the three specific objectives
of this thesis were:
1. To determine the role of CAL in regulating the trafficking and
signaling of CRFR1 and the mechanism for this regulation

2. To determine the role of MAGI proteins in regulating the trafficking
and signaling of CRFR1 and the mechanism for this regulation

3. To determine the role of MAGI proteins in regulating the trafficking
and signaling of 5-HT2AR and the mechanism for this regulation
In the second chapter of this thesis, the interaction of CAL with CRFR1 is
characterized and shown to be dependent on the PDZ-binding motif of the receptor. CAL
is shown to localize with CRFR1 at the Golgi and is demonstrated to have a role in
inhibiting CRFR1 endocytosis, cell surface expression, and CRF-mediated ERK1/2
signaling via the CRFR1 PDZ-binding motif (Hammad et al., 2015). CAL does not have
an effect on CRF-mediated cAMP formation. Interestingly and contrary to studies where
the mechanism of CAL regulation of receptor expression is attributed to an effect of CAL
on degradation (Cheng et al., 2010; Koliwer et al., 2015), our work demonstrates that CAL
can elicit its effects on CRFR1 by mediating the post-translational glycosylation of the
nascent receptor at the Golgi. By characterizing glycosylation-deficient mutants of CRFR1
with a point mutation on the asparagine residues, we find that the effects that CAL has on
CRFR1 expression are comparable to the receptor expression levels of CRFR1 mutants. In
addition, the cellular distribution of the glycosylation-deficient mutants reveals that they
are mainly expressed in the Golgi. Similar localization of CRFR1 is observed upon
overexpression with CAL since a big portion of the receptor is retained intracellularly in
the Golgi. We also find that the signaling of the mutants via the MAPK pathway is similar
to that of CRFR1 in the presence of CAL. Although multiple PDZ proteins were shown to
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regulate GPCRs, mediating post-translational modifications seems to be exclusive to CAL
(Hammad et al., 2015; Dunn and Ferguson, 2015). It is also unique to show an effect for a
PDZ- binding protein during the early biosynthesis pathway as opposed to the later stages
during the life cycle of a GPCR.
Data presented in the third and fourth chapters illustrate distinct functions for the
MAGI subfamily of proteins in regulating the trafficking and signaling of CRFR1
compared to that of 5-HT2AR. Furthermore, we present different mechanisms by which
MAGI proteins can elicit their effects. In terms of their effect on trafficking and
internalization, we show that MAGI proteins can regulate CRFR1 endocytosis, but have
no effect on 5-HT2AR internalization. We also show that MAGI proteins can mediate their
effect on CRFR1 internalization by interfering with β-arrestin2 recruitment to the receptor,
a key step in the endocytic pathway. We also show that while no effect is observed on the
basal plasma membrane expression of CRFR1 in response to overexpression or knockdown
of MAGI proteins, there is a trend for an increase in expression levels of 5-HT2AR when
MAGI proteins are overexpressed. The results from investigating the trafficking and
internalization reflect the specificity and distinct functions of the proteins in regulating the
receptors. Our findings from studying the effects on the signaling pathways are also very
intriguing. CRFR1 and 5-HT2AR differ in the G protein subtypes that they couple to, but
they both have the ability to activate the ERK1/2 signaling pathway. There is no effect of
MAGI proteins on Gαs-mediated cAMP upon activation of CRFR1. On the other hand, 5HT-stimulated IP accumulation via Gαq coupling appears to be enhanced by MAGI
proteins. There are two possible mechanisms for this regulation of IP3 formation. It could
be in part due to the increase in receptor expression levels at the plasma membrane but the
more appealing mechanism is the enhancement of PLCβ3 association with the receptor
when MAGI proteins are overexpressed. Studying signaling via the MAPK pathway, we
find that knockdown of the endogenous MAGI proteins results in an enhancement in both
CRF-mediated and 5-HT-mediated activation of ERK1/2 signaling. Taken together, the
data from the third and fourth chapters suggest that MAGI proteins play important roles in
regulating the trafficking of CRFR1 and the signaling of 5-HT2AR.
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5.2 Regulation of GPCRs Trafficking by MAGI and CAL
Proteins
Data presented in this thesis illustrate an important role for PDZ domain-containing
MAGI and CAL proteins in regulating the trafficking of CRFR1 and 5-HT2AR (Fig. 5.1).
The effect on CRFR1 is prominent upon studying agonist-induced internalization of the
receptor. The main effect that is reported here is a decrease in CRFR1 internalization when
CAL is overexpressed and when levels of MAGI proteins are altered either by
overexpression or siRNA-mediated knockdown. An effect on 5-HT2AR plasma membrane
expression levels is observed following altered MAGI protein expression. Although not
significant for all the MAGI transfection conditions, there is a trend towards an enhanced
surface receptor levels. The reason for the big variation in the flow measurement of 5-HTmediated endocytosis, as well as surface receptor levels could be attributed to the nature of
the receptor which exhibits constitutive internalization activity and exhibits poor
dependence on β-arrestins for internalization (Albert and Tiberi, 2001; Bhatnagar et al.,
2001; Gray et al., 2001; Bhattacharyya et al., 2002). Therefore, it might be worth repeating
the assays with a more sensitive approach to arrive at more conclusive results. Interestingly,
previous work from our laboratory demonstrates an effect of other PDZ proteins on the
trafficking of CRFR1 and 5-HT2AR. These include SAP97, PSD-95 and PDZK1. SAP97
and PSD-95 function to reduce the internalization of both CRFR1 and 5-HT2AR (Dunn et
al., 2013; Dunn et al., 2014; Dunn et al., 2016). PDZK1 also reduces 5-HT2AR
internalization, but has no effect on CRFR1 internalization (Walther et al., 2015). Other
groups show a role for MAGI-2 in regulating GPCR trafficking, where it reduces VPAC1
internalization (Gee et al., 2009), enhances β1-AR internalization (Xu et al., 2001) and
facilitates localization of mGluR1 to the Golgi (Sugi et al., 2007). MAGI-1 and MAGI-3
have not been shown to affect GPCRs trafficking prior to the studies presented in this
thesis.
Another aspect of GPCRs trafficking is the regulation of CRFR1 surface expression by
CAL. We show that overexpression of CAL results in the retention of CRFR1
intracellularly in the Golgi. Previous studies show a similar effect of CAL on other GPCRs
such as mGluRs, SSTR5 and β1-AR, as well as other transmembrane proteins including
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Figure 5.1: A schematic representation of the processes in GPCRs endocytosis and
biosynthesis summarizing the findings of this thesis in terms of the role of MAGI
and CAL proteins in regulating these functions.
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CFTR and the voltage-gated potassium channel KV10.1 (Cheng et al., 2002; Wente et al.,
2005; Zhang et al., 2008; Cheng et al., 2010; Herrmann et al., 2013; Koliwer et al., 2015).
It has been previously suggested that CAL might be playing a role as a sorting molecule,
but the mechanism was believed to be via ubiquitination and degradation (Cheng et al.,
2010; Koliwer et al., 2015). However, we show here that at least for the regulation of
CRFR1, CAL contributes to the regulation of post-translational glycosylation and to the
assessment of the maturation state of the receptor and whether it has achieved proper
folding to be transported from the Golgi and expressed at the plasma membrane.

5.3 Regulation of GPCRs Signaling by MAGI and CAL
Proteins
Data presented in the previous chapters demonstrate distinct roles for MAGI and
CAL proteins in regulating both G protein-dependent as well as G protein-independent
signaling pathways (Fig. 5.2). Although MAGI-2 has previously been shown to reduce
cAMP signaling mediated by VPAC1, it does not seem to affect Gαs-mediated signaling by
CRFR1 and neither did MAGI-1, MAGI-3 nor CAL. However, the MAGI proteins do have
a significant effect on Gαq-mediated IP3 formation as a result of 5-HT2AR activation. It is
of interest to observe an effect of the MAGI proteins on one G protein sub-type, but not
another and confirms the selectivity of their effect on G protein signaling pathways.
Previous studies from our laboratory have shown an effect of SAP97 and PDZK1 on 5HT-induced IP3 formation where knockdown of endogenous expression of the PDZ
proteins results in a reduction in Gαq-mediated signaling by 5-HT2AR (Dunn et al., 2014;
Walther et al., 2015). However, a noticeable difference among the previous studies with
SAP97 and PDZK1 and the data reported here is that the effects shown here with MAGI
proteins were observed with both 5-HT2AR and 5-HT2AR-ΔSCV, while SAP97 and PDZK1
could only elicit their functional effects on 5-HT2AR. This most likely suggests that the
effects of SAP97 and PDZK1 on 5-HT2AR signaling are PDZ motif-dependent and the
effects of MAGIs on 5-HT2AR signaling are PDZ motif-independent. Other examples of
PDZ domain-containing proteins that are known to regulate Gαq signaling include
NHERF1, which was demonstrated to increase coupling and activation of Gαq by
parathyroid 1 receptor (PTH1R), and NHERF2 which increases secondary messenger IP3
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Figure 5.2: A schematic representation of the signaling pathways activated by CRFR1
and 5-HT2AR and the involvement of MAGI and CAL proteins in regulating these
pathways as reported in this thesis.
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accumulation via LPA2R (Oh et al., 2004; Wang et al., 2010).
It is also essential to study the effects of our PDZ proteins of interest on the MAPK
pathway, which represents a signaling pathway shared by both CRFR1 and 5-HT2AR.
Interestingly, our data show that MAGI proteins can regulate ERK1/2 activation by both
CRFR1 and 5-HT2AR in a similar manner. We find that the overexpression of MAGI
proteins do not alter the extent of ERK1/2 phosphorylation stimulated by the activation of
either the CRFR1 or the 5-HT2AR. On the other hand, siRNA-mediated knockdown of
endogenous MAGI proteins in HEK 293 cells results in a significant enhancement in
MAPK activation by the CRFR1 and the 5-HT2AR. The only other MAGI protein to exhibit
an effect on ERK1/2 signaling is MAGI-3. MAGI-3 has been reported to show distinctive
effects on the MAPK pathway depending on the receptor being investigated (He et al.,
2006; Zhang et al., 2007; Yang et al., 2010; Stephenson et al., 2013). MAGI-3 expression
results in an enhancement in signaling for BAI-1 and LPA2R and a reduction in signaling
for the adrenergic receptors. Our laboratory has previously investigated the role of SAP97
in regulating GPCR-mediated ERK1/2 signaling (Dunn et al., 2013). This work
demonstrates a general role for SAP97 in regulating the MAPK signaling pathway
independently from the PDZ motif, since the effects are observed with CRFR1-ΔTAV as
well as CRFR2. Interestingly, SAP97 has an opposite effect to MAGI proteins in regulating
ERK1/2 phosphorylation by both CRFR1 and 5-HT2AR, as the knockdown of endogenous
SAP97 results in a reduction in ERK1/2 activation.
In this thesis, we also study the effects of CAL on CRFR1-mediated ERK1/2
signaling and demonstrate that CAL can negatively regulate this pathway. Our data indicate
that CAL overexpression results in a significant attenuation of ERK1/2 activation, while
CAL siRNA knockdown of endogenous levels of the CAL protein results in enhanced
CRFR1-mediated ERK1/2 signaling (Hammad et al., 2015). Similarly, CAL
overexpression reduces ERK1/2 activation by mGluR1 (He et al., 2004; Zhang et al., 2008)
and β1-AR (He et al., 2004). The effect of CAL on regulating 5-HT-mediated ERK1/2
signaling remains to be determined.
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5.4 Mechanisms of GPCRs Regulation by MAGI and CAL
Proteins
The various mechanisms underlying the functional regulation of PDZ motif
expressing GPCRs examined in the present thesis highlight the specificity and uniqueness
of this group of scaffolding proteins. While CAL mediates its effects via regulation of posttranslational glycosylation, MAGI proteins perform their functions by regulating receptor
interactions with key elements such as β-arrestin and PLCβ. This confirms the importance
of PDZ domain-containing proteins in regulating GPCRs functions and given that more
than 50% of pharmaceutical drugs directly or indirectly act on GPCRs, proper
characterization of PDZ protein-receptor interactions is essential.
Despite some differences in the extent of their effects on different aspects of
CRFR1 and 5-HT2AR activity, it is fair to say that MAGIs 1, 2 and 3 share some similar
effects on the trafficking and signaling of CRFR1 and 5-HT2AR. Therefore, we further
investigated their ability to compensate for one another and provided evidence for a
possible compensatory protein expression mechanism of up-regulation between MAGI-1
and MAGI-3 based on their similar functional roles, when the expression of either protein
is altered by siRNA knockdown. This is not the first report to suggest either compensatory
or complimentary effects of PDZ proteins. It has been previously documented that PSD93 and PSD-95 can compensate for one another (Sun and Turrigiano, 2011) and regulate
GPCRs function similarly.

5.5 MAGI and CAL Proteins in Disease
CAL-deficient mice are infertile and it has been suggested that they can present a
unique model for human globozoospermia, an inherited infertility syndrome in humans
where the acrosome is lost. The acrosome is a unique organelle that plays an important role
at the site of sperm-zona pellucida binding during the fertilization process and has been
reported to be completely lost in CAL knockout mouse models (Yao et al., 2002). It is
therefore suggested that CAL plays a role in the fusion of transport vesicles to the
acrosome. PCR analysis of mouse tissue reveals that CAL is ubiquitously distributed in
many different regions of the brain (cerebellum, cortex, hippocampus and hypothalamus)
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as well as the heart, kidney, lungs, testis and spinal cord (Charest et al., 2001; Cheng et al.,
2002; Herrmann et al., 2013). However, other than spermatogenesis, no overt abnormalities
are noted in CAL knockout mice (Yao et al., 2002). A study shows that β1-AR expression
levels are decreased in the hippocampus of CAL knockout mice (Koliwer et al., 2015).
Given its wide distribution in multiple areas of the brain as well as its confirmed role as an
essential sorting protein, further examination is required to understand the role of CAL and
whether it has any implications for mental illnesses.
MAGI proteins are important scaffolding proteins and have been implicated in
various physiological functions (Funke et al., 2005; Oliva et al., 2012). MAGI proteins are
suggested to be involved in learning and memory. All MAGI proteins are also believed to
be involved in cancer cell signaling via their interaction with PTEN, a tumor suppressor
gene (Zaric et al., 2012; Matsuda et al., 2013). MAGIs expression level is correlated with
the cancer cell invasion where their levels were shown to be reduced in different cancer
types (Matsuda et al., 2013). PCR results performed in our laboratory indicate that MAGIs
1, 2 and 3 are expressed in the human brain. RT-PCR in mouse tissues show that MAGI-1
is expressed in the colon, kidney, lung, liver, and pancreas and different areas of the brain
including the cerebellum, cortex and thalamus. MAGI-2 is expressed in the cortex and
thalamus as well as the kidneys and testis. MAGI-3 is very widely distributed in the
cerebellum, cortex and thalamus as well as heart, kidney, colon and lung (Wu et al., 2000;
Sugnet et al., 2006).
MAGI-1 expression is decreased in cancers and this correlates with poor prognosis,
suggesting MAGI-1 as a novel prognostic marker for cancer (Zaric et al., 2012). On the
other hand, overexpression of MAGI-1 induces stabilization of E-cadherin and β-catenin
localization at cell-cell junctions, enhances actin stress fiber and focal adhesion formation,
increases cell adhesion to matrix proteins and suppresses anchoragein dependent growth
and migration. In fact, MAGI-1 overexpression suppresses subcutaneous primary tumor
growth and attenuates spontaneous lung metastasis in experimental colon cancer
(Pleasance et al., 2010). MAGI-1 deficient mice are suggested to have renal problems but
further characterization of this model is required.
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MAGI-2 has been found to localize to the postsynaptic density area of the spine
and bind to N-methyl-D-aspartate receptor (Hirao et al., 1998; Iida et al., 2007; Sumita et
al., 2007). Furthermore, MAGI-2 has been shown to be localized to both excitatory and
inhibitory synapses. Taken together, this data suggest a neuronal role for MAGI-2. In fact,
MAGI-2 knockout mice models show abnormal elongation of dendritic spines, indicating
a possible role for MAGI-2 during morphogenesis of neurons (Iida et al., 2007). MAGI-2
has also been shown to be expressed in the kidneys and was recently found to play a critical
role in the formation and maintenance of the glomerular filtration barrier (Ihara et al.,
2014). It is reported that the renal function of excretion of waste matter was entirely lost in
MAGI-2 knockout mice and this caused neonatal lethality. MAGI- 2 gene has been shown
to undergo rearrangement in the genome of a melanoma cell line and prostate cancer
(Berger et al., 2011).
MAGI-3 has been shown to interact with Lysophosphatidic Acid (LPA) receptor
type 2 and regulate its signaling pathways. LPA is a potent inducer of colon cancer and
LPA receptor type 2 is overexpressed in colon tumors (Zhang et al., 2007). No reports are
published about a knockout model of MAGI-3.

5.6 Future Directions
Now that we have a better understanding for the role of MAGI proteins in
regulating both CRFR1 and 5-HT2AR, the next step would be to assess whether MAGI
proteins are involved in regulating the crosstalk between the receptors. The best way to test
this is by performing IP3 assays in cells transfected with 5-HT2AR and CRFR1 and either
overexpressed MAGI proteins or siRNA against the MAGI proteins. We could then
pretreat cells with CRF and measure IP3 formation to examine the effects of MAGI
proteins on the enhancement of signaling that was observed in Magalhaes et al. (2010). We
would expect that overexpression of MAGI proteins will result in further enhancement in
IP3 formation, because it had this effect even without CRF pretreatment. Given the similar
function of the three MAGI proteins and the apparent compensation mechanism governing
that function, one should also consider the possibility that a certain combination of
overexpression or knockdown might be involved and therefore, these conditions would
have to be tested as well.
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The effect of CAL on the signaling and trafficking of 5-HT2AR remains unknown.
CAL is one of the PDZ proteins that was detected as an interacting protein in the PDZ blot
overlay assay performed with the carboxyl-terminal tail of 5-HT2AR to screen 96 PDZ
domains. Despite containing one PDZ domain, it is still a candidate regulator of the
crosstalk between CRFR1 and 5-HT2AR because of its ability to self-dimerize via the coiled
coil motif. Given that CAL overexpression results in the reduction of expression of CRFR1
at the cell surface, it would be unlikely for CAL to be required for CRFR1-mediated 5HT2AR sensitization. In fact, we could speculate that maybe a knockdown of CAL would
facilitate this crosstalk since CAL seems to be retaining receptors in the intracellular
compartments as reported by us for CRFR1 and by others for mGluRs, β1-AR and SSTR5.
This would suggest that it is indeed a group of PDZ proteins that collectively work in
regulating the crosstalk as opposed to one PDZ protein.
Our studies confirm the importance of the family of PDZ domain-containing
proteins in regulating GPCRs activity. We illustrated the distinct function of the MAGI
subfamily of proteins in regulating the trafficking and signaling of CRF1 and 5-HT2A
receptors. We also showed a unique mechanism of regulation for CAL in mediating posttranslational modifications of the receptors. Considering the fact that more than 40% of
currently available pharmaceuticals act directly or indirectly on GPCRs, it is essential to
fully characterize their interacting partners and the consequences such interactions have on
receptor function. Multi-domain-containing proteins such as PDZ proteins present exciting
models since it would be possible to target either their interaction with the receptor, their
PDZ domains, the PDZ motifs of the receptor or allosteric sites on the proteins to change
their conformation. Therefore, the findings from these studies can be utilized in the design
of new pharmacological tools for the treatment of diseases including mental disorders.
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Authors: Maha M. Hammad, Cornelia Walther, Henry A. Dunn, and Stephen S.G.
Ferguson
Meeting: 6th International Conference on Drug Discovery and Therapy, Dubai, UAE.
Feb.10- 12, 2014
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Meeting: Phys/Pharm Research Day, Western University, London, Ontario. Nov. 4, 2013
Meeting: London Health Research Day, London, Ontario. March 18, 2014
Title: The role of PDZ proteins in regulating the corticotropin releasing factor 1 and the
serotonin 2A receptors
Authors: Maha M. Hammad, Cornelia Walther, Henry A. Dunn, and Stephen S.G.
Ferguson
Meeting: 14th annual joint meeting of the Great Lakes GPCR Retreat and le Club des
Recepteurs a Sept Domaines Transmembranaires du Québec, Cleveland, Ohio. October
2013
Title: Multiplexed analysis of inflammatory, metabolic and stress markers in obese
subjects before and after a defined exercise program
Authors: Baturcam E, Abubakr J, Abu-Farha M, Al-Arouj M, Al-Ghimlas F, Al-Khairi I,
Al-Mass A, Al-Mudhaf D, Bennakhi A, Cherian P, Hammad M, John J, Kavalakatt S,
Khadir A, Tiss A, Warsame S, Dermime S, Dehbi M
Meeting: 10th Joint Meeting of International Cytokine Society and International Society
for Interferon and Cytokine Research. Sept. 2012
Title: Association of obesity with down-regulation of heat shock protein 40 expression
and evidence that exercise retrieves its normal expression
Authors: Abubakr J, Abu-Farha M, Al-Arouj M, Al-Ghimlas F, Al-Khairi I, Al-Mudhaf
D, Baturcam E, Bennakhi A, Cherian P, Hammad M, John J, Kavalakatt S, Khadir A,
Tiss A, Warsame S, Dermime S, Dehbi M
Meeting: BMC Proceedings Washington, DC. May 29-30, 2012
Title: Increased expression of TLR-2 and 4 in monocytes of obese individuals: association
with the induction and progression of insulin resistance
Authors: Almass A, Ahmad R, Al-Ghawas D, Hasan A, Atizado VL, Hammad MM,
Lehe C, Zghoul N, Al-Ghimlas F, AlKandari J, Al-Yousef A, Al-Arouj M, Bennakhi A,
Dermime S
Meeting: Annual Congress of the British Society for Immunology, Liverpool, UK. Dec.
5-8, 2011
Title: Peripheral blood mononuclear cells (PBMCs) and adipose tissue from overweight
and obese individuals express significant high levels of matrix metallopeptidase 9 (MMP9)
Authors: Ahmad R, Al-Ghawas D, Al-Saleh S, Almass A, Hasan A, Atizado VL,
Hammad MM, Lehe C, Zghoul N, Al-Ghimlas F, AlKandari JR, Al-Yousef A, Al-Sabah
S, Al-Arouj M, Bennakhi A, Dermime S
Meeting: Annual Congress of the British Society for Immunology, Liverpool, UK.
December 5-8, 2011
Title: Different Roles for Chaperones and Scaffolds in GPCR Homo and Heterodimeric
Receptor Complexes Assembly and Functions
Authors: Dupré DJ, Hammad MM, Allen H, and Yan R.
Meeting: Bit-PepCon Life Sciences 3rd Annual Conference, Beijing, China
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Title: EBP50/NHERF1 Regulates CCR5 Homodimers, but not CXCR4 homo or CXCR4CCR5 Heterodimers
Authors: Hammad MM, Yan R, Allen H, and Dupré DJ
Meeting: The 10th Annual Joint Meeting of the Great Lakes G Protein-Coupled Receptor
Retreat and le Club des Récepteurs à Sept Domaines Transmembranaires – Rochester, New
York. October 15-18, 2009
Title: Characterization of Assembly, Trafficking and Signaling of Homo and
Heterodimeric G Protein Coupled Receptors
Authors: Allen H, Hammad MM, Yan R, and Dupré DJ
Meeting: The 8th European Symposium of The Protein Society – Zurich, Switzerland.
June 14-18, 2009
Title: The Specificity of Signaling of β2-Adrenergic/Angiotensin Heterodimeric Receptor
Complex
Authors: Hammad MM, Morse A, and Dupré DJ
Meeting: Graduate Student Research Day Poster Competition– Faculty of Medicine at
Dalhousie. May 2009
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Awards and Scholarships

 Doctoral Research Award from Canadian Institute of Health Research
Sept. 2014 - Aug. 2017
 “Image of the month” from the Confocal Facility at Robarts Research Institute
July 2015
 Second place poster prize in the 6th International Conference on Drug Discovery and
Therapy
Dubai, UAE, Feb.10-12, 2014
 Second place poster prize for the Neuroscience category in the Phys/Pharm Research
Day
Western University, Nov. 4, 2013
 Focus on Stroke Doctoral Research Award from Heart and Stroke Foundation
Sept. 2013 - Aug. 2016
Award terminated in Aug. 2014 after receiving the Doctoral Award from CIHR
 Dean's PhD Graduate Stipend award from Schulich School of Medicine & Dentistry
Western University from Sept. 2012 - Aug. 2016
Award terminated in Aug. 2013 after receiving the FOS Doctoral Award from HSF
 Student Research Award from the Nova Scotia Health Research Foundation (NSHRF)
Sept. 2009 - Aug. 2010
 Stipend Scholarship from the Department of Pharmacology, Dalhousie University
Sept. 2008 - Aug. 2010
 Conference Travel Grant from the Faculty of Graduate Studies, Dalhousie University
Oct. 2009
 First Place Prize in the Scientific Poster Day, Faculty of Science, Kuwait
May 2008
 Dean's Honor List from Faculty of Science, Kuwait University
Winter Semester 2004-05, Winter Semester 2005-06, Fall Semester 2006-07 and Fall
Semester 2007-08
 Highest GPA award in the Biochemistry Department, Kuwait University
2005 and 2006

